U.S. patent application number 17/073150 was filed with the patent office on 2021-01-28 for anti-cd40 antibody and their uses.
The applicant listed for this patent is AbbVie Biotherapeutics Inc.. Invention is credited to Diane Sau Mun COHEN, Diane HOLLENBAUGH, Shiming YE.
Application Number | 20210024642 17/073150 |
Document ID | / |
Family ID | 1000005150754 |
Filed Date | 2021-01-28 |
View All Diagrams
United States Patent
Application |
20210024642 |
Kind Code |
A1 |
COHEN; Diane Sau Mun ; et
al. |
January 28, 2021 |
ANTI-CD40 ANTIBODY AND THEIR USES
Abstract
The present disclosure provides novel anti-CD40 antibodies,
compositions including the new antibodies, nucleic acids encoding
the antibodies, and methods of making and using the same.
Inventors: |
COHEN; Diane Sau Mun; (San
Jose, CA) ; HOLLENBAUGH; Diane; (Mountain View,
CA) ; YE; Shiming; (Palo Alto, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
AbbVie Biotherapeutics Inc. |
Redwood City |
CA |
US |
|
|
Family ID: |
1000005150754 |
Appl. No.: |
17/073150 |
Filed: |
October 16, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16559504 |
Sep 3, 2019 |
10844131 |
|
|
17073150 |
|
|
|
|
16036691 |
Jul 16, 2018 |
10400041 |
|
|
16559504 |
|
|
|
|
15901560 |
Feb 21, 2018 |
10023645 |
|
|
16036691 |
|
|
|
|
15606227 |
May 26, 2017 |
10519243 |
|
|
15901560 |
|
|
|
|
16559504 |
Sep 3, 2019 |
10844131 |
|
|
15606227 |
|
|
|
|
15606227 |
May 26, 2017 |
10519243 |
|
|
16559504 |
|
|
|
|
62342417 |
May 27, 2016 |
|
|
|
62342417 |
May 27, 2016 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 2317/56 20130101;
A61K 2039/505 20130101; C07K 2317/565 20130101; C07K 2317/524
20130101; C07K 2317/732 20130101; C07K 2317/24 20130101; A61K
2039/54 20130101; C07K 2317/33 20130101; C07K 16/2878 20130101;
C07K 2317/92 20130101; A61K 2039/507 20130101; C07K 2317/75
20130101; C07K 2317/74 20130101; C07K 2317/70 20130101; C07K
2317/71 20130101; C07K 16/2818 20130101 |
International
Class: |
C07K 16/28 20060101
C07K016/28 |
Claims
1. An anti-CD40 antibody or binding fragment which comprises (i) a
V.sub.H chain comprising three CDRs; and (ii) a V.sub.L chain
comprising three CDRs, wherein: V.sub.H CDR #1 is selected from:
TABLE-US-00017 (SEQ ID NO: 6) GYTFTSYWMH, (SEQ ID NO: 7)
GYTFTDYYIN, (SEQ ID NO: 8) GYSITSNYYWN, (SEQ ID NO: 9) GYSISSNYYWN,
(SEQ ID NO: 10) GYDITSNYYWN;
V.sub.H CDR #2 is selected from: TABLE-US-00018 (SEQ ID NO: 17)
WIFPGSGSVYCNEQFKG, (SEQ ID NO: 18) YIRYDGSNNYNPSLKN, (SEQ ID NO:
19) NIDPSNGETHYAQKFQG, (SEQ ID NO: 20) WIFPGSGSVYSNEQFKG, (SEQ ID
NO: 21) YIRYDGSNNYNPSLKS, and (SEQ ID NO: 22) YIRYDGSNNYNPSLKG;
V.sub.H CDR #3 is selected from: TABLE-US-00019 (SEQ ID NO: 35)
LDY, (SEQ ID NO: 36) ERIYYSGSTYDGYFDV, and (SEQ ID NO: 37)
SLGKFAY;
V.sub.L CDR #1 is selected from: TABLE-US-00020 (SEQ ID NO: 56)
SASSSLSYMH, (SEQ ID NO: 57) KASQSVVTAVA, and (SEQ ID NO: 58)
RSSQSLENTNGNTFLN;
V.sub.L CDR #2 is selected from: TABLE-US-00021 (SEQ ID NO: 66)
DTSKLAS, (SEQ ID NO: 67) SASNRYT, and (SEQ ID NO: 68) RVSNRFS;
V.sub.L CDR #3 is selected from: TABLE-US-00022 (SEQ ID NO: 86)
QQWSSNPWT, (SEQ ID NO: 87) QQYSSYPYT, and (SEQ ID NO: 88)
LQVTHVPFT.
2. The anti-CD40 antibody or binding fragment of claim 1 which
comprises CDRS having the sequences of SEQ ID NOS: 8, 18, 35, 58,
68, and 88.
3. The anti-CD40 antibody or binding fragment of claim 1 which is
human or humanized.
4. The anti-CD40 antibody or binding fragment of claim 1, which
comprises a V.sub.H chain corresponding in sequence to any one of
SEQ ID NOS:110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120,
121, 122, or 123; and a V.sub.L chain corresponding in sequence to
any one of SEQ ID NOS:161, 162, 163, 164, 165, 166, 167, 168, 169,
170, or 171.
5. The anti-CD40 antibody or binding fragment of claim 1 which
comprises a V.sub.H chain corresponding to the sequence of SEQ ID
NO:117 and a V.sub.L chain corresponding to the sequence of SEQ ID
NO:170.
6. The anti-CD40 antibody or binding fragment of claim 1, which is
an IgG, optionally an IgG.sub.1.
7. The anti-CD40 antibody of claim 6, which is an IgG.sub.1 and
comprises a variant CH2 region comprising the amino acid
substitution V273E or V273Y.
8. The anti-CD40 antibody of claim 6, which is an IgG.sub.1 and
comprises a variant Fc region comprising the amino acid
substitutions D356E and L358M.
9. The anti-CD40 antibody of claim 6 comprising a kappa light chain
constant region.
10. The anti-CD40 antibody of claim 1 having a heavy chain sequence
according to any one of SEQ ID NOS:130-135, and light chain
sequence according to any one of SEQ ID NOS:140-142.
11. The anti-CD40 antibody of claim 10 having a heavy chain
sequence according to SEQ ID NOS:130 or 131, and a light chain
sequence according to SEQ ID NO:140.
12. The anti-CD40 antibody of claim 10 having a heavy chain
sequence according to SEQ ID NOS:132 or 133, and a light chain
sequence according to SEQ ID NO:141.
13. The anti-CD40 antibody of claim 10 having a heavy chain
sequence according to SEQ ID NOS:132 or 133, and a light chain
sequence according to SEQ ID NO:142.
14. A pharmaceutical composition comprising an anti-CD40 antibody
or binding fragment of claim 1, and a pharmaceutically acceptable
carrier.
15. A method of treating a cancer, comprising administering to a
patient in need thereof an anti-CD40 antibody or binding fragment
of claim 1.
16. A nucleic acid comprising a nucleotide sequence encoding an
anti-CD40 antibody or binding fragment of claim 1.
17. A vector comprising the nucleic acid of claim 16.
18. A prokaryotic host cell transformed with the vector of claim
17.
19. A eukaryotic host cell transformed with the vector of claim
17.
20. A eukaryotic host cell engineered to express the nucleic acid
of claim 16.
21. The eukaryotic host cell of claim 20 which is a mammalian host
cell.
22. A method of producing an anti-CD40 antibody or binding fragment
thereof, comprising: (a) culturing the host cell of claim 20 and
(b) recovering the antibody or binding fragment.
23. A method of activating the immune system, comprising
administering to a patient in need thereof an anti-CD40 antibody or
binding fragment of claim 1.
Description
1. CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 U.S.C. .sctn.
119(e) of U.S. Provisional Application No. 62/342,417, filed May
27, 2016, the contents of which are incorporated herein in its
entirety by reference thereto.
2. SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which
has been submitted electronically in ASCII format and is hereby
incorporated by reference in its entirety. Said ASCII copy, created
on May 17, 2017, is named 381493-285US_SL.txt and is 106,228 bytes
in size.
3. TECHNICAL FIELD
[0003] The present application pertains to, among other things,
novel anti-CD40 antibodies, compositions including the new
antibodies, nucleic acids encoding the antibodies, and methods of
making and using the same.
4. BACKGROUND
[0004] Cancer therapies comprise a wide range of therapeutic
approaches, including surgery, radiation, and chemotherapy. While
the various approaches allow a broad selection of treatments to be
available to the medical practitioner to treat the cancer, existing
therapeutics suffer from a number of disadvantages, such as a lack
of selectivity of targeting cancer cells over normal, healthy
cells, and the development of resistance by the cancer to the
treatment.
[0005] Recent approaches based on targeted therapeutics, which
interfere with cellular processes of cancer cells preferentially
over normal cells, have led to chemotherapeutic regimens with fewer
side effects as compared to non-targeted therapies such as
radiation treatment.
[0006] Cancer immunotherapy, in particular the development of
agents that activate T cells of the host's immune system to prevent
the proliferation of or kill cancer cells, has emerged as a
promising therapeutic approach to complement existing standards of
care. See, e.g., Miller, et al. Cancer Cell, 27, 439-449 (2015).
Such immunotherapy approaches include the development of antibodies
used to modulate the immune system to kill cancer cells. For
example, anti-PD-1 blocking antibodies pembrolizumab
(Keytruda.RTM.) and nivolumab (Opdivo.RTM.) have been approved in
the US and the European Union to treat diseases such as
unresectable or metastatic melanoma and metastatic non-small cell
lung cancer. Efforts to inhibit immunosuppressive proteins such as
CTLA-4 have led to the development and clinical evaluation of
anti-CTLA-4 antibodies, such as tremelimumab and ipilimumab
(Yervoy.RTM.).
[0007] There remains a need for alternative approaches and
additional cancer treatments to complement existing therapeutic
standards of care.
5. SUMMARY
[0008] Human CD40 (SEQ ID NO:40) is a tumor necrosis factor (TNF)
receptor superfamily member (TNF superfamily member 5) expressed on
antigen-presenting cells such as B cells, dendritic cells (DC), and
monocytes, and nonimmune cells, including certain types of tumor
cells. When activated by human CD40 ligand (SEQ ID NO:41), human
CD40 activates antigen-presenting cells and induces responses from
both innate and adaptive immune systems. Agonistic CD40 agents can
be used to induce the immune system to prevent proliferation of
and/or kill tumor cells, and thus provide effective therapeutic
treatment of solid tumors.
[0009] The present disclosure provides anti-CD40 antibodies and
binding fragments thereof that specifically bind to human CD40 (SEQ
ID NO:40). The amino acid sequences of exemplary CDRs, as well as
the amino acid sequence of the V.sub.H and V.sub.L regions of the
heavy and light chains of exemplary anti-CD40 antibodies are
provided in the Detailed Description below.
[0010] The V.sub.H and V.sub.L chains of the anti-CD40 antibodies
described herein afford an allosteric agonistic receptor response
that can activate human CD40 in the presence or absence of CD40
ligand (CD40L), without competing with the CD40L-CD40 binding
interaction. Moreover, the present anti-CD40 antibodies, by
interacting with CD40, can enhance CD40L binding to CD40.
[0011] The anti-CD40 antibodies may include modifications and/or
mutations that alter the properties of the antibodies, such as
increase half-life, increase or decrease ADCC, or increase
agonistic activity, as is known in the art.
[0012] Nucleic acids comprising nucleotide sequences encoding the
anti-CD40 antibodies of the disclosure are provided herein, as are
vectors comprising nucleic acids. Additionally, prokaryotic and
eukaryotic host cells transformed with a vector comprising a
nucleotide sequence encoding a disclosed anti-CD40 antibody are
provided herein, as well as eukaryotic (such as mammalian) host
cells engineered to express the nucleotide sequences. Methods of
producing antibodies, by culturing host cells and recovering the
antibodies are also provided, and discussed further in the Detailed
Description below.
[0013] In another aspect, the present disclosure provides
compositions including the anti-CD40 antibodies described herein.
The compositions generally comprise one or more anti-CD40 antibody
as described herein, and/or salts thereof, and one or more
excipients, carriers or diluents.
[0014] The present disclosure provides methods of treating
subjects, such as human subjects, diagnosed with a solid tumor with
an anti-CD40 antibody. The method generally involves administering
to the subject an amount of an anti-CD40 antibody described herein
effective to provide therapeutic benefit. The subject may be
diagnosed with any one of a number of solid tumors that may be
newly diagnosed, relapsed, or relapsed and refractory. An anti-CD40
antibody is typically administered as an intravenous infusion or
intratumoral injection at doses ranging from about 0.001 mg/kg to
about 4 mg/kg. An anti-CD40 antibody is typically administered as
an intravenous infusion or intratumoral injection twice a week,
once a week, once every two weeks, once every three weeks, once
every four weeks, once every five weeks, once every six weeks, once
every seven weeks, or once every eight weeks.
[0015] The anti-CD40 antibodies may be administered as single
therapeutic agents (monotherapy) or adjunctive to or with other
therapeutic agents typically, but not necessarily, those used for
the treatment of a solid tumor. Therapeutic agents typically will
be used at their approved dose, route of administration, and
frequency of administration, but may be used at lower dosages.
[0016] The anti-CD40 antibodies may be administered via a variety
of routes or modes of administration, including but not limited to,
intravenous infusion and/or injection, subcutaneous injection, and
intratumoral injection. The amount administered will depend upon
the route of administration, the dosing schedule, the type of
cancer being treated, the stage of the cancer being treated, and
other parameters such as the age and weight of the patient, as is
well known in the art. Specific exemplary dosing schedules expected
to provide therapeutic benefit are provided in the Detailed
Description.
[0017] Based on data presented herein, it is expected that the
anti-CD40 antibodies described herein will provide therapeutic
benefit to subjects diagnosed with a solid tumor.
6. BRIEF DESCRIPTION OF THE FIGURES
[0018] FIG. 1 shows the amino acid sequences of human CD40 receptor
(SEQ ID NO:40) and human CD40 ligand (SEQ ID NO:41).
[0019] FIGS. 2A-2G provide amino acid sequences for V.sub.H and
V.sub.L of exemplary mouse and humanized anti-CD40 antibodies. FIG.
2A shows the V.sub.H and V.sub.L amino acid sequences for muAb1
through muAb3; FIG. 2B shows the V.sub.H and V.sub.L amino acid
sequences for muAb4 through muAb7; FIG. 2C shows the V.sub.H and
V.sub.L amino acid sequences for muAb8 through muAb10; FIG. 2D
shows the V.sub.H and V.sub.L amino acid sequences for humanized
antibodies of muAb6 and muAb8; FIG. 2E shows the V.sub.H and
V.sub.L amino acid sequences for humanized antibodies of muAb8 and
muAb9; FIG. 2F shows the V.sub.H and V.sub.L amino acid sequences
for further humanized antibodies of muAb9; and FIG. 2G shows the
V.sub.H and V.sub.L amino acid sequences for additional humanized
antibodies of muAb9.
[0020] FIG. 3 provides the results of competition experiments on
human CD40 between CD40L and exemplary anti-CD40 antibodies. Upper
left shows exemplary anti-CD40 antibodies that compete with CD40L;
upper right shows antibodies that do not significantly compete with
CD40L; lower left shows antibodies that enhance CD40-CD40L
interaction; lower right shows effects of anti-CD40 antibody huAb9
A2I and CP-870,893. Y-axis depicts optical density (OD) at 650 nm;
x-axis depicts antibody dose ("Sample") in .mu.g/mL.
[0021] FIG. 4 shows the binding of fluorochrome-conjugated human
CD40 at a fixed concentration of 1 .mu.g/mL on Jurkat cells
expressing human CD40L in the presence of increasing amounts of
antibody huAb9 A2I, CP-870,893, human IgG.sub.1 ("huIgG1") isotype
or human IgG2 ("huIgG2") isotype. Y-axis depicts mean fluorescence
intensity ("MFI") representing the binding; x-axis depicts antibody
dose ("Sample") in .mu.g/mL.
[0022] FIGS. 5A-5B show the effects of an antibody dose ("Sample")
at 3 .mu.g/mL or media only on NF.kappa.B signal from HEK293 blue
CD40 NF.kappa.B reporter cells mixed with Jurkat D1.1 cells (1:1
ratio). Antibody huAb9 A2I, CP-870,893, human IgG.sub.1 ("huIgG1")
isotype or human IgG.sub.2 ("huIgG2") isotype, or media only, was
added to the individual sample. FIG. 5A depicts the NF.kappa.B
signal in cultures containing CD40L negative ("CD40L-") Jurkat D1.1
cells. FIG. 5B depicts the NF.kappa.B signal in cultures containing
CD40L positive ("CD40L+") Jurkat D1.1 cells. Y-axis depicts OD at
625 nm; x-axis depicts antibody or media only treatment
("Sample").
[0023] FIGS. 6A-6B show the binding of antibody doses ("Sample") in
.mu.g/mL of huAb9-5 with wild type huIgG.sub.1, or with V273Y or
V273E variant, or CP-870,893, in CHO cells expressing CD16F, CD16V,
CD32a, CD32b, or CD64. FIG. 6A shows binding of an anti-CD40
antibody on CHO cells expressing CD16F (upper left), CD16V (upper
right), CD32a (lower left), or CD32b (lower right). FIG. 6B shows
binding of an anti-CD40 antibody on CHO cells expressing CD64.
Y-axis depicts mean fluorescence intensity (MFI) representing the
binding; x-axis depicts antibody dose ("Sample") in .mu.g/mL.
[0024] FIG. 7 shows the antibody-dependent cell-mediated
cytotoxicity (ADCC) of constant region variants V273E or V273Y for
antibody huAb9-5 as compared with huAb9-5 with the wild type human
IgG.sub.1 in RL cells. Y-axis depicts percent cytotoxicity in RL
cells; x-axis depicts antibody dose ("Sample") in .mu.g/mL.
[0025] FIG. 8 shows the effect of antibody huAb6-1 (upper left),
huAb9-5 (lower left), huAb8-1 (upper right) with wild type human
IgG.sub.1, or a constant region variant V273E or V273Y, on B cell
proliferation. Lower right graph shows B cell proliferation effects
of huAb9 A2I with human IgG.sub.1 V273E variant or CP-870,893.
Y-axis depicts B cell proliferation in counts per minute (CPM);
x-axis depicts antibody dose ("Sample") in .mu.g/mL.
[0026] FIG. 9 shows the effect of antibody huAb6-1 (upper left),
huAb9-5 (lower left) and huAb8-1 (upper right) with wild type human
IgG.sub.1, or a constant region variant V273E or V273Y, on
dendritic cell (DC) activation as measured by IL-12p70 production
in pg/mL. Lower right graph shows DC activation of huAb9 A2I with
human IgG.sub.1 V273E variant or CP-870,893. Y-axis depicts
IL-12p70 in pg/mL; x-axis depicts antibody dose ("Sample") in
.mu.g/mL.
[0027] FIG. 10 shows the effect of a V273Y variant of huAb6-1,
huAb8-1, or huAb9-5 on DC and T-cell co-cultures as measured by
interferon-gamma (IFN-.gamma.) production in pg/mL.
[0028] FIG. 11 shows the effect of antibody huAb6-1 (upper),
huAb9-5 (middle) or huAb9 A2I (lower) on tumor volume (mm.sup.3) in
a prophylactic PC3 mouse model.
[0029] FIG. 12 shows in vivo effects following intratumoral (IT) or
intraperitoneal (IP) delivery of anti-CD40 antibody 1C10, or mIgG1
isotype, in a mouse model carrying bilaterally established CT26
syngeneic tumors. IT dosing was administered to one tumor at one
flank, with no injection to the tumor at the other flank.
[0030] FIG. 13 shows effects on tumor volume (mm.sup.3) following
dosing two times a week of anti-CD40 antibody 1C10 at 0.6 mg/kg, an
anti-PD-1 antibody at 10 mg/kg, or combination treatment of both
1C10 and the anti-PD-1 antibody in a CT26 mouse syngeneic
model.
[0031] FIG. 14 shows ALT (upper left), TNF.alpha. ("TNFa", lower
left), or IL-6 (lower right) levels 24 hours after dosing of
anti-CD40 antibody 1C10 ("anti-CD40"), anti-PD-1 antibody
("anti-PD-1") or combination treatment ("anti-CD40+anti-PD-1") in a
CT26 mouse syngeneic model. Upper right graph shows spleen weight 4
days post-dosing.
7. DETAILED DESCRIPTION
[0032] The present disclosure concerns antibodies and fragments
that specifically bind human CD40 (SEQ ID NO:40), compositions
comprising the antibodies, polynucleotides encoding anti-CD40
antibodies, host cells capable of producing the antibodies, methods
and compositions useful for making the antibodies and binding
fragments, and various methods of using the same.
[0033] As will be appreciated by skilled artisans, antibodies are
"modular" in nature. Throughout the disclosure, various specific
embodiments of the various "modules" composing the antibodies are
described. As specific non-limiting examples, various specific
embodiments of V.sub.H CDRs, V.sub.H chains, V.sub.L CDRs and
V.sub.L chains are described. It is intended that all of the
specific embodiments may be combined with each other as though each
specific combination were explicitly described individually.
7.1. Abbreviations
[0034] The antibodies, binding fragments, ADCs and polynucleotides
described herein are, in many embodiments, described by way of
their respective polypeptide or polynucleotide sequences. Unless
indicated otherwise, polypeptide sequences are provided in
N.fwdarw.C orientation; polynucleotide sequences in 5'.fwdarw.3'
orientation. For polypeptide sequences, the conventional three or
one-letter abbreviations for the genetically encoded amino acids
may be used, as noted in TABLE 1, below.
TABLE-US-00001 TABLE 1 Encoded Amino Acid Abbreviations Three
Letter One-Letter Amino Acid Abbreviation Abbreviation Alanine Ala
A Arginine Arg R Asparagine Asn N Aspartic acid Asp D Cysteine Cys
C Glutamic acid Glu E Glutamine Gln Q Glycine Gly G Histidine His H
Isoleucine Ile I Leucine Leu L Lysine Lys K Methionine Met M
Phenylalanine Phe F Proline Pro P Serine Ser S Threonine Thr T
Tryptophan Trp W Tyrosine Tyr Y Valine Val V
[0035] Certain sequences are defined by structural formulae
specifying amino acid residues belonging to certain classes (e.g.,
aliphatic, hydrophobic, etc.). The various classes to which the
genetically encoded amino acids belong as used herein are noted in
TABLE 2, below. Some amino acids may belong to more than one class.
Cysteine, which contains a sulfhydryl group, and proline, which is
conformationally constrained, are not assigned classes.
TABLE-US-00002 TABLE 2 Encoded Amino Acid Classes Class Amino Acids
Aliphatic A, I, L, V Aromatic F, Y, W Non-Polar M, A, I, L, V Polar
N, Q, S, T Basic H, K, R Acidic D, E Small A, G
[0036] The abbreviations used for the various exemplary antibodies
disclosed herein are provided in TABLE 3, below:
TABLE-US-00003 TABLE 3 Antibody Abbreviations Clone/Name
Abbreviation V.sub.H Sequence (FIGS. 2A-2G) V.sub.L Sequence (FIGS.
2A-2G) AD163.9.3 muAb1 muAb1 V.sub.H SEQ ID NO: 101 muAb1 V.sub.L
SEQ ID NO: 151 AD166.4.4 muAb2 muAb2 V.sub.H SEQ ID NO: 102 muAb2
V.sub.L SEQ ID NO: 152 AD175.14.11 muAb3 muAb3 V.sub.H SEQ ID NO:
103 muAb3 V.sub.L SEQ ID NO: 153 AD163.10.7 muAb4 muAb4 V.sub.H SEQ
ID NO: 104 muAb4 V.sub.L SEQ ID NO: 154 AD165.1.2 muAb5 muAb5
V.sub.H SEQ ID NO: 105 muAb5 V.sub.L SEQ ID NO: 155 AD163.162.1
muAb6 muAb6 V.sub.H SEQ ID NO: 106 muAb6 V.sub.L SEQ ID NO: 156
AD163.27.12 muAb7 muAb6 V.sub.H SEQ ID NO: 106 muAb7 V.sub.L SEQ ID
NO: 157 AD163.7.2 muAb8 muAb8 V.sub.H SEQ ID NO: 107 muAb8 V.sub.L
SEQ ID NO: 158 AD164.14.6 muAb9 muAb9 V.sub.H SEQ ID NO: 108 muAb9
V.sub.L SEQ ID NO: 159 AD164.76.3 muAb10 muAb10 V.sub.H SEQ ID NO:
109 muAb10 V.sub.L SEQ ID NO: 160 Humanized muAb6 #1 huAb6-1
huAb6-1 V.sub.H SEQ ID NO: 110 huAb6-1 V.sub.L SEQ ID NO: 161
Humanized muAb6 #2 huAb6-2 huAb6-2 V.sub.H SEQ ID NO: 111 huAb6-1
V.sub.L SEQ ID NO: 161 Humanized muAb6 #3 huAb6-3 huAb6-3 V.sub.H
SEQ ID NO: 112 huAb6-1 V.sub.L SEQ ID NO: 161 Humanized muAb8 #1
huAb8-1 huAb8-1 V.sub.H SEQ ID NO: 113 huAb8-1 V.sub.L SEQ ID NO:
162 Humanized muAb8 #2 huAb8-2 huAb8-2 V.sub.H SEQ ID NO: 114
huAb8-1 V.sub.L SEQ ID NO: 162 Humanized muAb8 #3 huAb8-3 huAb8-3
V.sub.H SEQ ID NO: 115 huAb8-1 V.sub.L SEQ ID NO: 162 Humanized
muAb9 #1 huAb9-1 huAb9-1 V.sub.H SEQ ID NO: 116 huAb9-1 V.sub.L SEQ
ID NO: 163 Humanized muAb9 #2 huAb9-2 huAb9-2 V.sub.H SEQ ID NO:
117 huAb9-1 V.sub.L SEQ ID NO: 163 Humanized muAb9 #3 huAb9-3
huAb9-3 V.sub.H SEQ ID NO: 118 huAb9-1 V.sub.L SEQ ID NO: 163
Humanized muAb9 #4 huAb9-4 huAb9-1 V.sub.H SEQ ID NO: 116 huAb9-4
V.sub.L SEQ ID NO: 164 Humanized muAb9 #5 huAb9-5 huAb9-2 V.sub.H
SEQ ID NO: 117 huAb9-4 V.sub.L SEQ ID NO: 164 Humanized muAb9 #6
huAb9-6 huAb9-3 V.sub.H SEQ ID NO: 118 huAb9-4 V.sub.L SEQ ID NO:
164 Humanized muAb9 #7 huAb9-7 huAb9-7 V.sub.H SEQ ID NO: 119
huAb9-7 V.sub.L SEQ ID NO: 165 Humanized muAb9 #8 huAb9-8 huAb9-8
V.sub.H SEQ ID NO: 120 huAb9-7 V.sub.L SEQ ID NO: 165 Humanized
muAb9 #9 huAb9-9 huAb9-9 V.sub.H SEQ ID NO: 121 huAb9-9 V.sub.L SEQ
ID NO: 166 Rehumanized muAb9 huAb9 rehu#1 huAb9 SEQ ID NO: 122
huAb9 SEQ ID NO: 167 version #1 rehuVH4 V.sub.H VK1 V.sub.L
Rehumanized muAb9 huAb9 rehu#2 huAb9 SEQ ID NO: 122 huAb9 SEQ ID
NO: 168 version #2 rehuVH4 V.sub.H rehuVK2 V.sub.L Rehumanized
muAb9 huAb9 rehu#3 huAb9 SEQ ID NO: 123 huAb9 SEQ ID NO: 169
version #3 rehuVH3 V.sub.H rehuVK1 V.sub.L Humanized muAb9 A2I
huAb9 A2I huAb9-2V.sub.H SEQ ID NO: 117 huAb9A2I V.sub.L SEQ ID NO:
170 Humanized muAb9 A2V huAb9 A2V huAb9-2V.sub.H SEQ ID NO: 117
huAb9A2V V.sub.L SEQ ID NO: 171
7.2. Definitions
[0037] Unless otherwise defined herein, scientific and technical
terms used in connection with the present disclosure shall have the
meanings that are commonly understood by those of ordinary skill in
the art.
7.3. Anti-CD40 Antibodies and Binding Fragments
[0038] In one aspect, the disclosure concerns antibodies and/or
binding fragments thereof that specifically bind human CD40
receptor (also known as tumor necrosis factor receptor superfamily
member 5, TNFRSF5, Bp50, and CD40L receptor).
[0039] As used herein, the term "antibody" (Ab) refers to an
immunoglobulin molecule that specifically binds to a particular
antigen-here, CD40. In some embodiments, the anti-CD40 antibodies
of the disclosure bind to human CD40 and thereby modulate, e.g.,
activate, the immune system. The resulting immune system response
inhibits proliferation of cells such as tumor cells, and in some
instances are cytotoxic to the tumor cells. Anti-CD40 antibodies of
the disclosure comprise complementarity determining regions (CDRs),
also known as hypervariable regions, in both the light chain and
the heavy chain variable domains. The more highly conserved
portions of variable domains are called the framework (FR). As is
known in the art, the amino acid position/boundary delineating a
hypervariable region of an antibody can vary, depending on the
context and the various definitions known in the art. Some
positions within a variable domain may be viewed as hybrid
hypervariable positions in that these positions can be deemed to be
within a hypervariable region under one set of criteria while being
deemed to be outside a hypervariable region under a different set
of criteria. One or more of these positions can also be found in
extended hypervariable regions. The disclosure provides antibodies
comprising modifications in these hybrid hypervariable positions.
The variable domains of native heavy and light chains each comprise
four FR regions, largely by adopting a .beta.-sheet configuration,
connected by three CDRs, which form loops connecting, and in some
cases forming part of, the .beta.-sheet structure. The CDRs in each
chain are held together in close proximity by the FR regions and,
with the CDRs from the other chain, contribute to the formation of
the target binding site of antibodies. See Kabat et al., Sequences
of Proteins of Immunological Interest (National Institute of
Health, Bethesda, Md. 1987). As used herein, numbering of
immunoglobulin amino acid residues is done according to the
immunoglobulin amino acid residue numbering system of Kabat et al.
unless otherwise indicated.
[0040] The antibodies of the disclosure may be polyclonal,
monoclonal, genetically engineered, and/or otherwise modified in
nature, including but not limited to chimeric antibodies, humanized
antibodies, human antibodies, primatized antibodies, single chain
antibodies, etc. In various embodiments, the antibodies comprise
all or a portion of a constant region of an antibody. In some
embodiments, the constant region is an isotype selected from: IgA
(e.g., IgA.sub.1 or IgA.sub.2), IgD, IgE, IgG (e.g., IgG.sub.1,
IgG.sub.2, IgG.sub.3 or IgG.sub.4), and IgM. In specific
embodiments, the anti-CD40 antibodies described herein comprise an
IgG.sub.1. In other embodiments, the anti-CD40 antibodies comprise
an IgG.sub.2. In yet other embodiments, the anti-CD40 antibodies
comprise an IgG.sub.4. As used herein, the "constant region" of an
antibody includes the natural constant region, allotypes or natural
variants, such as D356E and L358M, or A431G in human IgG.sub.1.
See, e.g., Jefferis and Lefranc, MAbs, 1(4): 332-338 (July-August
2009).
[0041] The light constant region of an anti-CD40 antibody may be a
kappa (.kappa.) light region or a lambda (.lamda.) region. A
.lamda. light region can be any one of the known subtypes, e.g.,
.lamda..sub.1, .lamda..sub.2, .lamda..sub.3, or .lamda..sub.4. In
some embodiments, the anti-CD40 antibody comprises a kappa
(.kappa.) light region.
[0042] The term "monoclonal antibody" as used herein is not limited
to antibodies produced through hybridoma technology. A monoclonal
antibody is derived from a single clone, including any eukaryotic,
prokaryotic, or phage clone, by any means available or known in the
art. Monoclonal antibodies useful with the present disclosure can
be prepared using a wide variety of techniques known in the art
including the use of hybridoma, recombinant, and phage display
technologies, or a combination thereof. In many uses of the present
disclosure, including in vivo use of the anti-CD40 antibodies in
humans, chimeric, primatized, humanized, or human antibodies can
suitably be used.
[0043] The term "chimeric" antibody as used herein refers to an
antibody having variable sequences derived from a non-human
immunoglobulin, such as a rat or a mouse antibody, and human
immunoglobulin constant regions, typically chosen from a human
immunoglobulin template. Methods for producing chimeric antibodies
are known in the art. See, e.g., Morrison, 1985, Science
229(4719):1202-7; Oi et al., 1986, BioTechniques 4:214-221; Gillies
et al., 1985, J. Immunol. Methods 125:191-202; U.S. Pat. Nos.
5,807,715; 4,816,567; and 4,816,397.
[0044] "Humanized" forms of non-human (e.g., murine) antibodies are
chimeric immunoglobulins that contain minimal sequences derived
from non-human immunoglobulin. In general, a humanized antibody
will comprise substantially all of at least one, and typically two,
variable domains, in which all or substantially all of the CDR
regions correspond to those of a non-human immunoglobulin and all
or substantially all of the FR regions are those of a human
immunoglobulin sequence. The humanized antibody can also comprise
at least a portion of an immunoglobulin constant region (Fc),
typically that of a human immunoglobulin consensus sequence.
Methods of antibody humanization are known in the art. See, e.g.,
Riechmann et al., 1988, Nature 332:323-7; U.S. Pat. Nos. 5,530,101;
5,585,089; 5,693,761; 5,693,762; and U.S. Pat. No. 6,180,370 to
Queen et al.; EP239400; PCT publication WO 91/09967; U.S. Pat. No.
5,225,539; EP592106; EP519596; Padlan, 1991, Mol. Immunol.,
28:489-498; Studnicka et al., 1994, Prot. Eng. 7:805-814; Roguska
et al., 1994, Proc. Natl. Acad. Sci. 91:969-973; and U.S. Pat. No.
5,565,332.
[0045] "Human antibodies" include antibodies having the amino acid
sequence of a human immunoglobulin and include antibodies isolated
from human immunoglobulin libraries or from animals transgenic for
one or more human immunoglobulin and that do not express endogenous
immunoglobulins. Human antibodies can be made by a variety of
methods known in the art including phage display methods using
antibody libraries derived from human immunoglobulin sequences. See
U.S. Pat. Nos. 4,444,887 and 4,716,111; and PCT publications WO
98/46645; WO 98/50433; WO 98/24893; WO 98/16654; WO 96/34096; WO
96/33735; and WO 91/10741. Human antibodies can also be produced
using transgenic mice which are incapable of expressing functional
endogenous immunoglobulins but which can express human
immunoglobulin genes. See, e.g., PCT publications WO 98/24893; WO
92/01047; WO 96/34096; WO 96/33735; U.S. Pat. Nos. 5,413,923;
5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318;
5,885,793; 5,916,771; and 5,939,598. In addition, companies such as
LakePharma, Inc. (Belmont, Calif.) or Creative BioLabs (Shirley,
N.Y.) can be engaged to provide human antibodies directed against a
selected antigen using technology similar to that described above.
Fully human antibodies that recognize a selected epitope can be
generated using a technique referred to as "guided selection." In
this approach, a selected non-human monoclonal antibody, e.g., a
mouse antibody, is used to guide the selection of a completely
human antibody recognizing the same epitope (see, Jespers et al.,
1988, Biotechnology 12:899-903).
[0046] "Primatized antibodies" comprise monkey variable regions and
human constant regions. Methods for producing primatized antibodies
are known in the art. See, e.g., U.S. Pat. Nos. 5,658,570;
5,681,722; and 5,693,780.
[0047] Anti-CD40 antibodies of the disclosure include full-length
(intact) antibody molecules that are capable of specifically
binding CD40, e.g., human CD40 (SEQ ID NO:40).
[0048] Also disclosed are anti-CD40 binding fragments that are
capable of specifically binding human CD40. Examples of antibody
binding fragments include by way of example and not limitation,
Fab, Fab', F(ab').sub.2, Fv fragments, single chain Fv fragments
and single domain fragments.
[0049] A Fab fragment contains the constant and variable domains of
the light chain and the first constant domain (CH1) and the
variable domain of the heavy chain. Fab' fragments differ from Fab
fragments by the addition of a few residues at the carboxyl
terminus of the heavy chain CH1 domain including one or more
cysteines from the antibody hinge region. F(ab') fragments are
produced by cleavage of the disulfide bond at the hinge cysteines
of the F(ab').sub.2 pepsin digestion product. Additional chemical
couplings of antibody fragments are known to those of ordinary
skill in the art. Fab and F(ab').sub.2 fragments lack the Fc
fragment of an intact antibody, clear more rapidly from the
circulation of animals, and may have less non-specific tissue
binding than an intact antibody (see, e.g., Wahl et al., 1983, J.
Nucl. Med. 24:316).
[0050] An "Fv" fragment is the minimum fragment of an antibody that
contains a complete target recognition and binding site. This
region consists of a dimer of one heavy and one light chain
variable domain in a tight, non-covalent association
(V.sub.H-V.sub.L dimer). It is in this configuration that the three
CDRs of each variable domain interact to define a target binding
site on the surface of the V.sub.H-V.sub.L dimer. Often, the six
CDRs confer target binding specificity to the antibody. However, in
some instances even a single variable domain (or half of an Fv
comprising only three CDRs specific for a target) can have the
ability to recognize and bind target, although at a lower affinity
than the entire binding site.
[0051] "Single-chain Fv" or "scFv" antibody binding fragments
comprise the V.sub.H and V.sub.L domains of an antibody, where
these domains are present in a single polypeptide chain. Generally,
the Fv polypeptide further comprises a polypeptide linker between
the V.sub.H and V.sub.L domains which enables the scFv to form the
desired structure for target binding.
[0052] "Single domain fragments" are composed of a single V.sub.H
or V.sub.L domains which exhibit sufficient affinity to human CD40.
In a specific embodiment, the single domain fragment is a camelized
fragment (See, e.g., Riechmann, 1999, Journal of Immunological
Methods 231:25-38).
[0053] The anti-CD40 antibodies of the disclosure include
derivatized antibodies. For example, but not by way of limitation,
derivatized antibodies are typically modified by glycosylation,
acetylation, pegylation, phosphorylation, amidation, derivatization
by known protecting/blocking groups, proteolytic cleavage, linkage
to a cellular ligand or other protein. Any of numerous chemical
modifications can be carried out by known techniques, including,
but not limited to, specific chemical cleavage, acetylation,
formylation, metabolic synthesis of tunicamycin, etc. Additionally,
the derivative can contain one or more non-natural amino acids,
e.g., using Ambryx technology (See, e.g., Wolfson, 2006, Chem.
Biol. 13(10):1011-2).
[0054] The anti-CD40 antibodies or binding fragments may be
antibodies or fragments whose sequences have been modified to alter
at least one constant region-mediated biological effector function.
For example, in some embodiments, an anti-CD40 antibody may be
modified to reduce at least one constant region-mediated biological
effector function relative to the unmodified antibody, e.g.,
reduced binding to one or more of the Fc receptors (Fc.gamma.R)
such as Fc.gamma.RI, Fc.gamma.RIIA, Fc.gamma.RIIB, Fc.gamma.RIIIA
and/or Fc.gamma.RIIIB. Fc.gamma.R binding can be reduced by
mutating the immunoglobulin constant region segment of the antibody
at particular regions necessary for Fc.gamma.R interactions (See,
e.g., Canfield and Morrison, 1991, J. Exp. Med. 173:1483-1491; and
Lund et al., 1991, J. Immunol. 147:2657-2662). Reduction in
Fc.gamma.R binding ability of the antibody can also reduce other
effector functions which rely on Fc.gamma.R interactions, such as
opsonization, phagocytosis and antigen-dependent cellular
cytotoxicity ("ADCC").
[0055] The anti-CD40 antibody or binding fragment described herein
include antibodies that have been modified to acquire or improve at
least one constant region-mediated biological effector function
relative to an unmodified antibody, e.g., to enhance Fc.gamma.R
interactions (See, e.g., US Patent Appl. No. 2006/0134709). For
example, an anti-CD40 antibody of the disclosure can have a
constant region that binds Fc.gamma.RI, Fc.gamma.RIIA,
Fc.gamma.RIIB, Fc.gamma.RIIIA and/or Fc.gamma.RIIIB with greater
affinity than the corresponding wild type constant region.
[0056] Thus, antibodies of the disclosure may have alterations in
biological activity that result in increased or decreased
opsonization, phagocytosis, or ADCC. Such alterations are known in
the art. For example, modifications in antibodies that reduce ADCC
activity are described in U.S. Pat. No. 5,834,597. An exemplary
ADCC lowering variant corresponds to "mutant 3" (also known as
"M3," shown in FIG. 4 of U.S. Pat. No. 5,834,597) in which residues
234 and 237 (using EU numbering) are substituted with alanines. A
mutant 3 (also known as "M3") variation may be used in a number of
antibody isotypes, e.g., IgG.sub.2.
[0057] In some embodiments, the anti-CD40 antibodies of the
disclosure have low levels of, or lack, fucose. Antibodies lacking
fucose have been correlated with enhanced ADCC activity, especially
at low doses of antibody. See Shields et al., 2002, J. Biol. Chem.
277:26733-26740; Shinkawa et al., 2003, J. Biol. Chem. 278:3466-73.
Methods of preparing fucose-less antibodies include growth in rat
myeloma YB2/0 cells (ATCC CRL 1662). YB2/0 cells express low levels
of FUT8 mRNA, which encodes .alpha.-1,6-fucosyltransferase, an
enzyme necessary for fucosylation of polypeptides.
[0058] The anti-CD40 antibodies of the disclosure can comprise
modified (or variant) CH2 domains or entire Fc domains that include
amino acid substitutions that increase binding to Fc.gamma.RIIB
and/or reduced binding to Fc.gamma.RIIIA as compared to the binding
of a corresponding wild-type CH2 or Fc region. Variant CH2 or
variant Fc domains have been described in U.S. Patent Appl. No.
2014/0377253. A variant CH2 or variant Fc domain typically includes
one or more substitutions at position 263, position 266, position
273, and position 305, wherein the numbering of the residues in the
Fc domain is that of the EU index as in Kabat. In some embodiments,
the anti-CD40 antibodies comprise one or more substitutions
selected from V263L, V266L, V273C, V273E, V273F, V273L, V273M,
V273S, V273Y, V305K, and V305W, relative to the wild-type CH2
domain. In specific embodiments, the one or more substitutions of
the CH2 domain are selected from V263L, V273E, V273F, V273M, V273S,
and V273Y, relative to the CH2 domain of a human IgG.sub.1. For
example, the one or more substitutions of an IgG.sub.1 CH2 domain
can be V273E. In another specific embodiment, the anti-CD40
antibody of the disclosure comprises a variant IgG.sub.1 CH2 region
comprising the amino acid substitution V263L.
[0059] Other examples of variant CH2 or variant Fc domains that can
afford increased binding to Fc.gamma.RIIB and/or reduced binding to
Fc.gamma.RIIIA as compared to the binding of a corresponding
wild-type CH2 or Fc region include those found in Vonderheide, et
al. Clin. Cancer Res., 19(5), 1035-1043 (2013), such as S267E or
S267E/L328F in human IgG.sub.1.
[0060] In some embodiments, the anti-CD40 antibodies or binding
fragments include modifications that increase or decrease their
binding affinities to the fetal Fc receptor, FcRn, for example, by
mutating the immunoglobulin constant region segment at particular
regions involved in FcRn interactions (see, e.g., WO 2005/123780).
In particular embodiments, an anti-CD40 antibody of the IgG class
is mutated such that at least one of amino acid residues 250, 314,
and 428 of the heavy chain constant region is substituted alone, or
in any combinations thereof, such as at positions 250 and 428, or
at positions 250 and 314, or at positions 314 and 428, or at
positions 250, 314, and 428, with positions 250 and 428 a specific
combination. For position 250, the substituting amino acid residue
can be any amino acid residue other than threonine, including, but
not limited to, alanine, cysteine, aspartic acid, glutamic acid,
phenylalanine, glycine, histidine, isoleucine, lysine, leucine,
methionine, asparagine, proline, glutamine, arginine, serine,
valine, tryptophan, or tyrosine. For position 314, the substituting
amino acid residue can be any amino acid residue other than
leucine, including, but not limited to, alanine, cysteine, aspartic
acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine,
lysine, methionine, asparagine, proline, glutamine, arginine,
serine, threonine, valine, tryptophan, or tyrosine. For position
428, the substituting amino acid residues can be any amino acid
residue other than methionine, including, but not limited to,
alanine, cysteine, aspartic acid, glutamic acid, phenylalanine,
glycine, histidine, isoleucine, lysine, leucine, asparagine,
proline, glutamine, arginine, serine, threonine, valine,
tryptophan, or tyrosine. An exemplary substitution known to modify
Fc effector function is the Fc substitution M428L, which can occur
in combination with the Fc substitution T250Q. Additional specific
combinations of suitable amino acid substitutions are identified in
Table 1 of U.S. Pat. No. 7,217,797. Such mutations increase binding
to FcRn, which protects the antibody from degradation and increases
its half-life.
[0061] An anti-CD40 antibody may have one or more amino acids
inserted into one or more of its CDRs, for example as described in
Jung and PlUckthun, 1997, Protein Engineering 10:9, 959-966; Yazaki
et al., 2004, Protein Eng. Des Sel. 17(5):481-9. Epub 2004 Aug. 17;
and U.S. Pat. Appl. No. 2007/0280931.
[0062] Anti-CD40 antibodies with affinity for human CD40 may be
desirable for therapeutic and diagnostic uses. Accordingly, the
present disclosure contemplates antibodies having binding affinity
to human CD40. In specific embodiments, the anti-CD40 antibodies
that bind human CD40 with an affinity of at least about 1000 nM,
but may exhibit higher affinity, for example, at least about 900
nM, 800 nM, 700 nM, 600 nM, 500 nM, 400 nM, 300 nM, 250 nM, 200 nM,
150 nM, 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 25
nM, 20 nM, 15 nM, 10 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM,
0.1 nM, 0.01 nM, or even higher. In some embodiments, the
antibodies bind human CD40 with an affinity in the range of about 1
pM to about 1000 nM, or an affinity ranging between any of the
foregoing values.
[0063] Affinity of anti-CD40 antibodies for human CD40 can be
determined using techniques well known in the art or described
herein, such as for example, but not by way of limitation, ELISA,
isothermal titration calorimetry (ITC), surface plasmon resonance,
or fluorescent polarization assay.
[0064] Anti-CD40 antibodies generally comprise a heavy chain
comprising a variable region (V.sub.H) having three complementarity
determining regions ("CDRs") referred to herein (in N.fwdarw.C
order) as V.sub.H CDR #1, V.sub.H CDR #2, and V.sub.H CDR #3, and a
light chain comprising a variable region (V.sub.L) having three
complementarity determining regions referred to herein (in
N.fwdarw.C order) as V.sub.L CDR #1, V.sub.L CDR #2, and V.sub.L
CDR #3. The amino acid sequences of exemplary CDRs, as well as the
amino acid sequence of the V.sub.H and V.sub.L regions of the heavy
and light chains of exemplary anti-CD40 are provided herein.
Specific embodiments of anti-CD40 antibodies include these
exemplary CDRs and/or V.sub.H and/or V.sub.L sequences, as well as
antibodies that compete for binding human CD40 with such
antibodies.
[0065] In some embodiments, the amino acid sequences of the CDRs of
an anti-CD40 antibody are selected from the following
sequences:
TABLE-US-00004 CDR Sequence (N.fwdarw.C) Identifier V.sub.H CDR#1:
GYTFTSYWIT (SEQ ID NO: 1) GYTFTGYWIQ (SEQ ID NO: 2) GYTFTDYYMN (SEQ
ID NO: 3) GFTFSDYYMS (SEQ ID NO: 4) GYSITTNYNWN (SEQ ID NO: 5)
GYTFTSYWMH (SEQ ID NO: 6) GYTFTDYYIN (SEQ ID NO: 7) GYSITSNYYWN
(SEQ ID NO: 8) GYSISSNYYWN (SEQ ID NO: 9) GYDITSNYYWN (SEQ ID NO:
10) V.sub.H CDR#2: EINPGSGSTNYNEKFKS (SEQ ID NO: 11)
EILPGGDHTKYNEKFRG (SEQ ID NO: 12) DINPNNGGTSYNQKFKG (SEQ ID NO: 13)
FIRNKANGYTTEFSASVKG (SEQ ID NO: 14) YIRHDGTNNYNPSLKN (SEQ ID NO:
15) NIDPSNGETHYNQKFKD (SEQ ID NO: 16) WIFPGSGSVYCNEQFKG (SEQ ID NO:
17) YIRYDGSNNYNPSLKN (SEQ ID NO: 18) NIDPSNGETHYAQKFQG (SEQ ID NO:
19) WIFPGSGSVYSNEQFKG (SEQ ID NO: 20) YIRYDGSNNYNPSLKS (SEQ ID NO:
21) YIRYDGSNNYNPSLKG (SEQ ID NO: 22) V.sub.H CDR#3: NRGTGDY (SEQ ID
NO: 31) VGGDY (SEQ ID NO: 32) RGGLGRGTYALDY (SEQ ID NO: 33)
YGGLRQGWYFDV (SEQ ID NO: 34) LDY (SEQ ID NO: 35) ERIYYSGSTYDGYFDV
(SEQ ID NO: 36) SLGKFAY (SEQ ID NO: 37) V.sub.L CDR#1:
RSSQSLVHSYGNTYLH (SEQ ID NO: 51) RSSQSLVNSNENTYLH (SEQ ID NO: 52)
RASQDISNYLN (SEQ ID NO: 53) RASQDIRNYLN (SEQ ID NO: 54)
RSSQSLENSYGNTFLN (SEQ ID NO: 55) SASSSLSYMH (SEQ ID NO: 56)
KASQSVVTAVA (SEQ ID NO: 57) RSSQSLENTNGNTFLN (SEQ ID NO: 58)
RSSQSLENSNGNTFLN (SEQ ID NO: 59) V.sub.L CDR#2: KVSNRIS (SEQ ID NO:
61) KVFNRYS (SEQ ID NO: 62) YTSRLHL (SEQ ID NO: 63) YTSRLHS (SEQ ID
NO: 64) RVSNRFC (SEQ ID NO: 65) DTSKLAS (SEQ ID NO: 66) SASNRYT
(SEQ ID NO: 67) RVSNRFS (SEQ ID NO: 68) RISNRFS (SEQ ID NO: 69)
V.sub.L CDR#3: SQSTHVPYT (SEQ ID NO: 81) FQSTHVPWT (SEQ ID NO: 82)
QQGNTLPLT (SEQ ID NO: 83) QQGKTLPWT (SEQ ID NO: 84) LQVTHVPYT (SEQ
ID NO: 85) QQWSSNPWT (SEQ ID NO: 86) QQYSSYPYT (SEQ ID NO: 87)
LQVTHVPFT (SEQ ID NO: 88)
[0066] In some embodiments, each CDR of an anti-CD40 antibody,
independently of the others, is selected to correspond in sequence
to the respective CDR of an antibody provided in TABLE 3. In some
embodiments, an anti-CD40 antibody is an IgG, and has a V.sub.H and
V.sub.L corresponding in sequence to the V.sub.H and V.sub.L of an
antibody provided in TABLE 3.
[0067] In some embodiments, an anti-CD40 antibody comprises a
V.sub.H chain corresponding in sequence to any one of SEQ ID
NOS:101, 102, 103, 104, 105, 106, 107, 108, or 109; and a V.sub.L
chain corresponding in sequence to any one of SEQ ID NOS:151, 152,
153, 154, 155, 156, 157, 158, 159, or 160. In some embodiments, an
anti-CD40 antibody comprises a V.sub.H chain corresponding in
sequence to SEQ ID NO:101 and a V.sub.L chain corresponding in
sequence to SEQ ID NO:151. In some embodiments, an anti-CD40
antibody comprises a V.sub.H chain corresponding in sequence to SEQ
ID NO:102 and a V.sub.L chain corresponding in sequence to SEQ ID
NO:152. In some embodiments, an anti-CD40 antibody comprises a
V.sub.H chain corresponding in sequence to SEQ ID NO:103 and a
V.sub.L chain corresponding in sequence to SEQ ID NO:153. In some
embodiments, an anti-CD40 antibody comprises a V.sub.H chain
corresponding in sequence to SEQ ID NO:104 and a V.sub.L chain
corresponding in sequence to SEQ ID NO:154. In some embodiments, an
anti-CD40 antibody comprises a V.sub.H chain corresponding in
sequence to SEQ ID NO:105 and a V.sub.L chain corresponding in
sequence to SEQ ID NO:155. In some embodiments, an anti-CD40
antibody comprises a V.sub.H chain corresponding in sequence to SEQ
ID NO:106 and a V.sub.L chain corresponding in sequence to SEQ ID
NO:156. In some embodiments, an anti-CD40 antibody and comprises a
V.sub.H chain corresponding in sequence to SEQ ID NO:106 and a
V.sub.L chain corresponding in sequence to SEQ ID NO:157. In some
embodiments, an anti-CD40 antibody and comprises a V.sub.H chain
corresponding in sequence to SEQ ID NO:107 and a V.sub.L chain
corresponding in sequence to SEQ ID NO:158. In some embodiments, an
anti-CD40 antibody and comprises a V.sub.H chain corresponding in
sequence to SEQ ID NO:108 and a V.sub.L chain corresponding in
sequence to SEQ ID NO:159. In some embodiments, an anti-CD40
antibody comprises a V.sub.H chain corresponding in sequence to SEQ
ID NO:109 and a V.sub.L chain corresponding in sequence to SEQ ID
NO:160.
[0068] Specific exemplary embodiments of anti-CD40 antibodies with
the above CDRs are described herein. In some embodiments, an
anti-CD40 antibody has the CDRs of SEQ ID NOS: 1, 11, 31, 51, 61,
and 81. In some embodiments, an anti-CD40 antibody has the CDRs of
SEQ ID NOS: 2, 12, 32, 52, 62, and 82. In some embodiments, an
anti-CD40 antibody has the CDRs of SEQ ID NOS: 3, 13, 33, 53, 63,
and 83. In some embodiments, an anti-CD40 antibody has the CDRs of
SEQ ID NOS: 4, 14, 34, 54, 64, and 84. In some embodiments, an
anti-CD40 antibody has the CDRs of SEQ ID NOS: 5, 15, 35, 55, 65,
and 85. In some embodiments, an anti-CD40 antibody has the CDRs of
SEQ ID NOS: 6, 16, 36, 56, 66, and 86. In some embodiments, an
anti-CD40 antibody has the CDRs of SEQ ID NOS: 6, 19, 36, 56, 66,
and 86. In some embodiments, an anti-CD40 antibody has the CDRs of
SEQ ID NOS: 7, 17, 37, 57, 67, and 87. In some embodiments, an
anti-CD40 antibody has the CDRs of SEQ ID NOS: 7, 20, 37, 57, 67,
and 87. In some embodiments, an anti-CD40 antibody has the CDRs of
SEQ ID NOS: 8, 18, 35, 58, 68, and 88. In some embodiments, an
anti-CD40 antibody has the CDRs of SEQ ID NOS: 9, 21, 35, 58, 68,
and 88. In some embodiments, an anti-CD40 antibody has the CDRs of
SEQ ID NOS: 10, 22, 35, 58, 68, and 88.
[0069] In some embodiments, an anti-CD40 antibody is suitable for
administration to humans. In a specific embodiment, the anti-CD40
antibody is humanized. In another specific embodiment, the amino
acid sequences of the CDRs of the anti-CD40 antibody are selected
from:
TABLE-US-00005 CDR Sequence (N.fwdarw.C) Identifier V.sub.H CDR#1:
GYTFTSYWMH (SEQ ID NO: 6) GYTFTDYYIN (SEQ ID NO: 7) GYSITSNYYWN
(SEQ ID NO: 8) GYSISSNYYWN (SEQ ID NO: 9) GYDITSNYYWN (SEQ ID NO:
10) V.sub.H CDR#2: WIFPGSGSVYCNEQFKG (SEQ ID NO: 17)
YIRYDGSNNYNPSLKN (SEQ ID NO: 18) NIDPSNGETHYAQKFQG (SEQ ID NO: 19)
WIFPGSGSVYSNEQFKG (SEQ ID NO: 20) YIRYDGSNNYNPSLKS (SEQ ID NO: 21)
YIRYDGSNNYNPSLKG (SEQ ID NO: 22) V.sub.H CDR#3: LDY (SEQ ID NO: 35)
ERIYYSGSTYDGYFDV (SEQ ID NO: 36) SLGKFAY (SEQ ID NO: 37) V.sub.L
CDR#1: SASSSLSYMH (SEQ ID NO: 56) KASQSVVTAVA (SEQ ID NO: 57)
RSSQSLENTNGNTFLN (SEQ ID NO: 58) V.sub.L CDR#2: DTSKLAS (SEQ ID NO:
66) SASNRYT (SEQ ID NO: 67) RVSNRFS (SEQ ID NO: 68) V.sub.L CDR#3:
QQWSSNPWT (SEQ ID NO: 86) QQYSSYPYT (SEQ ID NO: 87) LQVTHVPFT (SEQ
ID NO: 88)
[0070] In some embodiments, an anti-CD40 antibody comprises a
V.sub.H chain corresponding in sequence to any one of SEQ ID
NOS:110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121,
122, or 123; and a V.sub.L chain corresponding in sequence to any
one of SEQ ID NOS:161, 162, 163, 164, 165, 166, 167, 168, 169, 170,
or 171. In some embodiments, an anti-CD40 antibody comprises a
V.sub.H chain corresponding in sequence to SEQ ID NO:110 and a
V.sub.L chain corresponding in sequence to SEQ ID NO:161. In some
embodiments, an anti-CD40 antibody comprises a V.sub.H chain
corresponding in sequence to SEQ ID NO:111 and a V.sub.L chain
corresponding in sequence to SEQ ID NO:161. In some embodiments, an
anti-CD40 antibody comprises a V.sub.H chain corresponding in
sequence to SEQ ID NO:112 and a V.sub.L chain corresponding in
sequence to SEQ ID NO:161. In some embodiments, an anti-CD40
antibody comprises a V.sub.H chain corresponding in sequence to SEQ
ID NO:113 and a V.sub.L chain corresponding in sequence to SEQ ID
NO:162. In some embodiments, an anti-CD40 antibody comprises a
V.sub.H chain corresponding in sequence to SEQ ID NO:114 and a
V.sub.L chain corresponding in sequence to SEQ ID NO:162. In some
embodiments, an anti-CD40 antibody comprises a V.sub.H chain
corresponding in sequence to SEQ ID NO:115 and a V.sub.L chain
corresponding in sequence to SEQ ID NO:162. In some embodiments, an
anti-CD40 antibody comprises a V.sub.H chain corresponding in
sequence to SEQ ID NO:116 and a V.sub.L chain corresponding in
sequence to SEQ ID NO:163. In some embodiments, an anti-CD40
antibody comprises a V.sub.H chain corresponding in sequence to SEQ
ID NO:117 and a V.sub.L chain corresponding in sequence to SEQ ID
NO:163. In some embodiments, an anti-CD40 antibody comprises a
V.sub.H chain corresponding in sequence to SEQ ID NO:118 and a
V.sub.L chain corresponding in sequence to SEQ ID NO:163. In some
embodiments, an anti-CD40 antibody comprises a V.sub.H chain
corresponding in sequence to SEQ ID NO:116 and a V.sub.L chain
corresponding in sequence to SEQ ID NO:164. In some embodiments, an
anti-CD40 antibody comprises a V.sub.H chain corresponding in
sequence to SEQ ID NO:117 and a V.sub.L chain corresponding in
sequence to SEQ ID NO:164. In some embodiments, an anti-CD40
antibody comprises a V.sub.H chain corresponding in sequence to SEQ
ID NO:119 and a V.sub.L chain corresponding in sequence to SEQ ID
NO:165. In some embodiments, an anti-CD40 antibody comprises a
V.sub.H chain corresponding in sequence to SEQ ID NO:120 and a
V.sub.L chain corresponding in sequence to SEQ ID NO:165. In some
embodiments, an anti-CD40 antibody comprises a V.sub.H chain
corresponding in sequence to SEQ ID NO:121 and a V.sub.L chain
corresponding in sequence to SEQ ID NO:166. In some embodiments, an
anti-CD40 antibody comprises a V.sub.H chain corresponding in
sequence to SEQ ID NO:117 and a V.sub.L chain corresponding in
sequence to SEQ ID NO:167. In some embodiments, an anti-CD40
antibody comprises a V.sub.H chain corresponding in sequence to SEQ
ID NO:117 and a V.sub.L chain corresponding in sequence to SEQ ID
NO:168. In some embodiments, an anti-CD40 antibody comprises a
V.sub.H chain corresponding in sequence to SEQ ID NO:117 and a
V.sub.L chain corresponding in sequence to SEQ ID NO:169. In some
embodiments, an anti-CD40 antibody comprises a V.sub.H chain
corresponding in sequence to SEQ ID NO:117 and a V.sub.L chain
corresponding in sequence to SEQ ID NO:170. In some embodiments, an
anti-CD40 antibody comprises a V.sub.H chain corresponding in
sequence to SEQ ID NO:117 and a V.sub.L chain corresponding in
sequence to SEQ ID NO:171. In some embodiments, an anti-CD40
antibody comprises a V.sub.H chain corresponding in sequence to SEQ
ID NO:118 and a V.sub.L chain corresponding in sequence to SEQ ID
NO:164. In some embodiments, an anti-CD40 antibody comprises a
V.sub.H chain corresponding in sequence to SEQ ID NO:122 and a
V.sub.L chain corresponding in sequence to SEQ ID NO:167. In some
embodiments, an anti-CD40 antibody comprises a V.sub.H chain
corresponding in sequence to SEQ ID NO:122 and a V.sub.L chain
corresponding in sequence to SEQ ID NO:168. In some embodiments, an
anti-CD40 antibody comprises a V.sub.H chain corresponding in
sequence to SEQ ID NO:123 and a V.sub.L chain corresponding in
sequence to SEQ ID NO:169.
[0071] In some embodiments, the anti-CD40 antibodies compete for
binding human CD40 in in vitro assays with a reference antibody. In
some embodiments, the anti-CD40 antibodies compete for binding
human CD40 on cells expressing human CD40. The reference antibody
may be any of the anti-CD40 antibodies described herein. In some
embodiments, the reference antibody is an antibody provided in
TABLE 3. In specific embodiments, the reference antibody is
selected from antibody AD163.9.3 ("muAb1"); antibody AD166.4.4
("muAb2"); antibody AD175.14.11 ("muAb3"); antibody AD163.10.7
("muAb4"); antibody AD165.1.2 ("muAb5"); antibody AD163.162.1
("muAb6"); antibody AD163.27.12 ("muAb7"); antibody AD163.7.2
("muAb8"); antibody AD164.14.6 ("muAb9"); and antibody AD164.76.2
("muAb10"). In some embodiments, the reference antibody is a
humanized version of an antibody provided in TABLE 3. In some
embodiments, the reference antibody is a humanized version of
muAb6, muAb8, or muAb9. In a specific embodiment, the reference
antibody is huAb9-2. In another embodiment, the reference antibody
is huAb9-5. In another specific embodiment, the reference antibody
is huAb9 A2I.
[0072] Post-translational modifications to the sequences of an
anti-CD40 antibody may occur, such as cleavage of one or more
(e.g., 1, 2, 3, or more) amino acid residues on the C-terminal end
of the antibody heavy chain.
[0073] In some embodiments, an anti-CD40 antibody comprises a heavy
chain according to any one of SEQ ID NOS: 130-135, and a light
chain according to SEQ ID NOS: 140-142. In certain embodiments, an
anti-CD40 antibody comprises a heavy chain according to SEQ ID NOS:
130 or 131, and a light chain according to SEQ ID NO: 140. In
certain embodiments, an anti-CD40 antibody comprises a heavy chain
according to SEQ ID NOS: 132 or 133, and a light chain according to
SEQ ID NO: 140. In certain embodiments, an anti-CD40 antibody
comprises a heavy chain according to SEQ ID NOS: 134 or 135, and a
light chain according to SEQ ID NO: 140. In certain embodiments, an
anti-CD40 antibody comprises a heavy chain according to SEQ ID NOS:
132 or 133, and a light chain according to SEQ ID NO: 141. In
certain embodiments, an anti-CD40 antibody comprises a heavy chain
according to SEQ ID NOS: 132 or 133, and a light chain according to
SEQ ID NO: 142.
[0074] The anti-CD40 antibodies described herein generally bind
specifically to human CD40. Cross reactivity of the antibodies for
binding to CD40 from other species, for example, from monkey, e.g.,
cynomolgus monkey, may offer advantages, such as the ability to
test in monkey animal models for biological activity. Such animal
model testing may be used to screen anti-CD40 antibodies to select
for properties, e.g., favorable pharmacokinetics. In some
embodiments, the anti-CD40 antibodies bind to cynomolgus CD40.
[0075] Assays for competition include, but are not limited to, a
radioactive material labeled immunoassay (RIA), an enzyme-linked
immunosorbent assay (ELISA), a sandwich ELISA, fluorescence
activated cell sorting (FACS) assays, and surface plasmon resonance
assays.
[0076] In conducting an antibody competition assay between a
reference antibody and a test antibody (irrespective of species or
isotype), one may first label the reference with a detectable
label, such as a fluorophore, biotin or an enzymatic (or even
radioactive) label to enable subsequent identification. In this
case, cells expressing human CD40 are incubated with unlabeled test
antibody, labeled reference antibody is added, and the intensity of
the bound label is measured. If the test antibody competes with the
labeled reference antibody by binding to an overlapping epitope,
the intensity will be decreased relative to a control reaction
carried out without test antibody.
[0077] In a specific embodiment of this assay, the concentration of
labeled reference antibody that yields 80% of maximal binding
("conc.sub.80%") under the assay conditions (e.g., a specified
density of cells) is first determined, and a competition assay
carried out with 10.times. conc.sub.80% of unlabeled test antibody
and conc.sub.80% of labeled reference antibody.
[0078] The inhibition can be expressed as an inhibition constant,
or K.sub.i, which is calculated according to the following
formula:
K.sub.i=IC.sub.50/(1+[reference Ab concentration]/K.sub.d),
[0079] where IC.sub.50 is the concentration of test antibody that
yields a 50% reduction in binding of the reference antibody and
K.sub.d is the dissociation constant of the reference antibody, a
measure of its affinity for human CD40. Antibodies that compete
with anti-CD40 antibodies disclosed herein can have a K.sub.i from
10 pM to 1000 nM under assay conditions described herein.
[0080] In various embodiments, a test antibody is considered to
compete with a reference antibody if it decreases binding of the
reference antibody by at least about 20% or more, for example, by
at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or even
more, or by a percentage ranging between any of the foregoing
values, at a reference antibody concentration that is 80% of
maximal binding under the specific assay conditions used, and a
test antibody concentration that is 10-fold higher than the
reference antibody concentration.
[0081] The anti-CD40 antibodies described herein are capable of
agonizing human CD40 (SEQ ID NO:40) by activating human CD40 via at
least two mechanisms of action. In some embodiments, an anti-CD40
antibody binds human CD40 in the absence of CD40L (SEQ ID NO:41),
and enhances the signaling of human CD40. In some embodiments, an
anti-CD40 antibody binds the human CD40L-CD40 bound complex, and
enhances the signaling of human CD40. In some embodiments, an
anti-CD40 antibody competes for binding human CD40 (SEQ ID NO:40)
with a control antibody selected from a humanized antibody listed
in TABLE 3, and activates human CD40 independent of human CD40
ligand (SEQ ID NO:41), i.e., in the absence or presence of
CD40L.
[0082] The effect of the anti-CD40 antibodies on human CD40-CD40L
interaction can be determined by assays known in the art, such as
the CD40L competitive assay described in Example 2. A ratio of an
OD450 measured in samples containing anti-CD40 antibodies to an
OD.sub.450 taken from isotype control antibody samples (an
"OD.sub.450 ratio") can be used to determine the effect of an
anti-CD40 antibody on human CD40L binding to human CD40. A
OD.sub.450 ratio of 1 indicates no effect; less than 1 indicates
competition with CD40L; greater than 1 indicates an enhancement of
CD40L binding with CD40. In some embodiments, the anti-CD40
antibody increases (i.e., enhances) binding of human CD40L (SEQ ID
NO:41) to human CD40 (SEQ ID NO:40) as determined by OD.sub.450
ratio. An enhancement of CD40L binding to CD40 by OD.sub.450 ratio
is at least about 1.2, such as about 1.3, 1.4, 1.5, 1.6, 1.7, 1.8,
1.9, 2.0, 2.2, 2.4, 2.5, 2.6, 2.8, 3.0 or greater.
[0083] A specific assay and assay conditions useful for assessing
whether an antibody competes for binding human CD40 with a
reference antibody as described herein is provided in Example 2.
Antibody competition can be determined by a surface plasmon
resonance assay as described in Example 2, or in competitive
binding protocol described in Section 8.4.3.
[0084] While an agonistic anti-CD40 antibody activates the immune
system to exert an antitumor effect, broad systemic immune
activation across all cell types may lead to undesired side
effects. Accordingly, in some embodiments, an anti-CD40 antibody
activates a dendritic cell-mediated immune response selectively
over a B-cell immune response as compared to a reference anti-CD40
antibody. In some embodiments, the reference anti-CD40 antibody is
CP-870,893. In some embodiments, an anti-CD40 antibody has a
similar activity, e.g., a production of IL-12p70 at a given dose,
within about 200%, such as within about 180%, 150%, 130%, 110%,
100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, or
about 5%, in activating a dendritic cell as compared to the
production of IL-12p70 at the same dose of a reference anti-CD40
antibody in the assay described in Section 8.1.3. In some
embodiments, an anti-CD40 antibody has a lower potency in
activating a B cell as compared to a reference anti-CD40 antibody.
The B cell EC50 ratio of the anti-CD40 antibody to the reference
anti-CD40 antibody can be greater than about 1.5, such as about 2,
3, 4, 5, 6, 8, 10, 15, 20, 30, 40, 50 or greater, in the assay
described in Section 8.5.3. In some embodiments, an anti-CD40
antibody has a similar activity in activating a dendritic cell and
a lower potency in activating a B cell as compared to a reference
anti-CD40 antibody.
7.4. Polynucleotides Encoding the Anti-CD40 Antibodies, Expression
Systems and Methods of Making the Antibodies
[0085] The present disclosure encompasses nucleic acid molecules
encoding immunoglobulin light and heavy chain genes for anti-CD40
antibodies, vectors comprising such nucleic acids, and host cells
capable of producing the anti-CD40 antibodies of the
disclosure.
[0086] An anti-CD40 antibody of the disclosure can be prepared by
recombinant expression of immunoglobulin light and heavy chain
genes in a host cell. To express an antibody recombinantly, a host
cell is transfected with one or more recombinant expression vectors
carrying DNA fragments encoding the immunoglobulin light and heavy
chains of the antibody such that the light and heavy chains are
expressed in the host cell and, optionally, secreted into the
medium in which the host cells are cultured, from which medium the
antibodies can be recovered. Standard recombinant DNA methodologies
are used to obtain antibody heavy and light chain genes,
incorporate these genes into recombinant expression vectors and
introduce the vectors into host cells, such as those described in
Molecular Cloning; A Laboratory Manual, Second Edition (Sambrook,
Fritsch and Maniatis (eds), Cold Spring Harbor, N.Y., 1989),
Current Protocols in Molecular Biology (Ausubel, F. M. et al.,
eds., Greene Publishing Associates, 1989) and in U.S. Pat. No.
4,816,397.
[0087] To generate nucleic acids encoding such anti-CD40
antibodies, DNA fragments encoding the light and heavy chain
variable regions are first obtained. These DNAs can be obtained by
amplification and modification of germline DNA or cDNA encoding
light and heavy chain variable sequences, for example using the
polymerase chain reaction (PCR). Germline DNA sequences for human
heavy and light chain variable region genes are known in the art
(See, e.g., the "VBASE" human germline sequence database; see also
Kabat, E. A. et al., 1991, Sequences of Proteins of Immunological
Interest, Fifth Edition, U.S. Department of Health and Human
Services, NIH Publication No. 91-3242; Tomlinson et al., 1992, J.
Mol. Biol. 22T:116-198; and Cox et al., 1994, Eur. J. Immunol.
24:827-836; the contents of each of which are incorporated herein
by reference).
[0088] Once DNA fragments encoding anti-CD40 antibody-related
V.sub.H and V.sub.L segments are obtained, these DNA fragments can
be further manipulated by standard recombinant DNA techniques, for
example to convert the variable region genes to full-length
antibody chain genes, to Fab fragment genes or to a scFv gene. In
these manipulations, a V.sub.L- or V.sub.H-encoding DNA fragment is
operatively linked to another DNA fragment encoding another
protein, such as an antibody constant region or a flexible linker.
The term "operatively linked," as used in this context, is intended
to mean that the two DNA fragments are joined such that the amino
acid sequences encoded by the two DNA fragments remain
in-frame.
[0089] The isolated DNA encoding the V.sub.H region can be
converted to a full-length heavy chain gene by operatively linking
the V.sub.H-encoding DNA to another DNA molecule encoding heavy
chain constant regions (CH1, CH2, CH3 and, optionally, CH4). The
sequences of human heavy chain constant region genes are known in
the art (See, e.g., Kabat, E. A., et al., 1991, Sequences of
Proteins of Immunological Interest, Fifth Edition, U.S. Department
of Health and Human Services, NIH Publication No. 91-3242) and DNA
fragments encompassing these regions can be obtained by standard
PCR amplification. The heavy chain constant region can be an
IgG.sub.1, IgG.sub.2, IgG.sub.3, IgG.sub.4, IgA, IgE, IgM or IgD
constant region, but in certain embodiments is an IgG.sub.1 or
IgG.sub.4. For a Fab fragment heavy chain gene, the
V.sub.H-encoding DNA can be operatively linked to another DNA
molecule encoding only the heavy chain CH1 constant region.
[0090] The isolated DNA encoding the V.sub.L region can be
converted to a full-length light chain gene (as well as a Fab light
chain gene) by operatively linking the V.sub.L-encoding DNA to
another DNA molecule encoding the light chain constant region, CL.
The sequences of human light chain constant region genes are known
in the art (See, e.g., Kabat, et al., 1991, Sequences of Proteins
of Immunological Interest, Fifth Edition, U.S. Department of Health
and Human Services, NIH Publication No. 91-3242) and DNA fragments
encompassing these regions can be obtained by standard PCR
amplification. The light chain constant region can be a kappa or
lambda constant region, but in certain embodiments is a kappa
constant region. To create a scFv gene, the V.sub.H- and
V.sub.L-encoding DNA fragments are operatively linked to another
fragment encoding a flexible linker, e.g., encoding the amino acid
sequence (Gly.sub.4.about.Ser).sub.3 (SEQ ID NO:200), such that the
V.sub.H and V.sub.L sequences can be expressed as a contiguous
single-chain protein, with the V.sub.L and V.sub.H regions joined
by the flexible linker (See, e.g., Bird et al., 1988, Science
242:423-426; Huston et al., 1988, Proc. Natl. Acad. Sci. USA
85:5879-5883; McCafferty et al., 1990, Nature 348:552-554).
[0091] To express the anti-CD40 antibodies of the disclosure, DNAs
encoding partial or full-length light and heavy chains, obtained as
described above, are inserted into expression vectors such that the
genes are operatively linked to transcriptional and translational
control sequences. In this context, the term "operatively linked"
is intended to mean that an antibody gene is ligated into a vector
such that transcriptional and translational control sequences
within the vector serve their intended function of regulating the
transcription and translation of the antibody gene. The expression
vector and expression control sequences are chosen to be compatible
with the expression host cell used. The antibody light chain gene
and the antibody heavy chain gene can be inserted into separate
vectors or, more typically, both genes are inserted into the same
expression vector.
[0092] The antibody genes are inserted into the expression vector
by standard methods (e.g., ligation of complementary restriction
sites on the antibody gene fragment and vector, or blunt end
ligation if no restriction sites are present). Prior to insertion
of the anti-CD40 antibody-related light or heavy chain sequences,
the expression vector can already carry antibody constant region
sequences. For example, one approach to converting the anti-CD40
monoclonal antibody-related V.sub.H and V.sub.L sequences to
full-length antibody genes is to insert them into expression
vectors already encoding heavy chain constant and light chain
constant regions, respectively, such that the V.sub.H segment is
operatively linked to the CH segment(s) within the vector and the
V.sub.L segment is operatively linked to the CL segment within the
vector. Additionally or alternatively, the recombinant expression
vector can encode a signal peptide that facilitates secretion of
the antibody chain from a host cell. The antibody chain gene can be
cloned into the vector such that the signal peptide is linked
in-frame to the amino terminus of the antibody chain gene. The
signal peptide can be an immunoglobulin signal peptide or a
heterologous signal peptide (i.e., a signal peptide from a
non-immunoglobulin protein).
[0093] In addition to the antibody chain genes, the recombinant
expression vectors of the disclosure carry regulatory sequences
that control the expression of the antibody chain genes in a host
cell. The term "regulatory sequence" is intended to include
promoters, enhancers and other expression control elements (e.g.,
polyadenylation signals) that control the transcription or
translation of the antibody chain genes. Such regulatory sequences
are described, for example, in Goeddel, Gene Expression Technology:
Methods in Enzymology 185, Academic Press, San Diego, Calif., 1990.
It will be appreciated by those skilled in the art that the design
of the expression vector, including the selection of regulatory
sequences may depend on such factors as the choice of the host cell
to be transformed, the level of expression of protein desired, etc.
Suitable regulatory sequences for mammalian host cell expression
include viral elements that direct high levels of protein
expression in mammalian cells, such as promoters and/or enhancers
derived from cytomegalovirus (CMV) (such as the CMV
promoter/enhancer), Simian Virus 40 (SV40) (such as the SV40
promoter/enhancer), adenovirus, (e.g., the adenovirus major late
promoter (AdMLP)) and polyoma. For further description of viral
regulatory elements, and sequences thereof, see, e.g., U.S. Pat.
No. 5,168,062 by Stinski, U.S. Pat. No. 4,510,245 by Bell et al.,
and U.S. Pat. No. 4,968,615 by Schaffner et al.
[0094] In addition to the antibody chain genes and regulatory
sequences, the recombinant expression vectors of the disclosure can
carry additional sequences, such as sequences that regulate
replication of the vector in host cells (e.g., origins of
replication) and selectable marker genes. The selectable marker
gene facilitates selection of host cells into which the vector has
been introduced (See, e.g., U.S. Pat. Nos. 4,399,216, 4,634,665 and
5,179,017, all by Axel et al.). For example, typically the
selectable marker gene confers resistance to drugs, such as G418,
hygromycin or methotrexate, on a host cell into which the vector
has been introduced. Suitable selectable marker genes include the
dihydrofolate reductase (DHFR) gene (for use in DHFR.sup.- host
cells with methotrexate selection/amplification) and the neo gene
(for G418 selection). For expression of the light and heavy chains,
the expression vector(s) encoding the heavy and light chains is
transfected into a host cell by standard techniques. The various
forms of the term "transfection" are intended to encompass a wide
variety of techniques commonly used for the introduction of
exogenous DNA into a prokaryotic or eukaryotic host cell, e.g.,
electroporation, lipofection, calcium-phosphate precipitation,
DEAE-dextran transfection and the like.
[0095] It is possible to express the antibodies of the disclosure
in either prokaryotic or eukaryotic host cells. In certain
embodiments, expression of antibodies is performed in eukaryotic
cells, e.g., mammalian host cells, of optimal secretion of a
properly folded and immunologically active antibody. Exemplary
mammalian host cells for expressing the recombinant antibodies of
the disclosure include Chinese Hamster Ovary (CHO cells) (including
DHFR.sup.- CHO cells, described in Urlaub and Chasin, 1980, Proc.
Natl. Acad. Sci. USA 77:4216-4220, used with a DHFR selectable
marker, e.g., as described in Kaufman and Sharp, 1982, Mol. Biol.
159:601-621), NSO myeloma cells, COS cells and SP2 cells. When
recombinant expression vectors encoding antibody genes are
introduced into mammalian host cells, the antibodies are produced
by culturing the host cells for a period of time sufficient to
allow for expression of the antibody in the host cells or secretion
of the antibody into the culture medium in which the host cells are
grown. Antibodies can be recovered from the culture medium using
standard protein purification methods. Host cells can also be used
to produce portions of intact antibodies, such as Fab fragments or
scFv molecules. It is understood that variations on the above
procedure are within the scope of the present disclosure. For
example, it can be desirable to transfect a host cell with DNA
encoding either the light chain or the heavy chain (but not both)
of an anti-CD40 antibody of this disclosure.
[0096] Recombinant DNA technology can also be used to remove some
or all of the DNA encoding either or both of the light and heavy
chains that is not necessary for binding to human CD40. The
molecules expressed from such truncated DNA molecules are also
encompassed by the antibodies of the disclosure.
[0097] For recombinant expression of an anti-CD40 antibody of the
disclosure, the host cell can be co-transfected with two expression
vectors of the disclosure, the first vector encoding a heavy chain
derived polypeptide and the second vector encoding a light chain
derived polypeptide. The two vectors can contain identical
selectable markers, or they can each contain a separate selectable
marker. Alternatively, a single vector can be used which encodes
both heavy and light chain polypeptides.
[0098] Once a nucleic acid encoding one or more portions of an
anti-CD40 antibody, further alterations or mutations can be
introduced into the coding sequence, for example to generate
nucleic acids encoding antibodies with different CDR sequences,
antibodies with reduced affinity to the Fc receptor, or antibodies
of different subclasses.
[0099] The anti-CD40 antibodies of the disclosure can also be
produced by chemical synthesis (e.g., by the methods described in
Solid Phase Peptide Synthesis, 2.sup.nd ed., 1984 The Pierce
Chemical Co., Rockford, Ill.). Variant antibodies can also be
generated using a cell-free platform (See, e.g., Chu et al.,
Biochemia No. 2, 2001 (Roche Molecular Biologicals) and Murray et
al., 2013, Current Opinion in Chemical Biology, 17:420-426).
[0100] Once an anti-CD40 antibody of the disclosure has been
produced by recombinant expression, it can be purified by any
method known in the art for purification of an immunoglobulin
molecule, for example, by chromatography (e.g., ion exchange,
affinity, and sizing column chromatography), centrifugation,
differential solubility, or by any other standard technique for the
purification of proteins. Further, the anti-CD40 antibodies of the
present disclosure can be fused to heterologous polypeptide
sequences described herein or otherwise known in the art to
facilitate purification.
[0101] Once isolated, the anti-CD40 antibody can, if desired, be
further purified, e.g., by high performance liquid chromatography
(see, e.g., Fisher, Laboratory Techniques In Biochemistry And
Molecular Biology, Work and Burdon, eds., Elsevier, 1980), or by
gel filtration chromatography on a Superdex.TM. 75 column
(Pharmacia Biotech AB, Uppsala, Sweden).
7.5. Pharmaceutical Compositions
[0102] The anti-CD40 antibodies described herein may be in the form
of compositions comprising the antibody and one or more carriers,
excipients and/or diluents. The compositions may be formulated for
specific uses, such as for veterinary uses or pharmaceutical uses
in humans. The form of the composition (e.g., dry powder, liquid
formulation, etc.) and the excipients, diluents and/or carriers
used will depend upon the intended uses of the antibody and, for
therapeutic uses, the mode of administration.
[0103] For therapeutic uses, the compositions may be supplied as
part of a sterile, pharmaceutical composition that includes a
pharmaceutically acceptable carrier. This composition can be in any
suitable form (depending upon the desired method of administering
it to a subject, e.g., a human subject, i.e., patient). The
pharmaceutical composition can be administered to a subject by a
variety of routes such as orally, transdermally, subcutaneously,
intranasally, intravenously, intramuscularly, intratumorally,
intrathecally, topically or locally. The most suitable route for
administration in any given case will depend on the particular
antibody, the subject, and the nature and severity of the disease
and the physical condition of the subject. Typically, the
pharmaceutical composition will be administered intravenously or
subcutaneously.
[0104] Pharmaceutical compositions can be conveniently presented in
unit dosage forms containing a predetermined amount of an anti-CD40
antibody described herein per dose. The quantity of anti-CD40
antibody included in a unit dose will depend on the disease being
treated, as well as other factors as are well known in the art.
Such unit dosages may be in the form of a lyophilized dry powder
containing an amount of antibody suitable for a single
administration, or in the form of a liquid. Dry powder unit dosage
forms may be packaged in a kit with a syringe, a suitable quantity
of diluent and/or other components useful for administration. Unit
dosages in liquid form may be conveniently supplied in the form of
a syringe pre-filled with a quantity of the anti-CD40 antibody
suitable for a single administration.
[0105] The pharmaceutical compositions may also be supplied in bulk
form containing quantities of anti-CD40 antibody suitable for
multiple administrations.
[0106] Pharmaceutical compositions may be prepared for storage as
lyophilized formulations or aqueous solutions by mixing an antibody
having the desired degree of purity with optional
pharmaceutically-acceptable carriers, excipients or stabilizers
typically employed in the art (all of which are referred to herein
as "carriers"), i.e., buffering agents, stabilizing agents,
preservatives, isotonifiers, non-ionic detergents, antioxidants,
and other miscellaneous additives. See, Remington's Pharmaceutical
Sciences, 16th edition (Osol, ed. 1980). Such additives should be
nontoxic to the recipients at the dosages and concentrations
employed.
[0107] Buffering agents help to maintain the pH in the range which
approximates physiological conditions. They may be present at a
wide variety of concentrations, but will typically be present in
concentrations ranging from about 2 mM to about 50 mM. Suitable
buffering agents for use with the present disclosure include both
organic and inorganic acids and salts thereof such as citrate
buffers (e.g., monosodium citrate-disodium citrate mixture, citric
acid-trisodium citrate mixture, citric acid-monosodium citrate
mixture, etc.), succinate buffers (e.g., succinic acid-monosodium
succinate mixture, succinic acid-sodium hydroxide mixture, succinic
acid-disodium succinate mixture, etc.), tartrate buffers (e.g.,
tartaric acid-sodium tartrate mixture, tartaric acid-potassium
tartrate mixture, tartaric acid-sodium hydroxide mixture, etc.),
phosphate buffers (e.g., phosphoric acid-monosodium phosphate
mixture, phosphoric acid-disodium phosphate mixture, monosodium
phosphate-disodium phosphate mixture, etc.), gluconate buffers
(e.g., gluconic acid-sodium gluconate mixture, gluconic acid-sodium
hydroxide mixture, gluconic acid-potassium gluconate mixture,
etc.), oxalate buffer (e.g., oxalic acid-sodium oxalate mixture,
oxalic acid-sodium hydroxide mixture, oxalic acid-potassium oxalate
mixture, etc.), lactate buffers (e.g., lactic acid-sodium lactate
mixture, lactic acid-sodium hydroxide mixture, lactic
acid-potassium lactate mixture, etc.) and acetate buffers (e.g.,
acetic acid-sodium acetate mixture, acetic acid-sodium hydroxide
mixture, etc.). Additionally, fumarate buffers, histidine buffers
and trimethylamine salts such as
2-amino-2-hydroxymethyl-propane-1,3-diol (i.e., Tris, THAM, or
tris(hydroxymethyl)aminomethane) can be used.
[0108] Isotonicifiers sometimes known as "stabilizers" can be added
to ensure isotonicity of liquid compositions of the present
disclosure and include polyhydric sugar alcohols, for example
trihydric or higher sugar alcohols, such as glycerin, erythritol,
arabitol, xylitol, sorbitol and mannitol. Stabilizers refer to a
broad category of excipients which can range in function from a
bulking agent to an additive which solubilizes the therapeutic
agent or helps to prevent denaturation or adherence to the
container wall. Typical stabilizers can be polyhydric sugar
alcohols (enumerated above); amino acids such as arginine, lysine,
glycine, glutamine, asparagine, histidine, alanine, ornithine,
leucine, 2-phenylalanine, glutamic acid, threonine, etc., organic
sugars or sugar alcohols, such as lactose, trehalose, stachyose,
mannitol, sorbitol, xylitol, ribitol, myoinositol, galactitol,
glycerol and the like, including cyclitols such as inositol;
polyethylene glycol; amino acid polymers; sulfur containing
reducing agents, such as urea, glutathione, thioctic acid, sodium
thioglycolate, thioglycerol, .alpha.-monothioglycerol and sodium
thiosulfate; low molecular weight polypeptides (e.g., peptides of
10 residues or fewer); hydrophilic polymers, such as
polyvinylpyrrolidone monosaccharides, such as xylose, mannose,
fructose, glucose; disaccharides such as lactose, maltose, sucrose
and trehalose; and trisaccacharides such as raffinose; and
polysaccharides such as dextran. Stabilizers may be present in
amounts ranging from 0.5 to 10 weight % per weight of anti-CD40
antibody.
[0109] Non-ionic surfactants or detergents (also known as "wetting
agents") may be added to help solubilize the glycoprotein as well
as to protect the glycoprotein against agitation-induced
aggregation, which also permits the formulation to be exposed to
shear surface stressed without causing denaturation of the protein.
Suitable non-ionic surfactants include polysorbates (20, 80, etc.),
poloxamers (184, 188 etc.), and pluronic polyols. Non-ionic
surfactants may be present in a range of about 0.05 mg/mL to about
1.0 mg/mL.
[0110] A specific exemplary embodiment of an aqueous composition
suitable for administration via intravenous infusion comprises 10
mg/mL of anti-CD40 antibody, 15 mM histidine buffer, pH 6.0, 8.0%
(w/v) sucrose, and 0.05% (w/v) polysorbate 80. In certain
embodiments, the anti-CD40 antibody is any one of the humanized
antibodies described in TABLE 3. The composition may be in the form
of a lyophilized powder that, upon reconstitution with 2.0 mL
sterile water or other solution suitable for injection or infusion
(for example, 0.9% saline, Ringer's solution, lactated Ringer's
solution, etc.) provides the above aqueous composition. The
composition, or other embodiments of compositions, may also be in
the form of a syringe or other device suitable for injection and/or
infusion pre-filled with a quantity of composition suitable for a
single administration of the anti-CD40 antibody.
7.6. Methods of Use
[0111] 7.6.1. Therapeutic Benefit
[0112] Data provided herein demonstrate that anti-CD40 antibodies
described herein that agonize CD40 in the presence of tumor cells
exert potent anti-tumor activity against these solid tumors in
vivo. Accordingly, the anti-CD40 antibodies, binding fragments,
and/or pharmaceutical compositions comprising the anti-CD40
antibodies may be used therapeutically to treat solid tumors.
[0113] Generally, the methods involve administering to a human
patient having a solid tumor an effective amount of an anti-CD40
antibody that agonizes CD40, and kills and/or reduces proliferation
of tumor cells to provide therapeutic benefit. Solid tumors that
may be treated with the anti-CD40 antibody include, but are not
limited to, adrenal cancers, bone cancers, brain cancers, breast
cancers, colorectal cancers, esophageal cancers, eye cancers,
gastric cancers, head and neck cancers, kidney cancers, liver
cancers, lung cancers (e.g., non-small cell lung cancer,
mesothelioma), head and neck cancers (e.g., squamous cell carcinoma
of the head and neck), lymphomas (e.g., B cell lymphomas),
melanomas (e.g., advanced malignant melanoma, cutaneous melanoma),
oral cancers, ovarian cancers, penile cancers, prostate cancers,
pancreatic cancers, skin cancers, testicular cancers, thyroid
cancers, uterine cancers, and vaginal cancers. In some embodiments,
the solid tumor is head and neck cancer, lung cancer, melanoma or
pancreatic cancer.
[0114] The cancer may be newly diagnosed and naive to treatment, or
may be relapsed, refractory, or relapsed and refractory, or a
metastatic form of a solid tumor. Indeed, in vivo data in mouse PC3
prophylactic models (FIG. 12) show that the anti-CD40 antibodies
are effective in reducing tumor size in comparison to dosing with
isotype antibody.
[0115] Without wishing to be limited by theory, it is believed that
an anti-CD40 antibody activates the immune system by agonizing
CD40. The subsequent immune response then exerts an antitumor
effect on adjacent tumor cells, without regard to CD40 expression
levels. Accordingly, an anti-CD40 antibody of the disclosure is
expected to be effective against CD40-positive or CD40-negative
solid tumors.
[0116] An anti-CD40 antibody of the disclosure may be administered
alone (monotherapy) or adjunctive to, or with, other anti-cancer
therapies and/or targeted or non-targeted anti-cancer agents.
Whether administered as monotherapy or adjunctive to, or with,
other therapies or agents, an amount of anti-CD40 antibody is
administered such that the overall treatment regimen provides
therapeutic benefit.
[0117] By therapeutic benefit is meant that the use of anti-CD40
antibodies to treat cancer in a patient results in any demonstrated
clinical benefit compared with no therapy (when appropriate) or to
a known standard of care. Clinical benefit can be assessed by any
method known to one of ordinary skill in the art. In one
embodiment, clinical benefit is assessed based on objective
response rate (ORR) (determined using RECIST version 1.1), duration
of response (DOR), progression-free survival (PFS), and/or overall
survival (OS). In some embodiments, a complete response indicates
therapeutic benefit. In some embodiments, a partial response
indicates therapeutic benefit. In some embodiments, stable disease
indicates therapeutic benefit. In some embodiments, an increase in
overall survival indicates therapeutic benefit. In some
embodiments, therapeutic benefit may constitute an improvement in
time to disease progression and/or an improvement in symptoms or
quality of life. In other embodiments, therapeutic benefit may not
translate to an increased period of disease control, but rather a
markedly reduced symptom burden resulting in improved quality of
life. As will be apparent to those of skill in the art, a
therapeutic benefit may be observed using the anti-CD40 antibodies
alone (monotherapy) or adjunctive to, or with, other anti-cancer
therapies and/or targeted or non-targeted anti-cancer agents.
[0118] Typically, therapeutic benefit is assessed using standard
clinical tests designed to measure the response to a new treatment
for cancer. To assess the therapeutic benefits of the anti-CD40
antibodies described herein one or a combination of the following
tests can be used: (1) the Response Evaluation Criteria In Solid
Tumors (RECIST) version 1.1, (2) the Eastern Cooperative Oncology
Group (ECOG) Performance Status, (3) immune-related response
criteria (irRC), (4) disease evaluable by assessment of tumor
antigens, (5) validated patient reported outcome scales, and/or (6)
Kaplan-Meier estimates for overall survival and progression free
survival.
[0119] Assessment of the change in tumor burden is an important
feature of the clinical evaluation of cancer therapeutics. Both
tumor shrinkage (objective response) and time to the development of
disease progression are important endpoints in cancer clinical
trials. Standardized response criteria, known as RECIST (Response
Evaluation Criteria in Solid Tumors), were published in 2000. An
update (RECIST 1.1) was released in 2009. RECIST criteria are
typically used in clinical trials where objective response is the
primary study endpoint, as well as in trials where assessment of
stable disease, tumor progression or time to progression analyses
are undertaken because these outcome measures are based on an
assessment of anatomical tumor burden and its change over the
course of the trial. TABLE 4 provides the definitions of the
response criteria used to determine objective tumor response to a
study drug, such as the anti-CD40 antibodies described herein.
TABLE-US-00006 TABLE 4 Response Criteria Complete Disappearance of
all target lesions. Any pathological Response lymph nodes (whether
target or non-target) must have (CR) reduction in short axis to
<10 mm. Partial At least a 30% decrease in the sum of diameters
of Response target lesions, taking as reference the baseline sum
(PR) diameters. Progressive At least a 20% increase in the sum of
diameters of Disease target lesions, taking as reference the
smallest sum (PD) on study (this includes the baseline sum if that
is the smallest on study). In addition to the relative increase of
20%, the sum must also demonstrate an absolute increase of at least
5 mm. (Note: the appearance of one or more new lesions is also
considered progression). Stable Neither sufficient shrinkage to
qualify for PR nor Disease sufficient increase to qualify for PD,
taking as (SD) reference the smallest sum diameters while on
study.
[0120] Secondary outcome measures that can be used to determine the
therapeutic benefit of the anti-CD40 antibodies described herein
include, Objective Response Rate (ORR), Progression Free Survival
(PFS), Overall Survival (OS), Duration of Overall Response (DOR),
and Depth of Response (DpR). ORR is defined as the proportion of
the participants who achieve a complete response (CR) or partial
response (PR). PFS is defined as the time from the first dose date
of an anti-CD40 antibody to either disease progression or death,
whichever occurs first. OS is defined as the length of time from
either the date of diagnosis or the start of treatment for a
disease, that patients diagnosed with the disease are still alive.
DOR is defined as the time from the participant's initial CR or PR
to the time of disease progression. DpR is defined as the
percentage of tumor shrinkage observed at the maximal response
point compared to baseline tumor load. Clinical endpoints for both
ORR and PFS can be determined based on RECIST 1.1 criteria
described above.
[0121] The ECOG Scale of Performance Status shown in TABLE 5 is
used to describe a patient's level of functioning in terms of their
ability to care for themselves, daily activity, and physical
ability. The scale was developed by the Eastern Cooperative
Oncology Group (ECOG), now part of the ECOG-ACRIN Cancer Research
Group, and published in 1982.
TABLE-US-00007 TABLE 5 Grade ECOG Performance Status 0 Fully
active, able to carry on all pre-disease performance without
restriction 1 Restricted in physically strenuous activity but
ambulatory and able to carry out work of a light or sedentary
nature, e.g., light house work, office work 2 Ambulatory and
capable of all selfcare but unable to carry out any work
activities; up and about more than 50% of waking hours 3 Capable of
only limited selfcare; confined to bed or chair more than 50% of
waking hours 4 Completely disabled; cannot carry on any selfcare;
totally confined to bed or chair 5 Dead
[0122] Another set of criteria that can be used to characterize
fully and to determine response to immunotherapeutic agents, such
as antibody-based cancer therapies, is the immune-related response
criteria (irRC), which was developed for measurement of solid
tumors in 2009, and updated in 2013 (Wolchok, et al. Clin. Cancer
Res. 2009; 15(23): 7412-7420 and Nishino, et al. Clin. Cancer Res.
2013; 19(14): 3936-3943, each of which is incorporated by reference
in its entirety). The updated irRC criteria are typically used to
assess the effect of an immunotherapeutic agent, such as an
anti-CD40 antibody described herein, on tumor burden, and defines
response according to TABLE 6.
TABLE-US-00008 TABLE 6 Response Criteria Complete Disappearance of
all target lesions in two Response consecutive observations not
less than 4 weeks apart (CR) Partial At least a 30% decrease in the
sum of the longest Response diameters of target lesions, taking as
reference the (PR) baseline sum diameters. Progressive At least a
20% increase in the sum of diameters of Disease target lesions,
taking as reference the smallest sum (PD) on study (this includes
the baseline sum if that is the smallest on study). (Note: the
appearance of one or more new lesions is not considered
progression. The measurement of new lesions is included in the sum
of the measurements). Stable Neither sufficient shrinkage to
qualify for PR nor Disease sufficient increase to qualify for PD,
taking as (SD) reference the smallest sum diameters while on
study.
[0123] One exemplary therapeutic benefit resulting from the use of
anti-CD40 antibodies described herein to treat solid tumors,
whether administered as monotherapy or adjunctive to, or with,
other therapies or agents, is a complete response. Another
exemplary therapeutic benefit resulting from the use of anti-CD40
antibodies described herein to treat solid tumors, whether
administered as monotherapy or adjunctive to, or with, other
therapies or agents, is a partial response.
[0124] Validated patient reported outcome scales can also be used
to denote response provided by each patient through a specific
reporting system. Rather than being disease focused, such outcome
scales are concerned with retained function while managing a
chronic condition. One non-limiting example of a validated patient
reported outcome scale is PROMIS.RTM. (Patient Reported Outcomes
Measurement Information System) from the United States National
Institutes of Health. For example, PROMIS.RTM. Physical Function
Instrument for adult cancer patients can evaluate self-reported
capabilities for the functioning of upper extremities (e.g.,
dexterity), lower extremities (e.g., walking or mobility), and
central regions (e.g., neck, back mobility), and includes routine
daily activities, such as running errands.
[0125] Kaplan-Meier curves (Kaplan and Meier, J. Am. Stat. Assoc.
1958; 53(282): 457-481) can also be used to estimate overall
survival and progression free survival for cancer patients
undergoing anti-CD40 antibody therapy in comparison to standard of
care.
7.6.2. Adjunctive Therapies
[0126] The anti-CD40 antibodies may be used adjunctive to, or with,
other agents or treatments having anti-cancer properties. When used
adjunctively, the anti-CD40 antibody and other agent(s) may be
formulated together in a single, combination pharmaceutical
formulation, or may be formulated and administered separately,
either on a single coordinated dosing regimen or on different
dosing regimens. Agents administered adjunctive to or with the
anti-CD40 antibodies will typically have complementary activities
to the anti-CD40 antibodies such that the antibodies and other
agents do not adversely affect each other.
[0127] Agents that may be administered adjunctive to or with an
anti-CD40 antibody include, but are not limited to, alkylating
agents, angiogenesis inhibitors, antibodies, antimetabolites,
antimitotics, antiproliferatives, antivirals, aurora kinase
inhibitors, apoptosis promoters (for example, Bcl-2 family
inhibitors), activators of death receptor pathway, Bcr-Abl kinase
inhibitors, BiTE (Bi-Specific T cell Engager) antibodies, antibody
drug conjugates, biologic response modifiers, cyclin-dependent
kinase inhibitors, cell cycle inhibitors, cyclooxygenase-2
inhibitors, DVDs, leukemia viral oncogene homolog (ErbB2) receptor
inhibitors, growth factor inhibitors, heat shock protein (HSP)-90
inhibitors, histone deacetylase (HDAC) inhibitors, hormonal
therapies, immunologicals, inhibitors of inhibitors of apoptosis
proteins (IAPs), intercalating antibiotics, kinase inhibitors,
kinesin inhibitors, Jak2 inhibitors, mammalian target of rapamycin
(mTor) inhibitors, microRNAs, mitogen-activated extracellular
signal-regulated kinase inhibitors, non-steroidal anti-inflammatory
drugs (NSAIDs), poly ADP (adenosine diphosphate)-ribose polymerase
(PARP) inhibitors, platinum chemotherapeutics, Bruton's tyrosine
kinase (BTK) inhibitors (e.g., ibrutinib, acalabrutinib), polo-like
kinase (Plk) inhibitors, phosphoinositide-3 kinase (PI3K)
inhibitors, proteasome inhibitors, purine analogs, pyrimidine
analogs, receptor tyrosine kinase inhibitors, retinoids/deltoids
plant alkaloids, small inhibitory ribonucleic acids (siRNAs),
topoisomerase inhibitors, ubiquitin ligase inhibitors, and the
like, as well as combinations of one or more of these agents.
[0128] Examples of immunologicals include, but are not limited to,
interferons, immune checkpoint inhibitors, and other
immune-enhancing agents. Interferons include interferon alpha,
interferon alpha-2a, interferon alpha-2b, interferon beta,
interferon gamma-1a, ACTIMMUNE.RTM. (interferon gamma-1b) or
interferon gamma-n1, combinations thereof and the like. Immune
check point inhibitors include antibodies that target PD-1 (e.g.,
pembrolizumab and nivolumab), PD-L1 (e.g., durvalumab,
atezolizumab, avelumab, MEDI4736, MSB0010718C and MPDL3280A), and
CTLA4 (cytotoxic lymphocyte antigen 4; e.g., ipilimumab,
tremelimumab). Immune-enhancing agents include anti-OX40 agonist
antibodies that activate T cells. In certain embodiments, a
humanized anti-CD40 antibody shown in TABLE 3 is administered
adjunctive to pembrolizumab. In other certain embodiments, a
humanized anti-CD40 antibody shown in TABLE 3 is administered
adjunctive to nivolumab.
[0129] An anti-CD40 antibody may also be used to enhance the
efficacy of radiation therapy. Examples of radiation therapy
include external beam radiation therapy, internal radiation therapy
(i.e., brachytherapy) and systemic radiation therapy.
7.7. Dosages and Administration Regimens
[0130] The amount of anti-CD40 antibodies administered will depend
upon a variety of factors, including but not limited to, the
particular type of solid tumor treated, the stage of the solid
tumor being treated, the mode of administration, the frequency of
administration, the desired therapeutic benefit, and other
parameters such as the age, weight and other characteristics of the
patient, etc. Determination of dosages effective to provide
therapeutic benefit for specific modes and frequency of
administration is within the capabilities of those skilled in the
art.
[0131] Dosages effective to provide therapeutic benefit may be
estimated initially from in vivo animal models or clinical.
Suitable animal models for a wide variety of diseases are known in
the art.
[0132] The anti-CD40 antibodies disclosed herein may be
administered by any route appropriate to the condition to be
treated. In some embodiments, the anti-CD40 antibody is any one of
the humanized antibodies listed in TABLE 3. An anti-CD40 antibody
will typically be administered parenterally, i.e., infusion,
subcutaneous, intramuscular, intravenous (IV), intradermal,
intrathecal, bolus, intratumoral (IT) injection or epidural ((Shire
et al., 2004, J Pharm. Sciences 93(6):1390-1402)). In one
embodiment, an anti-CD40 antibody is provided as a lyophilized
powder in a vial. The vials may contain 21 mg of anti-CD40
antibody. Prior to administration, the lyophilized powder is
reconstituted with sterile water for injection (SWFI) or other
suitable medium to provide a solution containing 10 mg/mL anti-CD40
antibody. In some embodiments, the resulting reconstituted solution
is further diluted with saline or other suitable medium and
administered via an IV infusion twice every 7 days, once every 7
days, once every 14 days, once every 21 days, once every 28 days,
once every 35 days, once every 42 days, once every 49 days, or once
every 56 days. In some embodiments, for the first cycle, the
infusion occurs over 90 minutes. In some embodiments, subsequent
infusions are over 60 minutes. In other embodiments, the resulting
reconstituted solution is further diluted with saline or other
suitable medium and administered via an IT injection twice every 7
days, once every 7 days, once every 14 days, once every 21 days,
once every 28 days, once every 35 days, once every 42 days, once
every 49 days, or once every 56 days.
[0133] In one exemplary embodiment, an anti-CD40 antibody is any
one of the humanized antibodies listed in TABLE 3. The anti-CD40
antibody is administered as an IV infusion once every 7 days at
0.005 mg/kg, 0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05
mg/kg, 0.06 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4
mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2
mg/kg, 1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8
mg/kg, 1.9 mg/kg, 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8
mg/kg, 3.0 mg/kg, 3.2 mg/kg, 3.4 mg/kg, 3.6 mg/kg, 3.8 mg/kg, or
4.0 mg/kg.
[0134] In another exemplary embodiment, an anti-CD40 antibody is
any one of the humanized antibodies listed in TABLE 3. The
anti-CD40 antibody is administered as an IV infusion once every 14
days at 0.005 mg/kg, 0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04
mg/kg, 0.05 mg/kg, 0.06 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg,
0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg,
1.1 mg/kg, 1.2 mg/kg, 1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg,
1.7 mg/kg, 1.8 mg/kg, 1.9 mg/kg, 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg,
2.6 mg/kg, 2.8 mg/kg, 3.0 mg/kg, 3.2 mg/kg, 3.4 mg/kg, 3.6 mg/kg,
3.8 mg/kg, or 4.0 mg/kg.
[0135] In another exemplary embodiment, an anti-CD40 antibody is
any one of the humanized antibodies listed in TABLE 3. The
anti-CD40 antibody is administered as an IV infusion once every 28
days at 0.005 mg/kg, 0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04
mg/kg, 0.05 mg/kg, 0.06 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg,
0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg,
1.1 mg/kg, 1.2 mg/kg, 1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg,
1.7 mg/kg, 1.8 mg/kg, 1.9 mg/kg, 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg,
2.6 mg/kg, 2.8 mg/kg, 3.0 mg/kg, 3.2 mg/kg, 3.4 mg/kg, 3.6 mg/kg,
3.8 mg/kg, or 4.0 mg/kg.
[0136] In another exemplary embodiment, an anti-CD40 antibody is
any one of the humanized antibodies listed in TABLE 3. The
anti-CD40 antibody is administered as an IT injection once every 7
days at 0.001 mg/kg, 0.002 mg/kg, 0.003 mg/kg, 0.004 mg/kg, 0.005
mg/kg, 0.006 mg/kg, 0.007 mg/kg, 0.008 mg/kg, 0.009 mg/kg, 0.01
mg/kg, 0.015 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05 mg/kg,
0.06 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg,
0.5 mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2 mg/kg,
1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8 mg/kg,
1.9 mg/kg, or 2.0 mg/kg.
[0137] In another exemplary embodiment, an anti-CD40 antibody is
any one of the humanized antibodies listed in TABLE 3. The
anti-CD40 antibody is administered as an IT injection once every 14
days at 0.001 mg/kg, 0.002 mg/kg, 0.003 mg/kg, 0.004 mg/kg, 0.005
mg/kg, 0.006 mg/kg, 0.007 mg/kg, 0.008 mg/kg, 0.009 mg/kg, 0.01
mg/kg, 0.015 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05 mg/kg,
0.06 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg,
0.5 mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2 mg/kg,
1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8 mg/kg,
1.9 mg/kg, or 2.0 mg/kg.
[0138] In another exemplary embodiment, an anti-CD40 antibody is
any one of the humanized antibodies listed in TABLE 3. The
anti-CD40 antibody is administered as an IT injection once every 28
days at 0.001 mg/kg, 0.002 mg/kg, 0.003 mg/kg, 0.004 mg/kg, 0.005
mg/kg, 0.006 mg/kg, 0.007 mg/kg, 0.008 mg/kg, 0.009 mg/kg, 0.01
mg/kg, 0.015 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05 mg/kg,
0.06 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg,
0.5 mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2 mg/kg,
1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8 mg/kg,
1.9 mg/kg, or 2.0 mg/kg.
[0139] When administered adjunctive to or with other agents, such
as other chemotherapeutic agents, the anti-CD40 antibodies may be
administered on the same schedule as the other agent(s), or on a
different schedule. When administered on the same schedule, the
anti-CD40 antibody may be administered before, after, or
concurrently with the other agent. In some embodiments where an
anti-CD40 antibody is administered adjunctive to, or with,
standards of care, the anti-CD40 antibody may be initiated prior to
commencement of the standard therapy, for example a day, several
days, a week, several weeks, a month, or even several months before
commencement of standard of care therapy.
[0140] In one exemplary embodiment, an anti-CD40 antibody is used
adjunctive to nivolumab (OPDIVO.RTM.) to treat non-small cell lung
cancer. In some embodiments, the anti-CD40 antibody is any one of
the humanized antibodies listed in TABLE 3. The anti-CD40 antibody
is administered via IV infusion once every 7 days at 0.005 mg/kg,
0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05 mg/kg, 0.06
mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5
mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2 mg/kg, 1.3
mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8 mg/kg, 1.9
mg/kg, 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8 mg/kg, 3.0
mg/kg, 3.2 mg/kg, 3.4 mg/kg, 3.6 mg/kg, 3.8 mg/kg, or 4.0 mg/kg.
Nivolumab is administered by intravenous infusion at a dose of 3
mg/kg over 60 minutes once every two weeks. The adjunctive
anti-CD40 antibody/nivolumab therapy is continued until disease
progression or no longer tolerated by the patient.
[0141] In another exemplary embodiment, an anti-CD40 antibody is
used adjunctive to nivolumab (OPDIVO.RTM.) to treat non-small cell
lung cancer. In some embodiments, the anti-CD40 antibody is any one
of the humanized antibodies listed in TABLE 3. The anti-CD40
antibody is administered via IV infusion once every 14 days at
0.005 mg/kg, 0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05
mg/kg, 0.06 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4
mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2
mg/kg, 1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8
mg/kg, 1.9 mg/kg, 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8
mg/kg, 3.0 mg/kg, 3.2 mg/kg, 3.4 mg/kg, 3.6 mg/kg, 3.8 mg/kg, or
4.0 mg/kg. Nivolumab is administered by intravenous infusion at a
dose of 3 mg/kg over 60 minutes once every two weeks. The
adjunctive anti-CD40 antibody/nivolumab therapy is continued until
disease progression or no longer tolerated by the patient.
[0142] In another exemplary embodiment, an anti-CD40 antibody is
used adjunctive to nivolumab (OPDIVO.RTM.) to treat non-small cell
lung cancer. In some embodiments, the anti-CD40 antibody is any one
of the humanized antibodies listed in TABLE 3. The anti-CD40
antibody is administered via IV infusion once every 28 days at
0.005 mg/kg, 0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05
mg/kg, 0.06 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4
mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2
mg/kg, 1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8
mg/kg, 1.9 mg/kg, 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8
mg/kg, 3.0 mg/kg, 3.2 mg/kg, 3.4 mg/kg, 3.6 mg/kg, 3.8 mg/kg, or
4.0 mg/kg. Nivolumab is administered by intravenous infusion at a
dose of 3 mg/kg over 60 minutes once every two weeks. The
adjunctive anti-CD40 antibody/nivolumab therapy is continued until
disease progression or no longer tolerated by the patient.
[0143] In another exemplary embodiment, an anti-CD40 antibody is
used adjunctive to nivolumab (OPDIVO.RTM.) to treat non-small cell
lung cancer. In some embodiments, the anti-CD40 antibody is any one
of the humanized antibodies listed in TABLE 3. The anti-CD40
antibody is administered as an IT injection once every 7 days at
0.001 mg/kg, 0.002 mg/kg, 0.003 mg/kg, 0.004 mg/kg, 0.005 mg/kg,
0.006 mg/kg, 0.007 mg/kg, 0.008 mg/kg, 0.009 mg/kg, 0.01 mg/kg,
0.015 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05 mg/kg, 0.06
mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5
mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2 mg/kg, 1.3
mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8 mg/kg, 1.9
mg/kg, or 2.0 mg/kg. Nivolumab is administered by intravenous
infusion at a dose of 3 mg/kg over 60 minutes once every two weeks.
The adjunctive anti-CD40 antibody/nivolumab therapy is continued
until disease progression or no longer tolerated by the
patient.
[0144] In another exemplary embodiment, an anti-CD40 antibody is
used adjunctive to nivolumab (OPDIVO.RTM.) to treat non-small cell
lung cancer. In some embodiments, the anti-CD40 antibody is any one
of the humanized antibodies listed in TABLE 3. The anti-CD40
antibody is administered as an IT injection once every 14 days at
0.001 mg/kg, 0.002 mg/kg, 0.003 mg/kg, 0.004 mg/kg, 0.005 mg/kg,
0.006 mg/kg, 0.007 mg/kg, 0.008 mg/kg, 0.009 mg/kg, 0.01 mg/kg,
0.015 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05 mg/kg, 0.06
mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5
mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2 mg/kg, 1.3
mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8 mg/kg, 1.9
mg/kg, or 2.0 mg/kg. Nivolumab is administered by intravenous
infusion at a dose of 3 mg/kg over 60 minutes once every two weeks.
The adjunctive anti-CD40 antibody/nivolumab therapy is continued
until disease progression or no longer tolerated by the
patient.
[0145] In another exemplary embodiment, an anti-CD40 antibody is
used adjunctive to nivolumab (OPDIVO.RTM.) to treat non-small cell
lung cancer. In some embodiments, the anti-CD40 antibody is any one
of the humanized antibodies listed in TABLE 3. The anti-CD40
antibody is administered as an IT injection once every 28 days at
0.001 mg/kg, 0.002 mg/kg, 0.003 mg/kg, 0.004 mg/kg, 0.005 mg/kg,
0.006 mg/kg, 0.007 mg/kg, 0.008 mg/kg, 0.009 mg/kg, 0.01 mg/kg,
0.015 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05 mg/kg, 0.06
mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5
mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2 mg/kg, 1.3
mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8 mg/kg, 1.9
mg/kg, or 2.0 mg/kg. Nivolumab is administered by intravenous
infusion at a dose of 3 mg/kg over 60 minutes once every two weeks.
The adjunctive anti-CD40 antibody/nivolumab therapy is continued
until disease progression or no longer tolerated by the
patient.
[0146] In another exemplary embodiment, an anti-CD40 antibody is
used adjunctive to pembrolizumab (Keytruda.RTM.) to treat non-small
cell lung cancer. In some embodiments, the anti-CD40 antibody is
any one of the humanized antibodies listed in TABLE 3. The
anti-CD40 antibody is administered via IV infusion once every 7
days at 0.005 mg/kg, 0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04
mg/kg, 0.05 mg/kg, 0.06 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg,
0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg,
1.1 mg/kg, 1.2 mg/kg, 1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg,
1.7 mg/kg, 1.8 mg/kg, 1.9 mg/kg, 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg,
2.6 mg/kg, 2.8 mg/kg, 3.0 mg/kg, 3.2 mg/kg, 3.4 mg/kg, 3.6 mg/kg,
3.8 mg/kg, or 4.0 mg/kg. Pembrolizumab is administered by
intravenous infusion at a dose of 2 mg/kg over 30 minutes once
every three weeks. The adjunctive anti-CD40 antibody/pembrolizumab
therapy is continued until disease progression or no longer
tolerated by the patient.
[0147] In another exemplary embodiment, an anti-CD40 antibody is
used adjunctive to pembrolizumab (Keytruda.RTM.) to treat non-small
cell lung cancer. In some embodiments, the anti-CD40 antibody is
any one of the humanized antibodies listed in TABLE 3. The
anti-CD40 antibody is administered via IV infusion once every 14
days at 0.005 mg/kg, 0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04
mg/kg, 0.05 mg/kg, 0.06 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg,
0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg,
1.1 mg/kg, 1.2 mg/kg, 1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg,
1.7 mg/kg, 1.8 mg/kg, 1.9 mg/kg, 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg,
2.6 mg/kg, 2.8 mg/kg, 3.0 mg/kg, 3.2 mg/kg, 3.4 mg/kg, 3.6 mg/kg,
3.8 mg/kg, or 4.0 mg/kg. Pembrolizumab is administered by
intravenous infusion at a dose of 2 mg/kg over 30 minutes once
every three weeks. The adjunctive anti-CD40 antibody/pembrolizumab
therapy is continued until disease progression or no longer
tolerated by the patient.
[0148] In another exemplary embodiment, an anti-CD40 antibody is
used adjunctive to pembrolizumab (Keytruda.RTM.) to treat non-small
cell lung cancer. In some embodiments, the anti-CD40 antibody is
any one of the humanized antibodies listed in TABLE 3. The
anti-CD40 antibody is administered via IV infusion once every 28
days at 0.005 mg/kg, 0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04
mg/kg, 0.05 mg/kg, 0.06 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg,
0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg,
1.1 mg/kg, 1.2 mg/kg, 1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg,
1.7 mg/kg, 1.8 mg/kg, 1.9 mg/kg, 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg,
2.6 mg/kg, 2.8 mg/kg, 3.0 mg/kg, 3.2 mg/kg, 3.4 mg/kg, 3.6 mg/kg,
3.8 mg/kg, or 4.0 mg/kg. Pembrolizumab is administered by
intravenous infusion at a dose of 2 mg/kg over 30 minutes once
every three weeks. The adjunctive anti-CD40 antibody/pembrolizumab
therapy is continued until disease progression or no longer
tolerated by the patient.
[0149] In another exemplary embodiment, an anti-CD40 antibody is
used adjunctive to pembrolizumab (Keytruda.RTM.) to treat non-small
cell lung cancer. In some embodiments, the anti-CD40 antibody is
any one of the humanized antibodies listed in TABLE 3. The
anti-CD40 antibody is administered as an IT injection once every 7
days at 0.001 mg/kg, 0.002 mg/kg, 0.003 mg/kg, 0.004 mg/kg, 0.005
mg/kg, 0.006 mg/kg, 0.007 mg/kg, 0.008 mg/kg, 0.009 mg/kg, 0.01
mg/kg, 0.015 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05 mg/kg,
0.06 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg,
0.5 mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2 mg/kg,
1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8 mg/kg,
1.9 mg/kg, or 2.0 mg/kg. Pembrolizumab is administered by
intravenous infusion at a dose of 2 mg/kg over 30 minutes once
every three weeks. The adjunctive anti-CD40 antibody/pembrolizumab
therapy is continued until disease progression or no longer
tolerated by the patient.
[0150] In another exemplary embodiment, an anti-CD40 antibody is
used adjunctive to pembrolizumab (Keytruda.RTM.) to treat non-small
cell lung cancer. In some embodiments, the anti-CD40 antibody is
any one of the humanized antibodies listed in TABLE 3. The
anti-CD40 antibody is administered as an IT injection once every 14
days at 0.001 mg/kg, 0.002 mg/kg, 0.003 mg/kg, 0.004 mg/kg, 0.005
mg/kg, 0.006 mg/kg, 0.007 mg/kg, 0.008 mg/kg, 0.009 mg/kg, 0.01
mg/kg, 0.015 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05 mg/kg,
0.06 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg,
0.5 mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2 mg/kg,
1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8 mg/kg,
1.9 mg/kg, or 2.0 mg/kg. Pembrolizumab is administered by
intravenous infusion at a dose of 2 mg/kg over 30 minutes once
every three weeks. The adjunctive anti-CD40 antibody/pembrolizumab
therapy is continued until disease progression or no longer
tolerated by the patient.
[0151] In another exemplary embodiment, an anti-CD40 antibody is
used adjunctive to pembrolizumab (Keytruda.RTM.) to treat non-small
cell lung cancer. In some embodiments, the anti-CD40 antibody is
any one of the humanized antibodies listed in TABLE 3. The
anti-CD40 antibody is administered as an IT injection once every 28
days at 0.001 mg/kg, 0.002 mg/kg, 0.003 mg/kg, 0.004 mg/kg, 0.005
mg/kg, 0.006 mg/kg, 0.007 mg/kg, 0.008 mg/kg, 0.009 mg/kg, 0.01
mg/kg, 0.015 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05 mg/kg,
0.06 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg,
0.5 mg/kg, 0.6 mg/kg, 0.8 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2 mg/kg,
1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8 mg/kg,
1.9 mg/kg, or 2.0 mg/kg. Pembrolizumab is administered by
intravenous infusion at a dose of 2 mg/kg over 30 minutes once
every three weeks. The adjunctive anti-CD40 antibody/pembrolizumab
therapy is continued until disease progression or no longer
tolerated by the patient.
[0152] As will be appreciated by those of skill in the art, the
recommended dosages for the various agents described above may need
to be adjusted to optimize patient response and maximize
therapeutic benefit.
8. EXAMPLES
[0153] The following Examples, which highlight certain features and
properties of the exemplary embodiments of the anti-CD40 antibodies
described herein are provided for purposes of illustration, and not
limitation.
Example 1: Generation of Mouse Anti-Human CD40 Antibodies
[0154] Monoclonal antibodies were generated by immunizing Balb/C
mice or SJL mice intraperitoneally with mouse 3T12 cells
overexpressing human CD40. Spleens were harvested, and splenocytes
were fused with the multiple myeloma cell line NSO. Hybridomas were
selected using aminopterin. Selected hybridomas expressing
anti-CD40 antibodies with agonistic activities were screened and
subcloned to isolate individual clones.
[0155] To screen for antibodies with agonistic activity, a panel of
functional assays was developed, including NF.kappa.B pathway
stimulation, monocytes activation, dendritic cell (DC) activation
and CD40 ligand (CD40L) competition. In these assays, anti-human
CD40 G28-5 (mouse IgG1) (Biolegend) was included as positive
control and an isotype matched mouse antibody (mIgG1) as negative
control.
[0156] 8.1.1. HEK293 Blue CD40 NF.kappa.B Reporter Assay
[0157] HEK293 blue CD40 cell line (InVivogen) stably expressing
human CD40 and a NF.kappa.B reporter gene were maintained in DMEM,
10% heat-inactivated fetal bovine serum (FBS), supplemented with 30
.mu.g/mL Blasticidin and 100 .mu.g/mL Zeocin. Activation of CD40 on
the surface of HEK293 blue CD40 cells triggers a signaling cascade
leading to the activation of NF.kappa.B and the subsequent
secretion of embryonic alkaline phosphatase (SEAP). Incubation of
hybridoma supernatants containing agonistic anti-CD40 with
2.5.times.10.sup.5/mL of HEK293 blue CD40 cells stimulated
production of SEAP which was measured by a colorimetic enzyme
assay. The level of SEAP thus corresponded to the activity of
anti-CD40 in the hybridoma supernatants.
[0158] 8.1.2. Monocyte Activation Assay
[0159] The monocyte activity assay was performed using the
monocytic cell line THP1-XBlue cells (InVivogen). This cell line
stably expresses an NF.kappa.B and AP-1-inducible SEAP reporter
gene and was maintained in RPMI 1640 with 10% heat-inactivated FBS
and 200 .mu.g/mL Zeocin. In the assay, 5.times.10.sup.5/mL
THP1-XBlue cells were first primed with 40 ng/mL IFN.gamma. for 24
hours, and were subsequently incubated with testing samples for an
additional 24 hours. Agonistic anti-CD40-induced SEAP activity was
monitored by enzymatic assay.
[0160] 8.1.3. Primary Dendritic Cell IL-12p70 Production Assay
[0161] Anti-CD40 clones were also screened for their ability to
activate monocyte-derived dendritic cells (moDC). Activation was
monitored by IL-12p70 production. Human peripheral blood
mononuclear cells (PBMC) were first isolated on a Ficoll gradient.
Briefly, whole blood from healthy human donors, diluted with an
equal volume of PBS, was added to a Leucosep (Greiner Bio One)
tube, containing Ficoll-Paque Plus below the frit (15 mL). The
blood was then centrifuged at 1,000 g for 15 minutes without brake.
PBMC were collected and washed once with PBS, centrifuged at 1,300
rpm for 5 minutes at room temperature, and washed once with RPMI
1640. Cells were re-suspended in culture medium (RPMI1640+10%
heat-inactivated FBS). Monocytes were subsequently isolated from
PBMC with an enrichment kit from StemCell and were cultured in
StemSep serum free medium supplemented with 10 ng/mL GM-CSF and 20
ng/mL IL-4 at 37.degree. C., 5% CO.sub.2 for 6 days. Fresh GM-CSF
and IL-4 were added to the culture at day 3 to help maintain DC
differentiation. After 6 days in culture, monocyte-derived immature
DC were subject to FACS analysis to verify immature DC phenotype:
Lin-, CD80/CD86+, HLA-DR+, or CD11c+. Immature moDC were primed
with IFN.gamma. and stimulated with samples containing an anti-CD40
antibody for 48 hours in StemSep serum free medium supplemented
with GM-CSF and IL-4. The culture supernatant was harvested and
assayed for IL-12p70 production by a commercially available ELISA
kit. The screening results and representative activity are
summarized in Table 1-1.
[0162] Table 1-1 shows the range of agonistic anti-CD40 activity
across isolated hybridomas. All of the new clones demonstrated
monocyte activation comparable to literature CD40 antibody G28-5
(see, e.g., Bishop, G. A. Journal of Immunology 188, 4127-4129
(2012)). Clones AD166.4.4 and AD175.14.11 demonstrated monocyte
activation but did not show dendritic cell activation. The
remainder of the clones displayed monocyte activation comparable to
G28-5, as well as enhanced dendritic cell activation as compared
with G28-5.
TABLE-US-00009 TABLE 1-1 Summary of agonistic anti-CD40 clone
screen Monocyte activation.sup.1 moDC activation Clone (THP1-Xblue,
OD.sub.655) (IL-12p70, pg/mL) AD163.7.2 0.13 905.3 AD163.9.3 0.19
2216.3 AD163.10.7 0.16 1318.8 AD163.27.12 0.12 1514.5 AD163.162.1
0.11 2155.5 AD164.14.6 0.15 878 AD164.76.3 0.16 769.8 AD165.1.2
0.14 719.8 AD166.4.4 0.24 0 AD175.14.11 0.2 0 G28-5 0.12 138.8
muIgG1 0.06 0 .sup.1Monocyte activation is SEAP activity released
from THP1-XBlue cells recorded at OD.sub.655
[0163] The cDNA sequences encoding the heavy and light chain
variable regions often monoclonal antibodies were cloned from
hybridomas AD163.9.3, AD166.4.4, AD175.14.11, AD163.10.7,
AD165.1.2, AD163.162.1, AD163.27.12, AD163.7.2, AD164.14.6, and
AD164.76.3, respectively, using standard PCR techniques and were
sequenced using standard DNA sequencing techniques. The full
corresponding antibody amino acid sequences encoded by the DNA are
shown in FIGS. 2A-2C.
Example 2: Epitope Classification of Mouse Anti-Human CD40
Antibodies
[0164] BIAcore analysis and an ELISA method were used to classify
mouse anti-human CD40 agonistic antibodies based on their ability
to compete with each other or CD40 ligand (CD40L) for binding to
CD40.
[0165] BIAcore analysis was performed using a BIAcore T100
instrument at 12.degree. C. A goat anti-mouse Fc antibody (Pierce,
cat #31170) was first immobilized on CM5 sensor chip followed by
capture of the first test antibody on the surface. After blocking
by 50 .mu.g/mL of mouse isotype antibody cocktail, the flow cells
were injected with the soluble form of the extracellular domain of
human CD40 (Creative BioMart, cat #CD402221H). Subsequently, the
second test antibody or CD40L (PeproTech, cat #0308145) was
injected to measure their binding to the complex of CD40 and the
first test antibody. As shown in Table 2-1, the anti-CD40
antibodies of the disclosure were classified into three epitope
groups. Epitope group 1 was exemplified by AD163.7.2 ("muAb8") and
AD175.14.11 ("muAb3"), which blocked CD40L binding to CD40. Epitope
group 2 was determined from clones AD163.162.1 ("muAb6") and
AD163.27.12 ("muAb7"), which did not compete with CD40L or to
antibodies in epitope group 1. The third epitope group was
exemplified by clones AD163.9.3 ("muAb1"), AD166.4.4 ("muAb2"), and
AD165.1.2 ("muAb5"), which did not compete with CD40L binding to
CD40, but did compete with antibodies in epitope groups 1 and
2.
TABLE-US-00010 TABLE 2-1 Epitope classification by BIAcore analysis
first second antibody antibody muAb6 muAb1 muAb2 muAb7 muAb5 muAb8
muAb3 CD40L muAb6 -- X X X X Y Y Y muAb1 X -- X X X X X Y muAb2 X X
-- X X X X Y muAb7 X X X -- X Y Y Y muAb5 X X X X -- X X Y muAb8 Y
X X Y X -- X X muAb3 Y X X Y X X -- X X: second antibody unable to
bind; Y: simultaneous binding
[0166] An ELISA assay was developed to measure the effects of the
anti-CD40 antibodies on the human CD40-CD40L interaction. Briefly,
a CD40-human Fc (huFc) fusion protein (Creative BioMart) was mixed
with an anti-CD40 antibody or an isotype control antibody and added
to 96-well plates coated with HA-tagged CD40L (R&D Systems).
The binding of the CD40-huFc complex to the plate-bound CD40L was
detected by HRP conjugated anti-human Fc antibody (Jackson
ImmunoResearch). After development with TMB (3, 3', 5,
5'-tetramethylbenzidine) substrate, the plates were read at
OD.sub.450.
[0167] The effect of the anti-CD40 antibodies on CD40-CD40L
interaction was determined by calculating the ratio of the
OD.sub.450 in the samples containing anti-CD40 antibodies to the
OD.sub.450 in the sample containing the isotype control antibody
("OD.sub.450 ratio"). OD.sub.450 ratios of .ltoreq.0.1 showed
inhibition of human CD40L binding to human CD40. OD.sub.450 ratios
between 0.1 and 1 showed partial inhibition of CD40L binding to
CD40. OD.sub.450 ratios >1 showed enhanced binding of human
CD40L to human CD40, thereby enhancing CD40 signaling.
[0168] The data are summarized in Table 2-2. Antibodies muAb8 and
muAb3 blocked CD40 binding to CD40L exhibited a ratio less than
0.1. Antibodies muAb6 and muAb7 showed a ratio around 0.5,
suggesting a modest effect on CD40-CD40L interaction. Antibodies
muAb1, muAb2, muAb4, muAb5, muAb9, and muAb10 exhibited an
OD.sub.450 ratio of about 1 or greater than 1, indicating either no
effect or an effect that promoted CD40 binding to CD40L.
TABLE-US-00011 TABLE 2-2 Competition with CD40 for CD40L Binding
Antibody OD.sub.450 with anti-CD40 antibody OD.sub.450 Ratio muAb8
0.066 0.08 muAb3 0.068 0.09 muAb7 0.328 0.41 muAb6 0.455 0.57 muAb1
1.779 2.22 muAb4 1.343 1.68 muAb9 1.883 2.35 muAb10 2.107 2.63
muAb5 0.989 1.24 muAb2 1.025 1.28
Example 3: Humanization of Mouse Anti-Human CD40 Antibodies
[0169] Humanization of the antibody V region was carried out as
outlined by Queen, C. et al. (Proc. Natl. Acad. Sci. USA, 1989;
86:10029-10033). The canonical structures of the CDRs were
determined according to Huang et al. (Methods, 2005; 36:35-42).
Human variable germline sequences with the same or most similar CDR
canonical structures were identified, and appropriate human
V.sub.H, V.sub.L, and J segment sequences were selected to provide
the frameworks for the anti-CD40 variable region. At framework
positions in which the computer model suggested significant contact
with the CDRs, the amino acids from the murine anti-CD40 V regions
were substituted for the original human framework amino acids
(back-mutations). The constant regions of human IgG.sub.1 with
natural variants D356E and L358M in the heavy chain, and a kappa
light chain were used unless otherwise specified. Full amino acid
sequences of the V.sub.H and V.sub.L regions of the humanized
antibodies are shown in FIGS. 2D-2G.
[0170] Anti-CD40 clone AD163.162.1 ("muAb6") was humanized
according to the method described above. The humanized versions of
muAb6 were huAb6-1, huAb6-2 and huAb6-3. Antibody huAb6-1 carried
V.sub.H (SEQ ID NO: 110) framework back-mutations: M48I, V67A,
I69L, and A71V. Antibody huAb6-2 carried V.sub.H (SEQ ID NO: 111)
framework back-mutations M48I and A71V. Antibody huAb6-3 carried
V.sub.H (SEQ ID NO: 112) framework back-mutations M48I and A71V, as
well as V.sub.H CDR germlining changes N60A, K64Q and D65G to
increase identity to human germline sequence. Antibodies huAb6-1,
huAb6-2 and huAb6-3 carried V.sub.L (SEQ ID NO: 161) framework
back-mutations: A43S, L46R, L47W and F71Y.
[0171] The humanized versions of anti-CD40 clone AD163.7.2
("muAb8") were huAb8-1, huAb8-2 and huAb8-3 (FIGS. 2D-2E). Antibody
huAb8-1 carried V.sub.H (SEQ ID NO: 113) framework back-mutations:
M48I, V67A, I69L, A71V, K73R, Y91F, and R94S. Antibody huAb8-2
carried V.sub.H (SEQ ID NO: 114) framework back-mutations: M48I,
V67A, I69L, A71V, K73R, Y91F, and R94S; as well as V.sub.H CDR C59S
mutation. Antibody huAb8-3 carried V.sub.H (SEQ ID NO: 115)
framework back-mutations: M48I, A71V and R94S. Antibodies huAb8-1,
huAb8-2 and huAb8-3 all carried V.sub.L (SEQ ID NO: 162) framework
back-mutations: A43S, and Y87F.
[0172] Anti-CD40 clone AD164.14.6 ("muAb9") was humanized to
provide huAb9-1, huAb9-2, huAb9-3, huAb9-4, huAb9-5 and huAb9-6.
Antibodies huAb9-1 and huAb9-4 displayed V.sub.H (SEQ ID NO: 116)
framework back-mutations: I48M, V671 and V71R. Antibodies huAb9-2
and huAb9-5 carried V.sub.H (SEQ ID NO: 117) framework
back-mutations: I48M and V71R. Antibodies huAb9-3 and huAb9-6
carried V.sub.H (SEQ ID NO: 118) framework back-mutations: I48M and
V71R, as well as additional two CDR germline changes T30S and N65S
to improve identity to human germline sequence. Antibodies huAb9-1,
huAb9-2 and huAb9-3 carried V.sub.L (SEQ ID NO: 163) framework
back-mutations: I2A, Y36F and Y87F. Antibodies huAb9-4, huAb9-5 and
huAb9-6 carried V.sub.L (SEQ ID NO: 164) framework back-mutation
I2A. Clone AD164.14.6 was further modified to remove a signal
peptide cleavage site found at the second position of the light
chain, by reverting the framework back-mutation I2A of the V.sub.L.
Antibodies huAb9 A2I and huAb9 A2V carried V.sub.H (SEQ ID NO:117)
and V.sub.L containing framework revert mutations A2I (SEQ ID
NO:170) and A2V (SEQ ID NO:171), respectively, prevented the
formation of an undesired cleavage product.
[0173] Humanized antibodies in the present Example were generated
with a human IgG1 heavy chain constant region and kappa light chain
constant region. The C-terminal lysine may be partially cleaved by
post-translational processing after protein expression of the human
IgG1 heavy chain. Accordingly, huAb9-5 had a heavy chain according
to SEQ ID NOS:130 or 131 and a light chain according to SEQ ID
NO:140. Antibody huAb9-5 also was produced with V273E and V273Y
amino acid mutations in the heavy chain constant region,
corresponding to a heavy chain according to SEQ ID NOS:132 or 133
and SEQ ID NOS:134 or 135, respectively, and a light chain
according to SEQ ID NO:140. Antibodies huAb9 A2I and huAb9 A2V were
generated with a human IgG1 V273E heavy chain constant region.
Accordingly, huAb9 A2I had a heavy chain according to SEQ ID
NOS:132 or 133 and a light chain according to SEQ ID NO:141.
Analogously, huAb9 A2V had a heavy chain according to SEQ ID
NOS:132 or 133 and a light chain according to SEQ ID NO:142.
Example 4: Characterization of the Humanized Anti-Human CD40
Antibodies
[0174] To ensure the humanized anti-CD40 antibodies retained the
agonistic and other desired properties of the parental murine
antibodies, a panel of characterization assays was performed to
determine NF.kappa.B activation, CD40 binding kinetics, species
cross-reactivity and epitope classes of the humanized antibodies of
the disclosure.
[0175] 8.4.1. NF.kappa.B Activation
[0176] NF.kappa.B activation by humanized anti-CD40 antibody of the
invention was evaluated in HEK293 blue CD40 NF.kappa.B reporter
cells. The activation was represented as SEAP (secreted embryonic
alkaline phosphatase) reporter gene activity measured at
OD.sub.655. The maximal OD655 measured and the concentration for
half-maximal activation (EC.sub.50) are summarized in Table
4-1.
TABLE-US-00012 TABLE 4-1 NF.kappa.B activation in HEK293 blue CD40
NF.kappa.B reporter cells Humanized EC.sub.50 Maximal activation
antibody (.mu.g/mL) (OD.sub.655) huAb6-1 1.09 0.26 huAb6-2 1.21
0.20 huAb6-3 4.31 0.32 huAb8-1 0.14 0.45 huAb8-3 0.07 0.46 huAb9-1
0.19 0.26 huAb9-2 0.29 0.27 huAb9-3 0.18 0.27 huAb9-4 5.55 0.61
huAb9-5 1.13 0.67 huAb9-6 5.95 0.54
[0177] 8.4.2. CD40 Binding Kinetics and Species
Cross-Reactivity
[0178] The binding affinities of the disclosed humanized anti-CD40
antibodies were analyzed by both BIAcore and flow cytometry
analysis.
[0179] CD40 binding kinetics was analyzed by BIAcore assay with a
BIAcore T200 instrument. Briefly, a goat anti-mouse Fc antibody
(Pierce, cat #31170) or goat anti-human Fc (Pierce, cat #31125) was
immobilized on a CM5 sensor chip, followed by capture of the
anti-CD40 antibodies on the test surface. Subsequently, the soluble
form of the extracellular domain of human CD40 (Creative BioMart,
cat #CD402221H) or cynomolgus (cyno) CD40 (Creative BioMart, cat
#CD40-8824C) was injected, and the binding and dissociation were
measured.
[0180] Surface plasmon resonance data indicated that humanized
huAb8-1, huAb9-5, huAb9 A2I, and huAb9 A2V antibodies retained
similar binding affinities (K.sub.D) as that of their parental
clones AD163.7.2 ("muAb8") or clone AD164.14.6 ("muAb9"), and
showed similar binding to human or cynomolgus CD40 (Table 4-2).
TABLE-US-00013 TABLE 4-2 Affinity measured by BIAcore* Human CD40
Cynomolgus CD40 Antibody k.sub.a (1/Ms) k.sub.d (1/s) K.sub.D (M)
k.sub.a (1/Ms) k.sub.d (1/s) K.sub.D (M) muAb6 7.6E+04 4.8E-03
6.3E-08 Not determined muAb7 7.5E+04 4.8E-03 6.4E-08 Not determined
muAb8 1.0E+06 4.2E-03 4.1E-09 Not determined muAb3 6.9E+04 1.2E-02
1.7E-07 Not determined muAb1 4.7E+05 1.6E-02 3.5E-08 Not determined
muAb2 2.8E+06 9.6E-03 3.5E-09 Not determined muAb4 2.3E+06 1.7E-01
7.6E-08 Not determined muAb5 2.3E+06 2.0E-03 8.8E-10 Not determined
muAb10 2.6E+06 3.4E-02 1.3E-08 Not determined muAb9 2.8E+06 5.2E-02
1.9E-08 Not determined huAb8-1 7.7E+05 2.3E-03 3.0E-09 1.0E+06
7.1E-03 7.1E-09 huAb9-5 1.7E+06 2.6E-02 1.5E-08 1.8E+06 2.4E-02
1.3E-08 huAb9 A2I 1.3E+06 2.2E-01 1.7E-07 1.7E+06 2.5E-01 1.5E-07
huAb9 A2V 1.5E+06 2.6E-01 1.7E-07 1.9E+06 2.7E-01 1.4E-07 *Numbers
refer to scientific notation, e.g., 3.0E-09 = 3.0 * 10.sup.-9.
[0181] The humanized anti-CD40 antibodies were also evaluated for
binding to cell-surface CD40 on HEK293 cells stably transfected
with human or cynomolgus CD40, as well as B cells derived from
cynomolgus or human PBMC. Humanized anti-CD40 antibodies were
incubated with HEK293 transfectants for 15 minutes on ice, and the
binding was detected with a fluorescence-conjugated anti-human
secondary antibody (Jackson ImmunoResearch). FACS analysis of the
cells confirmed that the humanized antibodies bound to human and
cynomolgus CD40 stable cell lines. In contrast, no binding was
observed in similar experiments performed with mouse, rat or dog
CD40.
[0182] The anti-CD40 antibodies were also assessed for their
ability to bind to primary human and cynomolgus CD40-expressing
cells. PBMCs isolated from human or cynomolgus blood were incubated
with anti-CD40 antibodies conjugated to the fluorescence dye
CF640R. After FACS analysis, the data were analyzed by FlowJo
(FlowJo, LLC) software. These results demonstrated that the
humanized antibodies bound to primary CD40-positive cells derived
from both human and cynomolgus PBMC.
[0183] 8.4.3. Epitope Classification
[0184] Flow cytometry analysis and an ELISA method were used to
classify humanized agonistic anti-CD40 antibodies based on their
ability to compete with each other or CD40 ligand (CD40L) for
binding to CD40.
[0185] A flow cytometry analysis was developed to assess whether an
antibody competes for binding human CD40 with another antibody. In
this assay, CP-870,893, prepared from a fully human IgG.sub.2
anti-human CD40 antibody clone 21.4.1 (see, Gladue, R P. et al.,
Cancer Immunol. Immunother. 2011; 60:1009-17 and U.S. Pat. No.
7,618,633), was used as the reference antibody. The heavy and light
chains, respectively, of CP-870,893 were:
TABLE-US-00014 (SEQ ID NO: 181)
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGW
INPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQ
PLGYCTNGVCSYFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAA
LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS
NFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQ
FNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPRE
PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP
PMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK, and (SEQ ID
NO: 182) DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYT
ASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANIFPLTFGG
GTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKV
DNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKFIKVYACEVTHQ
GLSSPVTKSFNRGEC.
[0186] All anti-CD40 human or humanized antibodies, including
huAb6-1, huAb8-1, huAb9 A2I, and CP-870,893, were labeled with
Alexa Fluor (AF)-488. Each fluorescence-labeled antibody with fixed
concentration at 1 .mu.g/mL was separately mixed with increasing
amount of other unlabeled anti-CD40 antibodies ranging from 0.5
ng/mL up to 50 .mu.g/mL, and incubated with HEK293 cells stably
expressing human CD40. The binding of fluorescence-labeled antibody
was then monitored by flow cytometry.
[0187] The competitive antibodies identified by dose-dependent
reduction of mean fluorescence intensity (MFI) and non-competitive
antibodies identified by constant MFI were summarized in Table 4-3.
While huAb6-1 did not compete for binding human CD40 with huAb8-1,
both huAb9 A2I and the CP-870,893 competed with huAb6-1 and
huAb8-1. Additionally, huAb9 A2I and CP-870,893 competed with each
other.
TABLE-US-00015 TABLE 4-3 Epitope classification by flow cytometry
analysis second antibody first antibody huAb6-1 huAb8-1 huAb9 A2I
CP-870,893 huAb6-1 -- Y X X huAb8-1 Y -- X X huAb9 A2I X X -- X
CP-870,893 X X X -- X: mutually competitive; Y: mutually
non-competitive
[0188] Epitope classification of the humanized antibodies of the
invention was also confirmed by an ELISA assay measuring the
binding of anti-CD40 antibody and CD40 complex to plate-bound CD40L
as described in Example 2. In this assay, CP-870,893 as prepared
above was used as a reference anti-CD40 antibody. Increasing
amounts of anti-CD40 antibodies or human IgG.sub.1 (huIgG.sub.1)
control antibody were incubated with 1 .mu.g/mL of CD40-huFc fusion
protein, and added to a plate coated with CD40L. As shown in FIG.
3, humanized antibodies huAb8-1 and huAb8-3 blocked interaction of
CD40 and CD40L (upper left); huAb6-1 and huAb6-2 showed minimal
effect on CD40-CD40L interaction (upper right); and huAb9-5 and
huAb9-6 promoted CD40 binding to CD40L (lower left). Humanized
antibody huAb9 A2I also promoted CD40 binding to CD40L as compared
to CP-870,893, which showed minimal effect on CD40-CD40L
interaction (lower right).
[0189] The results were consistent with those obtained in a flow
cytometry based assay with cells expressing CD40L (FIG. 4). CD40L+
Jurkat cells were incubated with fluorochrome Alexa Fluor
488-conjugated soluble human CD40 protein at a constant
concentration of 1 .mu.g/mL. The binding of fluorochrome-conjugated
CD40 to Jurkat cell surface CD40L was measured by flow cytometry
analysis in the presence of humanized antibody huAb9 A2I and
reference anti-CD40 antibody CP-870,893. Enhanced fluorescence
intensity was detected upon increased amount of huAb9 A2I in the
sample, but not with reference antibody CP-870,893. These results
suggested that huAb9 A2I promoted CD40 binding to CD40L+ Jurkat
cells while the reference CP-870,893 did not.
[0190] The functional impact of huAb9 A2I on CD40 signaling driven
by CD40L was also determined in an assay comprising both CD40 and
CD40L expressing cells. CD40-expressing cells (HEK293 blue CD40
NF.kappa.B reporter cells described in Section 8.1.1) were mixed
with CD40L- or CD40L+ Jurkat cells at the ratio of 1:1, and
incubated with either huAb9 A2I, CP-870,893 or control antibody at
3 .mu.g/mL. The CD40 signaling was measured by SEAP reporter
activity through a colorimetric assay as described in Section
8.4.1. When CD40 reporter cells were co-cultured with CD40L-Jurkat
cells (FIG. 5A), CD40 signaling was significantly enhanced only
after addition of either huAb9 A2I or CP-870,893, but not with
treatment of control antibody or with no addition. Although both
antibodies activated CD40, huAb9 A2I was not significantly more
potent than CP-870,893 in stimulating CD40 under these conditions.
When CD40 reporter cells were co-cultured with CD40L+ Jurkat cells
(FIG. 5B), cell surface CD40L activated CD40 as indicated by SEAP
reporter activity. Treatment with CP-870,893 did not further
enhance CD40 activity signaling with SEAP reporter activity similar
to the control huIgG1 or huIgG2 isotype, or no antibody (media
only) treatment. In contrast, treatment with huAb9 A2I further
increased CD40 signaling with reporter activity significantly
greater than CP-870,893 and the control treatments
(p<0.001).
[0191] These data indicated that when cell surface CD40 was
activated by a saturated amount of cell surface CD40L, huAb9 A2I
further enhanced CD40 activation by effecting greater downstream
NF.kappa.B signaling as compared with an equivalent amount of known
anti-CD40 antibody CP-870,893.
Example 5: Fc Region Variants of Anti-CD40 Antibodies
[0192] Greater agonistic activity of CD40 can be achieved through
modifying the Fc region to enhance Fc.gamma.RIIB binding (Li and
Ravetch, Science, 2011; 333:1030-1034; and White, et al., J.
Immunol, 2011; 187:1754-1763). Two mutations, V273E and V273Y, at
position 273 in the human IgG.sub.1 constant region were introduced
into the humanized anti-CD40 antibodies huAb6-1, huAb8-1, huAb9-5,
and huAb9 A2I. The impact of the Fc mutations on binding to
Fc.gamma. receptors was monitored by FACS analysis and by
antibody-dependent cell-mediated cytotoxicity (ADCC). The agonistic
activities of humanized anti-CD40 with Fc modification were
monitored through activation of NF-kB reporter, B cells,
monocyte-derived DC and T cells.
[0193] 8.5.1. Fc.gamma. Receptor Binding and ADCC Function
[0194] Increasing amounts of anti-CD40 human IgG.sub.1 antibodies
and their Fc variants were incubated with CHO cells stably
expressing different human Fc.gamma. receptors, including
Fc.gamma.RI (CD64), Fc.gamma.RIIA (CD32a), Fc.gamma.RIIB (CD32b),
and Fc.gamma.RIIIA (CD16) with either F or V polymorphism. The
binding was detected with a fluorescence-conjugated anti-human
F(ab')2 specific secondary antibody (Jackson ImmunoResearch). The
mutations V273E or V273Y reduced binding to Fc.gamma.RIIIA (CD16F
or V) while maintaining Fc.gamma.RI (CD64) binding, and enhancing
Fc.gamma.RIIA (CD32a) or Fc.gamma.RIIB (CD32b) binding (FIGS.
6A-6B).
[0195] The ADCC of the Fc variants of the humanized anti-CD40
antibodies was measured using a standard protocol (Law et al.,
2005, Cancer Res. 65:8331-8). In an illustrative example, ADCC was
reduced with constant region variants V273E or V273Y as compared
with wild type IgG.sub.1 for antibody huAb9-5 in RL cells (FIG.
7).
[0196] 8.5.2. Enhanced Agonistic Activity Upon Fc.gamma.R
Binding
[0197] To evaluate the impact of Fc.gamma. receptor binding on
agonistic activity of anti-CD40, huAb9 A2I with huIgG.sub.1 V273E
mutation was used to treat HEK293 blue CD40 NF.kappa.B reporter
cells co-cultured with CHO cells stably expressing different human
Fc.gamma. receptors, and NF.kappa.B activity was monitored. As
shown in Table 5-1, agonistic activity of CP-870,893 in stimulating
NF.kappa.B activation was independent of Fc.gamma. receptor
binding, while agonistic activity of huAb9 A2I was found to be
dependent on Fc.gamma. receptor binding. The potency of huAb9 A2I
was ten-fold higher in stimulating NF.kappa.B activity when
reporter cells were co-cultured with CHO cells expressing CD32a,
CD32b or CD64 than when co-cultured with CHO cells without
Fc.gamma. receptor expression, or expressing CD16V or CD16F.
TABLE-US-00016 TABLE 5-1 NF.kappa.B activity (EC.sub.50, nM) CHO
(Fc.gamma.R) huAb9 A2I (huIgG.sub.1 V273E) CP-870,893 (huIgG.sub.2)
Fc.gamma.R negative 0.72 0.03 CD16F 0.39 0.03 CD16V 0.30 0.02 CD32a
0.08 0.02 CD32b 0.07 0.02 CD64 0.01 0.02
[0198] 8.5.3. Fc Variants on B Cell Proliferation
[0199] The impact of Fc V273E or V273Y mutation on agonistic
activity of anti-CD40 was also evaluated with B cell proliferation
assay. In this assay, human B cells were enriched by B cell
enrichment kit (StemCell Technologies) through negative selection.
The purified B cells were seeded into 96 well plates at
5.times.10.sup.5/ml, 200 .mu.L per well in AIM-V serum free medium
(GIBCO). Serially diluted anti-CD40 antibodies were added and
cultured with B cells for 6 days. In the last 16 hours of culture,
1 .mu.Ci of H.sup.3TdR were added to each well of the culture and B
cell proliferation was determined by H.sup.3TdR incorporation. The
radioactivity associated with H.sup.3TdR incorporation was recorded
by a scintillation counter as count per minute (CPM). Compared to
the corresponding human IgG1 wild-type antibodies, the anti-CD40
(huAb6-1, huAb8-1 and huAb9-5) human IgG1 Fc variants V273E and
V273Y showed enhanced B cell activation (FIG. 8). However, when
compared to CP-870,893, huAb9 A2I (human IgG.sub.1 V273E) showed
about ten-fold lower potency in stimulating B cell proliferation
(lower right graph).
[0200] 8.5.4. Fc Variants on DC IL-12p70 Production
[0201] The impact of Fc V273E or V273Y mutation on agonistic
activity of anti-CD40 was further evaluated with DC activation
assay using IL-12p70 as read-out. In this assay, immature DCs were
first derived from monocytes purified from human PBMC and treated
with IL4 and GM-CSF. DC maturation and IL-12p70 production were
induced by anti-CD40 after priming with IFN.gamma.. The V273E or
V273Y Fc mutated versions enhanced potency on DC activation by
enhancing IL-12p70 production. As illustrated in FIG. 9, huAb6-1
(upper left), huAb8-1 (upper right), and huAb9-5 (lower left) with
huIgG.sub.1 Fc variants V273E or V273Y showed increased IL-12p70
production as compared with their corresponding antibodies having
wild type huIgG.sub.1. For huAb6-1 and huAb8-1, the variant with
huIgG.sub.1 V273Y mutation was more effective at enhancing in vitro
IL-12p70 production than the one with the V273E mutation. For
huAb9-5, variants with huIgG.sub.1 V273E or V273Y showed similar
potency. In the case of huAb9 A2I (lower right graph), the variant
with huIgG.sub.1 V273E mutation demonstrated similar potency as
CP-870,893 in stimulating DC to produce IL-12p70.
[0202] 8.5.5. Fc Variants on T Cell Activation in Allogeneic DC and
T Cell Co-Culture
[0203] To demonstrate anti-CD40 could drive T cell activation
through stimulating antigen presenting cells such as DC, anti-CD40
Fc variants were tested in allogeneic DC and T cell co-culture. In
this assay, dendritic cells (5.times.10.sup.3) were first derived
from monocytes using the method described above, then mixed with
1.times.10.sup.5 T cells purified from a different donor. Various
amounts of anti-CD40 antibody huAb6-1, huAb8-1, or huAb9-5 with
either the wild-type human IgG.sub.1 constant region or their Fc
variants V273Y were added to the DC and T cell co-culture. After 4
days incubation, supernatants were collected and IFN-.gamma. was
measured by ELISA.
[0204] FIG. 10 illustrates exemplary antibodies that showed
enhanced IFN-.gamma. production in the co-culture with cells from
two different donor-pairs. In each instance, the V273Y variants of
huAb6-1, huAb8-1, and huAb9-5 demonstrated T cell activation as
evidenced by significant increases in IFN-.gamma. as compared with
an isotype control huIgG.sub.1 antibody.
Example 6: In Vivo Antitumor Activity of Anti-CD40 Antibodies
[0205] The humanized anti-CD40 antibodies huAb6-1, huAb9-5, and
huAb9 A2I with wild-type human IgG.sub.1 or Fc variants were
assessed for their ability to inhibit tumor growth in NSG mice
bearing the prostate PC3 tumors in the presence of human immune
cells.
[0206] NSG mice were inoculated subcutaneously with a mixture of
PC3 cells (1.times.10.sup.6), purified T cells (5.times.10.sup.5),
and autologous DCs (1.times.10.sup.5). A single dose of the
anti-CD40 antibodies or control antibodies at 1 mg/kg was injected
intraperitoneally immediately after inoculation. Tumor volumes were
measured every other day with calipers. Anti-CD40 antibodies
including huAb6-1, huAb9-5, huAb9 A2I and their Fc variants V273E
or V273Y reduced tumor growth as compared to isotype control
antibody in the PC3 model as shown in FIG. 11.
Example 7: Proof-of-Concept Studies in Mouse Syngeneic Tumor
Model
[0207] Due to the lack of mouse CD40 binding of exemplary anti-CD40
antibodies of the disclosure, evaluation of pharmacologic effects
in mouse was performed using a murine CD40 agonist antibody 1C10
muIgG.sub.1. In analogy to the huIgG.sub.1 Fc V273E mutation
discussed above, 1C10 with murine IgG.sub.1 (muIgG.sub.1) Fc
demonstrated strong binding to muFc.gamma.RIIB and minimal binding
to muFc.gamma.RI and muFc.gamma.RIV, the functional equivalent to
human Fc.gamma.RIII. Similar to the anti-CD40 antibodies of the
disclosure, 1C10 muIgG.sub.1 demonstrated potency in stimulating
mouse splenic B cell activation in vitro and in vivo. Therefore,
anti-murine CD40 antibody 1C10 with murine IgG.sub.1 constant
region was used as a proof of concept molecule to explore potential
clinical development paths, which included using intratumoral
delivery or combination therapy with co-administration of an
anti-PD-1 antibody.
[0208] 8.7.1. Intratumoral Administration
[0209] A CT26 syngeneic model in which mice harbored bilateral
subcutaneous tumors was used to investigate intratumoral
administration. Viable cells (1.times.10.sup.5) per mouse were
inoculated subcutaneously into the right and left hind flanks of
female Balb/c mice on Day 0. Animals were randomized into groups on
Day 12 with ten mice per group. The mean tumor volume of the right
flank at initiation of dosing was about 85 mm.sup.3. Three animals
from each group were sacrificed 24 hr after the first dose for
assessment of serum ALT. The remaining animals were monitored for
growth of both tumors. Tumor volume was determined twice weekly.
Measurements of the length (L), width (W) and height (H) of the
tumor were taken via electronic caliper and the volume was
calculated according to the following equation:
L.times.W.times.H/2. Antibody dosing began immediately following
randomization.
[0210] When anti-CD40 antibody 1C10 was directly injected into one
tumor (3 mg/kg, 2 to 3 times a week), the growth of tumors at both
the injected site ("IT dosed") as well as at a distal site ("Not IT
dosed") was reduced, suggesting the establishment of systemic
anti-tumor immunity (FIG. 12). Liver toxicity was monitored by
liver enzyme ALT measured by VetScan (Abaxis Inc., Union City,
Calif.). Intratumoral (IT) dosing of anti-CD40 antibody 1C10
incurred lower ALT elevation than systemic intraperitoneal (IP)
dosing.
[0211] 8.7.2. Combination Therapy with Co-Administration of an
Anti-PD-1 Antibody
[0212] CT26 tumor was established by inoculating 1.times.10.sup.5
viable cells per mouse subcutaneously into the right flank of
female BALB/c mice on Day 0. Animals were randomized into groups on
Day 15. Anti-CD40 antibody 1C10 (0.6 mg/kg) in combination with a
proprietary anti-PD1 muIgG.sub.2a antibody (10 mg/kg) were dosed IP
twice a week in a syngeneic CT26 mouse model. The combined
administration regimen exhibited significant anti-tumor activity (7
out of 10 mice showed tumor regression vs. 0 in control and 1 out
of 10 in each of anti-PD1 or anti-CD40 treated group), supporting
the development of this combination (FIG. 13).
[0213] Treatment of anti-CD40 antibody 1C10 was performed at 0.6
mg/kg, which was a sub-therapeutic dose for monotherapy in this
model. In some cases, maintaining a level of anti-tumor efficacy at
such doses of each monoclonal antibody may afford reduced toxicity,
as evidenced, e.g., by liver enzyme levels. In this experiment, the
combination treatment did not increase liver enzyme levels, spleen
weight, or cytokine levels, such as TNF.alpha. or IL-6 (FIG. 14).
Liver enzyme levels were measured by VetScan, and cytokine levels
were measured with MILLIPLEX Map Mouse Cytokine Kit (EMD
Millipore).
[0214] All publications, patents, patent applications and other
documents cited in this application are hereby incorporated by
reference in their entireties for all purposes to the same extent
as if each individual publication, patent, patent application or
other document were individually indicated to be incorporated by
reference for all purposes.
[0215] While various specific embodiments have been illustrated and
described, it will be appreciated that various changes can be made
without departing from the spirit and scope of the invention(s).
Sequence CWU 1 SEQUENCE LISTING <160> NUMBER OF SEQ ID
NOS: 200 <210> SEQ ID NO 1 <211> LENGTH: 10 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic peptide <400> SEQUENCE: 1 Gly Tyr Thr Phe
Thr Ser Tyr Trp Ile Thr 1 5 10 <210> SEQ ID NO 2 <211>
LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 2 Gly Tyr Thr Phe Thr Gly Tyr Trp Ile Gln 1 5 10
<210> SEQ ID NO 3 <211> LENGTH: 10 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 3 Gly Tyr Thr Phe Thr Asp
Tyr Tyr Met Asn 1 5 10 <210> SEQ ID NO 4 <211> LENGTH:
10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 4 Gly
Phe Thr Phe Ser Asp Tyr Tyr Met Ser 1 5 10 <210> SEQ ID NO 5
<211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 5 Gly Tyr Ser Ile Thr Thr Asn Tyr Asn Trp Asn
1 5 10 <210> SEQ ID NO 6 <211> LENGTH: 10 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic peptide <400> SEQUENCE: 6 Gly Tyr Thr Phe
Thr Ser Tyr Trp Met His 1 5 10 <210> SEQ ID NO 7 <211>
LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 7 Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile Asn 1 5 10
<210> SEQ ID NO 8 <211> LENGTH: 11 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 8 Gly Tyr Ser Ile Thr Ser
Asn Tyr Tyr Trp Asn 1 5 10 <210> SEQ ID NO 9 <211>
LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 9 Gly Tyr Ser Ile Ser Ser Asn Tyr Tyr Trp Asn 1 5 10
<210> SEQ ID NO 10 <211> LENGTH: 11 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 10 Gly Tyr Asp Ile Thr Ser
Asn Tyr Tyr Trp Asn 1 5 10 <210> SEQ ID NO 11 <211>
LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 11 Glu Ile Asn Pro Gly Ser Gly Ser Thr Asn Tyr Asn Glu
Lys Phe Lys 1 5 10 15 Ser <210> SEQ ID NO 12 <211>
LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 12 Glu Ile Leu Pro Gly Gly Asp His Thr Lys Tyr Asn Glu
Lys Phe Arg 1 5 10 15 Gly <210> SEQ ID NO 13 <211>
LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 13 Asp Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln
Lys Phe Lys 1 5 10 15 Gly <210> SEQ ID NO 14 <211>
LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 14 Phe Ile Arg Asn Lys Ala Asn Gly Tyr Thr Thr Glu Phe
Ser Ala Ser 1 5 10 15 Val Lys Gly <210> SEQ ID NO 15
<211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 15 Tyr Ile Arg His Asp Gly Thr Asn Asn Tyr
Asn Pro Ser Leu Lys Asn 1 5 10 15 <210> SEQ ID NO 16
<211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 16 Asn Ile Asp Pro Ser Asn Gly Glu Thr His
Tyr Asn Gln Lys Phe Lys 1 5 10 15 Asp <210> SEQ ID NO 17
<211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 17 Trp Ile Phe Pro Gly Ser Gly Ser Val Tyr
Cys Asn Glu Gln Phe Lys 1 5 10 15 Gly <210> SEQ ID NO 18
<211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 18 Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr
Asn Pro Ser Leu Lys Asn 1 5 10 15 <210> SEQ ID NO 19
<211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 19 Asn Ile Asp Pro Ser Asn Gly Glu Thr His
Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> SEQ ID NO 20
<211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 20 Trp Ile Phe Pro Gly Ser Gly Ser Val Tyr
Ser Asn Glu Gln Phe Lys 1 5 10 15 Gly <210> SEQ ID NO 21
<211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 21 Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr
Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> SEQ ID NO 22
<211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 22 Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr
Asn Pro Ser Leu Lys Gly 1 5 10 15 <210> SEQ ID NO 23
<400> SEQUENCE: 23 000 <210> SEQ ID NO 24 <400>
SEQUENCE: 24 000 <210> SEQ ID NO 25 <400> SEQUENCE: 25
000 <210> SEQ ID NO 26 <400> SEQUENCE: 26 000
<210> SEQ ID NO 27 <400> SEQUENCE: 27 000 <210>
SEQ ID NO 28 <400> SEQUENCE: 28 000 <210> SEQ ID NO 29
<400> SEQUENCE: 29 000 <210> SEQ ID NO 30 <400>
SEQUENCE: 30 000 <210> SEQ ID NO 31 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 31 Asn
Arg Gly Thr Gly Asp Tyr 1 5 <210> SEQ ID NO 32 <211>
LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 32 Val Gly Gly Asp Tyr 1 5 <210> SEQ ID NO 33
<211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 33 Arg Gly Gly Leu Gly Arg Gly Thr Tyr Ala
Leu Asp Tyr 1 5 10 <210> SEQ ID NO 34 <211> LENGTH: 12
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 34 Tyr
Gly Gly Leu Arg Gln Gly Trp Tyr Phe Asp Val 1 5 10 <210> SEQ
ID NO 35 <211> LENGTH: 3 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide <400> SEQUENCE: 35 Leu Asp Tyr 1 <210> SEQ ID
NO 36 <211> LENGTH: 16 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide <400> SEQUENCE: 36 Glu Arg Ile Tyr Tyr Ser Gly Ser
Thr Tyr Asp Gly Tyr Phe Asp Val 1 5 10 15 <210> SEQ ID NO 37
<211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 37 Ser Leu Gly Lys Phe Ala Tyr 1 5
<210> SEQ ID NO 38 <400> SEQUENCE: 38 000 <210>
SEQ ID NO 39 <400> SEQUENCE: 39 000 <210> SEQ ID NO 40
<211> LENGTH: 277 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 40 Met Val Arg Leu Pro Leu Gln
Cys Val Leu Trp Gly Cys Leu Leu Thr 1 5 10 15 Ala Val His Pro Glu
Pro Pro Thr Ala Cys Arg Glu Lys Gln Tyr Leu 20 25 30 Ile Asn Ser
Gln Cys Cys Ser Leu Cys Gln Pro Gly Gln Lys Leu Val 35 40 45 Ser
Asp Cys Thr Glu Phe Thr Glu Thr Glu Cys Leu Pro Cys Gly Glu 50 55
60 Ser Glu Phe Leu Asp Thr Trp Asn Arg Glu Thr His Cys His Gln His
65 70 75 80 Lys Tyr Cys Asp Pro Asn Leu Gly Leu Arg Val Gln Gln Lys
Gly Thr 85 90 95 Ser Glu Thr Asp Thr Ile Cys Thr Cys Glu Glu Gly
Trp His Cys Thr 100 105 110 Ser Glu Ala Cys Glu Ser Cys Val Leu His
Arg Ser Cys Ser Pro Gly 115 120 125 Phe Gly Val Lys Gln Ile Ala Thr
Gly Val Ser Asp Thr Ile Cys Glu 130 135 140 Pro Cys Pro Val Gly Phe
Phe Ser Asn Val Ser Ser Ala Phe Glu Lys 145 150 155 160 Cys His Pro
Trp Thr Ser Cys Glu Thr Lys Asp Leu Val Val Gln Gln 165 170 175 Ala
Gly Thr Asn Lys Thr Asp Val Val Cys Gly Pro Gln Asp Arg Leu 180 185
190 Arg Ala Leu Val Val Ile Pro Ile Ile Phe Gly Ile Leu Phe Ala Ile
195 200 205 Leu Leu Val Leu Val Phe Ile Lys Lys Val Ala Lys Lys Pro
Thr Asn 210 215 220 Lys Ala Pro His Pro Lys Gln Glu Pro Gln Glu Ile
Asn Phe Pro Asp 225 230 235 240 Asp Leu Pro Gly Ser Asn Thr Ala Ala
Pro Val Gln Glu Thr Leu His 245 250 255 Gly Cys Gln Pro Val Thr Gln
Glu Asp Gly Lys Glu Ser Arg Ile Ser 260 265 270 Val Gln Glu Arg Gln
275 <210> SEQ ID NO 41 <211> LENGTH: 261 <212>
TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:
41 Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly
1 5 10 15 Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val
Phe Leu 20 25 30 Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val
Tyr Leu His Arg 35 40 45 Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn
Leu His Glu Asp Phe Val 50 55 60 Phe Met Lys Thr Ile Gln Arg Cys
Asn Thr Gly Glu Arg Ser Leu Ser 65 70 75 80 Leu Leu Asn Cys Glu Glu
Ile Lys Ser Gln Phe Glu Gly Phe Val Lys 85 90 95 Asp Ile Met Leu
Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu 100 105 110 Met Gln
Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser 115 120 125
Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly 130
135 140 Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys
Gln 145 150 155 160 Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr
Ala Gln Val Thr 165 170 175 Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln
Ala Pro Phe Ile Ala Ser 180 185 190 Leu Cys Leu Lys Ser Pro Gly Arg
Phe Glu Arg Ile Leu Leu Arg Ala 195 200 205 Ala Asn Thr His Ser Ser
Ala Lys Pro Cys Gly Gln Gln Ser Ile His 210 215 220 Leu Gly Gly Val
Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn 225 230 235 240 Val
Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe 245 250
255 Gly Leu Leu Lys Leu 260 <210> SEQ ID NO 42 <400>
SEQUENCE: 42 000 <210> SEQ ID NO 43 <400> SEQUENCE: 43
000 <210> SEQ ID NO 44 <400> SEQUENCE: 44 000
<210> SEQ ID NO 45 <400> SEQUENCE: 45 000 <210>
SEQ ID NO 46 <400> SEQUENCE: 46 000 <210> SEQ ID NO 47
<400> SEQUENCE: 47 000 <210> SEQ ID NO 48 <400>
SEQUENCE: 48 000 <210> SEQ ID NO 49 <400> SEQUENCE: 49
000 <210> SEQ ID NO 50 <400> SEQUENCE: 50 000
<210> SEQ ID NO 51 <211> LENGTH: 16 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 51 Arg Ser Ser Gln Ser Leu
Val His Ser Tyr Gly Asn Thr Tyr Leu His 1 5 10 15 <210> SEQ
ID NO 52 <211> LENGTH: 16 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide <400> SEQUENCE: 52 Arg Ser Ser Gln Ser Leu Val Asn
Ser Asn Glu Asn Thr Tyr Leu His 1 5 10 15 <210> SEQ ID NO 53
<211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 53 Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu
Asn 1 5 10 <210> SEQ ID NO 54 <211> LENGTH: 11
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 54 Arg
Ala Ser Gln Asp Ile Arg Asn Tyr Leu Asn 1 5 10 <210> SEQ ID
NO 55 <211> LENGTH: 16 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide <400> SEQUENCE: 55 Arg Ser Ser Gln Ser Leu Glu Asn
Ser Tyr Gly Asn Thr Phe Leu Asn 1 5 10 15 <210> SEQ ID NO 56
<211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 56 Ser Ala Ser Ser Ser Leu Ser Tyr Met His 1
5 10 <210> SEQ ID NO 57 <211> LENGTH: 11 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic peptide <400> SEQUENCE: 57 Lys Ala Ser
Gln Ser Val Val Thr Ala Val Ala 1 5 10 <210> SEQ ID NO 58
<211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 58 Arg Ser Ser Gln Ser Leu Glu Asn Thr Asn
Gly Asn Thr Phe Leu Asn 1 5 10 15 <210> SEQ ID NO 59
<211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 59 Arg Ser Ser Gln Ser Leu Glu Asn Ser Asn
Gly Asn Thr Phe Leu Asn 1 5 10 15 <210> SEQ ID NO 60
<400> SEQUENCE: 60 000 <210> SEQ ID NO 61 <211>
LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 61 Lys Val Ser Asn Arg Ile Ser 1 5 <210> SEQ ID NO
62 <211> LENGTH: 7 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide <400> SEQUENCE: 62 Lys Val Phe Asn Arg Tyr Ser 1 5
<210> SEQ ID NO 63 <211> LENGTH: 7 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 63 Tyr Thr Ser Arg Leu His
Leu 1 5 <210> SEQ ID NO 64 <211> LENGTH: 7 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic peptide <400> SEQUENCE: 64 Tyr Thr Ser
Arg Leu His Ser 1 5 <210> SEQ ID NO 65 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 65 Arg
Val Ser Asn Arg Phe Cys 1 5 <210> SEQ ID NO 66 <211>
LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 66 Asp Thr Ser Lys Leu Ala Ser 1 5 <210> SEQ ID NO
67 <211> LENGTH: 7 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide <400> SEQUENCE: 67 Ser Ala Ser Asn Arg Tyr Thr 1 5
<210> SEQ ID NO 68 <211> LENGTH: 7 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 68 Arg Val Ser Asn Arg Phe
Ser 1 5 <210> SEQ ID NO 69 <211> LENGTH: 7 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic peptide <400> SEQUENCE: 69 Arg Ile Ser
Asn Arg Phe Ser 1 5 <210> SEQ ID NO 70 <400> SEQUENCE:
70 000 <210> SEQ ID NO 71 <400> SEQUENCE: 71 000
<210> SEQ ID NO 72 <400> SEQUENCE: 72 000 <210>
SEQ ID NO 73 <400> SEQUENCE: 73 000 <210> SEQ ID NO 74
<400> SEQUENCE: 74 000 <210> SEQ ID NO 75 <400>
SEQUENCE: 75 000 <210> SEQ ID NO 76 <400> SEQUENCE: 76
000 <210> SEQ ID NO 77 <400> SEQUENCE: 77 000
<210> SEQ ID NO 78 <400> SEQUENCE: 78 000 <210>
SEQ ID NO 79 <400> SEQUENCE: 79 000 <210> SEQ ID NO 80
<400> SEQUENCE: 80 000 <210> SEQ ID NO 81 <211>
LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 81 Ser Gln Ser Thr His Val Pro Tyr Thr 1 5 <210>
SEQ ID NO 82 <211> LENGTH: 9 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 82 Phe Gln Ser Thr His Val
Pro Trp Thr 1 5 <210> SEQ ID NO 83 <211> LENGTH: 9
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 83 Gln
Gln Gly Asn Thr Leu Pro Leu Thr 1 5 <210> SEQ ID NO 84
<211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 84 Gln Gln Gly Lys Thr Leu Pro Trp Thr 1 5
<210> SEQ ID NO 85 <211> LENGTH: 9 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 85 Leu Gln Val Thr His Val
Pro Tyr Thr 1 5 <210> SEQ ID NO 86 <211> LENGTH: 9
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 86 Gln
Gln Trp Ser Ser Asn Pro Trp Thr 1 5 <210> SEQ ID NO 87
<211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 87 Gln Gln Tyr Ser Ser Tyr Pro Tyr Thr 1 5
<210> SEQ ID NO 88 <211> LENGTH: 9 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 88 Leu Gln Val Thr His Val
Pro Phe Thr 1 5 <210> SEQ ID NO 89 <400> SEQUENCE: 89
000 <210> SEQ ID NO 90 <400> SEQUENCE: 90 000
<210> SEQ ID NO 91 <400> SEQUENCE: 91 000 <210>
SEQ ID NO 92 <400> SEQUENCE: 92 000 <210> SEQ ID NO 93
<400> SEQUENCE: 93 000 <210> SEQ ID NO 94 <400>
SEQUENCE: 94 000 <210> SEQ ID NO 95 <400> SEQUENCE: 95
000 <210> SEQ ID NO 96 <400> SEQUENCE: 96 000
<210> SEQ ID NO 97 <400> SEQUENCE: 97 000 <210>
SEQ ID NO 98 <400> SEQUENCE: 98 000 <210> SEQ ID NO 99
<400> SEQUENCE: 99 000 <210> SEQ ID NO 100 <400>
SEQUENCE: 100 000 <210> SEQ ID NO 101 <211> LENGTH: 116
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
101 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
Ser Tyr 20 25 30 Trp Ile Thr Trp Val Lys Gln Arg Pro Gly Gln Gly
Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Gly Ser Gly Ser Thr
Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val
Asp Thr Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu
Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg
Gly Thr Gly Asp Tyr Trp Gly Gln Gly Thr Thr Leu 100 105 110 Thr Val
Ser Ser 115 <210> SEQ ID NO 102 <211> LENGTH: 114
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
102 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly Ala
1 5 10 15 Ser Ala Lys Leu Ser Cys Lys Ala Thr Gly Tyr Thr Phe Thr
Gly Tyr 20 25 30 Trp Ile Gln Trp Val Lys Gln Arg Pro Gly His Gly
Leu Glu Trp Ile 35 40 45 Gly Glu Ile Leu Pro Gly Gly Asp His Thr
Lys Tyr Asn Glu Lys Phe 50 55 60 Arg Gly Lys Ala Thr Phe Thr Ser
Asp Thr Ser Ser Asn Thr Val Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu
Thr Thr Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg Val Gly
Gly Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 100 105 110 Ser Ser
<210> SEQ ID NO 103 <211> LENGTH: 122 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 103 Glu Val Gln Leu Gln
Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys
Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr
Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40
45 Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe
50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr
Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala
Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Gly Gly Leu Gly Arg Gly Thr
Tyr Ala Leu Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Ser Val Thr Val
Ser Ser 115 120 <210> SEQ ID NO 104 <211> LENGTH: 113
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
104 Leu Val Gln Pro Gly Gly Ser Leu Ser Leu Ser Cys Ala Ala Ser Gly
1 5 10 15 Phe Thr Phe Ser Asp Tyr Tyr Met Ser Trp Val Arg Gln Pro
Pro Gly 20 25 30 Lys Ala Leu Glu Trp Leu Gly Phe Ile Arg Asn Lys
Ala Asn Gly Tyr 35 40 45 Thr Thr Glu Phe Ser Ala Ser Val Lys Gly
Arg Phe Thr Ile Ser Arg 50 55 60 Asp Asn Ser Gln Ser Ile Leu Tyr
Leu Gln Met Asn Ala Leu Arg Ala 65 70 75 80 Glu Asp Ser Ala Thr Tyr
Tyr Cys Ala Arg Tyr Gly Gly Leu Arg Gln 85 90 95 Gly Trp Tyr Phe
Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser 100 105 110 Ser
<210> SEQ ID NO 105 <211> LENGTH: 112 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 105 Asp Val Gln Leu Gln
Glu Ser Gly Pro Gly Leu Val Glu Pro Ser Gln 1 5 10 15 Ser Leu Phe
Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Thr Asn 20 25 30 Tyr
Asn Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 35 40
45 Met Gly Tyr Ile Arg His Asp Gly Thr Asn Asn Tyr Asn Pro Ser Leu
50 55 60 Lys Asn Arg Ile Ser Ile Ile Arg Asp Thr Pro Lys Asn Gln
Phe Phe 65 70 75 80 Leu Lys Leu Asn Ser Val Thr Thr Glu Asp Thr Ala
Ile Tyr Phe Cys 85 90 95 Thr Arg Leu Asp Tyr Trp Gly Gln Gly Thr
Ser Val Thr Val Ser Ser 100 105 110 <210> SEQ ID NO 106
<211> LENGTH: 125 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 106 Gln Val Gln Leu Gln Gln Pro
Gly Ala Glu Leu Val Arg Pro Gly Ser 1 5 10 15 Ser Val Lys Leu Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His
Trp Val Lys Gln Arg Pro Ile Gln Gly Leu Glu Trp Ile 35 40 45 Gly
Asn Ile Asp Pro Ser Asn Gly Glu Thr His Tyr Asn Gln Lys Phe 50 55
60 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Glu Arg Ile Tyr Tyr Ser Gly Ser Thr Tyr
Asp Gly Tyr Phe 100 105 110 Asp Val Trp Gly Thr Gly Thr Thr Val Thr
Val Ser Ser 115 120 125 <210> SEQ ID NO 107 <211>
LENGTH: 116 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 107 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu
Leu Val Lys Ser Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Ile Asn Trp Val Lys
Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Phe
Pro Gly Ser Gly Ser Val Tyr Cys Asn Glu Gln Phe 50 55 60 Lys Gly
Gln Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr 65 70 75 80
Met Leu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85
90 95 Ala Ser Ser Leu Gly Lys Phe Ala Tyr Trp Gly Gln Gly Thr Leu
Val 100 105 110 Thr Val Ser Ala 115 <210> SEQ ID NO 108
<211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 108 Asp Val Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Ser Leu Ser Leu Thr
Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp
Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 35 40 45 Met
Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55
60 Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
65 70 75 80 Leu Lys Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr
Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu
Thr Val Ser Ser 100 105 110 <210> SEQ ID NO 109 <211>
LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 109 Asp Val Gln Leu Gln Glu Ser Gly Pro Gly
Leu Val Lys Pro Ser Gln 1 5 10 15 Ser Leu Ser Leu Thr Cys Ser Val
Thr Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp Asn Trp Ile
Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 35 40 45 Met Gly Tyr Ile
Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55 60 Lys Asn
Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 65 70 75 80
Leu Arg Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85
90 95 Thr Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser
Ser 100 105 110 <210> SEQ ID NO 110 <211> LENGTH: 125
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
110 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly
Leu Glu Trp Ile 35 40 45 Gly Asn Ile Asp Pro Ser Asn Gly Glu Thr
His Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Arg Ala Thr Leu Thr Val
Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu
Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Arg
Ile Tyr Tyr Ser Gly Ser Thr Tyr Asp Gly Tyr Phe 100 105 110 Asp Val
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210>
SEQ ID NO 111 <211> LENGTH: 125 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 111 Glu Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp
Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40
45 Gly Asn Ile Asp Pro Ser Asn Gly Glu Thr His Tyr Asn Gln Lys Phe
50 55 60 Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr
Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Arg Ile Tyr Tyr Ser Gly Ser
Thr Tyr Asp Gly Tyr Phe 100 105 110 Asp Val Trp Gly Gln Gly Thr Thr
Val Thr Val Ser Ser 115 120 125 <210> SEQ ID NO 112
<211> LENGTH: 125 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 112 Glu Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly
Asn Ile Asp Pro Ser Asn Gly Glu Thr His Tyr Ala Gln Lys Phe 50 55
60 Gln Gly Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Glu Arg Ile Tyr Tyr Ser Gly Ser Thr Tyr
Asp Gly Tyr Phe 100 105 110 Asp Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 125 <210> SEQ ID NO 113 <211>
LENGTH: 116 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 113 Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Ile Asn Trp Val Arg
Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Phe
Pro Gly Ser Gly Ser Val Tyr Cys Asn Glu Gln Phe 50 55 60 Lys Gly
Arg Ala Thr Leu Thr Val Asp Arg Ser Thr Ser Thr Ala Tyr 65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85
90 95 Ala Ser Ser Leu Gly Lys Phe Ala Tyr Trp Gly Gln Gly Thr Leu
Val 100 105 110 Thr Val Ser Ser 115 <210> SEQ ID NO 114
<211> LENGTH: 116 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 114 Glu Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Ile Asn
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly
Trp Ile Phe Pro Gly Ser Gly Ser Val Tyr Ser Asn Glu Gln Phe 50 55
60 Lys Gly Arg Ala Thr Leu Thr Val Asp Arg Ser Thr Ser Thr Ala Tyr
65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr
Phe Cys 85 90 95 Ala Ser Ser Leu Gly Lys Phe Ala Tyr Trp Gly Gln
Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> SEQ ID
NO 115 <211> LENGTH: 116 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 115 Glu Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Ile Asn
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly
Trp Ile Phe Pro Gly Ser Gly Ser Val Tyr Cys Asn Glu Gln Phe 50 55
60 Lys Gly Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Ser Ser Leu Gly Lys Phe Ala Tyr Trp Gly Gln
Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> SEQ ID
NO 116 <211> LENGTH: 112 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 116 Glu Val Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr
Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp
Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met
Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55
60 Lys Asn Arg Ile Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser
65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Val
Thr Val Ser Ser 100 105 110 <210> SEQ ID NO 117 <211>
LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 117 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly
Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val
Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp Asn Trp Ile
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met Gly Tyr Ile
Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55 60 Lys Asn
Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser 65 70 75 80
Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser
Ser 100 105 110 <210> SEQ ID NO 118 <211> LENGTH: 112
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
118 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Ser
Ser Asn 20 25 30 Tyr Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys
Gly Leu Glu Trp 35 40 45 Met Gly Tyr Ile Arg Tyr Asp Gly Ser Asn
Asn Tyr Asn Pro Ser Leu 50 55 60 Lys Ser Arg Val Thr Ile Ser Arg
Asp Thr Ser Lys Asn Gln Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val
Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Asp
Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110
<210> SEQ ID NO 119 <211> LENGTH: 112 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 119 Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Glu 1 5 10 15 Thr Leu Ser
Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40
45 Met Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu
50 55 60 Lys Gly Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln
Phe Tyr 65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr
Thr Val Thr Val Ser Ser 100 105 110 <210> SEQ ID NO 120
<211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 120 Glu Val Gln Leu Val Glu Ser
Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp
Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met
Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55
60 Lys Gly Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Leu Tyr
65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser 100 105 110 <210> SEQ ID NO 121 <211>
LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 121 Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Lys Pro Gly Glu 1 5 10 15 Thr Leu Ile Leu Thr Cys Thr Val
Ser Gly Tyr Asp Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp Asn Trp Ile
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met Gly Tyr Ile
Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55 60 Lys Gly
Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Tyr 65 70 75 80
Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser
Ser 100 105 110 <210> SEQ ID NO 122 <211> LENGTH: 112
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
122 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr
Ser Asn 20 25 30 Tyr Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys
Gly Leu Glu Trp 35 40 45 Met Gly Tyr Ile Arg Tyr Asp Gly Ser Asn
Asn Tyr Asn Pro Ser Leu 50 55 60 Lys Asn Arg Ile Thr Ile Ser Arg
Asp Thr Ser Lys Asn Gln Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val
Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Asp
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 100 105 110
<210> SEQ ID NO 123 <211> LENGTH: 112 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 123 Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr
Tyr Trp Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 35 40
45 Met Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu
50 55 60 Lys Asn Arg Ile Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr
Phe Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr
Leu Val Thr Val Ser Ser 100 105 110 <210> SEQ ID NO 124
<400> SEQUENCE: 124 000 <210> SEQ ID NO 125 <400>
SEQUENCE: 125 000 <210> SEQ ID NO 126 <400> SEQUENCE:
126 000 <210> SEQ ID NO 127 <400> SEQUENCE: 127 000
<210> SEQ ID NO 128 <400> SEQUENCE: 128 000 <210>
SEQ ID NO 129 <400> SEQUENCE: 129 000 <210> SEQ ID NO
130 <211> LENGTH: 442 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 130 Glu Val Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr
Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp
Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met
Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55
60 Lys Asn Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser
65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Val
Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala
Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185
190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His
Glu Asp Pro Glu Val Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310
315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu
Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420 425 430
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 <210> SEQ ID
NO 131 <211> LENGTH: 441 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 131 Glu Val Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr
Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp
Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met
Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55
60 Lys Asn Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser
65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Val
Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala
Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185
190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His
Glu Asp Pro Glu Val Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310
315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu
Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420 425 430
Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 <210> SEQ ID NO
132 <211> LENGTH: 442 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 132 Glu Val Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr
Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp
Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met
Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55
60 Lys Asn Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser
65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Val
Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala
Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185
190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His
Glu Asp Pro Glu Glu Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310
315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu
Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420 425 430
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 <210> SEQ ID
NO 133 <211> LENGTH: 441 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 133 Glu Val Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr
Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp
Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met
Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55
60 Lys Asn Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser
65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Val
Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala
Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185
190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His
Glu Asp Pro Glu Glu Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310
315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu
Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420 425 430
Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 <210> SEQ ID NO
134 <211> LENGTH: 442 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 134 Glu Val Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr
Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp
Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met
Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55
60 Lys Asn Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser
65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Val
Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala
Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185
190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His
Glu Asp Pro Glu Tyr Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310
315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu
Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420 425 430
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 <210> SEQ ID
NO 135 <211> LENGTH: 441 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 135 Glu Val Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr
Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp
Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met
Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55
60 Lys Asn Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser
65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Val
Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala
Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185
190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His
Glu Asp Pro Glu Tyr Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310
315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu
Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420 425 430
Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 <210> SEQ ID NO
136 <400> SEQUENCE: 136 000 <210> SEQ ID NO 137
<400> SEQUENCE: 137 000 <210> SEQ ID NO 138 <400>
SEQUENCE: 138 000 <210> SEQ ID NO 139 <400> SEQUENCE:
139 000 <210> SEQ ID NO 140 <211> LENGTH: 219
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
140 Asp Ala Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly
1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu
Asn Thr 20 25 30 Asn Gly Asn Thr Phe Leu Asn Trp Tyr Leu Gln Lys
Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn
Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu
Asp Val Gly Val Tyr Tyr Cys Leu Gln Val 85 90 95 Thr His Val Pro
Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg Thr
Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130
135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp
Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu
Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu
Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe
Asn Arg Gly Glu Cys 210 215 <210> SEQ ID NO 141 <211>
LENGTH: 219 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 141 Asp Ile Val Met Thr Gln Thr Pro Leu Ser
Leu Ser Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg
Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn Gly Asn Thr Phe Leu
Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu
Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Val 85
90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys
Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp
Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu
Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu
Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His
Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> SEQ
ID NO 142 <211> LENGTH: 219 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 142 Asp Val Val Met Thr Gln Thr
Pro Leu Ser Leu Ser Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile
Ser Cys Arg Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn Gly Asn
Thr Phe Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro
Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro 50 55
60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu
Gln Val 85 90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly Thr Lys
Leu Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile
Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser
Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys
Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn
Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185
190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215
<210> SEQ ID NO 143 <400> SEQUENCE: 143 000 <210>
SEQ ID NO 144 <400> SEQUENCE: 144 000 <210> SEQ ID NO
145 <400> SEQUENCE: 145 000 <210> SEQ ID NO 146
<400> SEQUENCE: 146 000 <210> SEQ ID NO 147 <400>
SEQUENCE: 147 000 <210> SEQ ID NO 148 <400> SEQUENCE:
148 000 <210> SEQ ID NO 149 <400> SEQUENCE: 149 000
<210> SEQ ID NO 150 <400> SEQUENCE: 150 000 <210>
SEQ ID NO 151 <211> LENGTH: 112 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 151 Asp Val Val Met Thr
Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala
Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Tyr
Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40
45 Pro Lys Phe Leu Ile Tyr Lys Val Ser Asn Arg Ile Ser Gly Val Pro
50 55 60 Asp Arg Leu Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
Lys Ile 65 70 75 80 Ser Arg Val Glu Pro Glu Asp Leu Gly Val Tyr Phe
Cys Ser Gln Ser 85 90 95 Thr His Val Pro Tyr Thr Phe Gly Gly Gly
Thr Lys Leu Glu Ile Lys 100 105 110 <210> SEQ ID NO 152
<211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 152 Asp Val Val Met Thr Gln Thr
Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile
Ser Cys Arg Ser Ser Gln Ser Leu Val Asn Ser 20 25 30 Asn Glu Asn
Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro
Lys Leu Leu Ile Tyr Lys Val Phe Asn Arg Tyr Ser Gly Val Pro 50 55
60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Phe
Gln Ser 85 90 95 Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys
Leu Glu Ile Lys 100 105 110 <210> SEQ ID NO 153 <211>
LENGTH: 107 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 153 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser
Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg
Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln
Lys Pro Asp Gly Thr Val Lys Pro Leu Ile 35 40 45 Tyr Tyr Thr Ser
Arg Leu His Leu Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Leu 85
90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105
<210> SEQ ID NO 154 <211> LENGTH: 107 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 154 Asp Ile Gln Met Thr
Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val
Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Arg Asn Tyr 20 25 30 Leu
Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40
45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu
Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Lys
Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Ser Lys Leu Glu Met
Lys 100 105 <210> SEQ ID NO 155 <211> LENGTH: 112
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
155 Asp Ala Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu
Asn Ser 20 25 30 Tyr Gly Asn Thr Phe Leu Asn Trp Phe Leu Gln Arg
Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn
Arg Phe Cys Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu
Asp Leu Gly Ile Tyr Phe Cys Leu Gln Val 85 90 95 Thr His Val Pro
Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110
<210> SEQ ID NO 156 <211> LENGTH: 106 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 156 Gln Ile Val Leu Thr
Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val
Thr Met Thr Cys Ser Ala Ser Ser Ser Leu Ser Tyr Met 20 25 30 His
Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr 35 40
45 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser
50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser
Asn Pro Trp Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 <210> SEQ ID NO 157 <211> LENGTH: 106
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
157 Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
1 5 10 15 Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Leu Ser
Tyr Met 20 25 30 His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys
Arg Trp Ile Tyr 35 40 45 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro
Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu
Thr Ile Ser Ser Met Glu Gly Glu 65 70 75 80 Asp Gly Ala Thr Tyr Tyr
Cys Gln Gln Trp Ser Ser Asn Pro Trp Thr 85 90 95 Phe Gly Gly Gly
Thr Lys Leu Glu Ile Lys 100 105 <210> SEQ ID NO 158
<211> LENGTH: 107 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 158 Asp Ile Val Met Thr Gln Ser
Gln Lys Phe Met Ser Thr Thr Val Gly 1 5 10 15 Asp Arg Val Ser Ile
Thr Cys Lys Ala Ser Gln Ser Val Val Thr Ala 20 25 30 Val Ala Trp
Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr
Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55
60 Ser Gly Ser Gly Thr Asp Phe Ala Leu Thr Ile Arg Thr Met Gln Ser
65 70 75 80 Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr
Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100
105 <210> SEQ ID NO 159 <211> LENGTH: 112 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic polypeptide <400> SEQUENCE: 159 Asp Ala
Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu Asn Thr 20
25 30 Asn Gly Asn Thr Phe Leu Asn Trp Phe Leu Gln Lys Pro Gly Gln
Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser
Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly
Val Tyr Phe Cys Leu Gln Val 85 90 95 Thr His Val Pro Phe Thr Phe
Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> SEQ ID
NO 160 <211> LENGTH: 112 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 160 Asp Ala Val Met Thr Gln Thr
Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile
Ser Cys Arg Ser Ser Gln Ser Leu Glu Asn Ser 20 25 30 Asn Gly Asn
Thr Phe Leu Asn Trp Phe Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro
Gln Leu Leu Ile Tyr Arg Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55
60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Leu
Gln Val 85 90 95 Thr His Val Pro Phe Thr Phe Gly Ser Gly Thr Lys
Leu Glu Ile Lys 100 105 110 <210> SEQ ID NO 161 <211>
LENGTH: 106 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 161 Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser
Ala Ser Ser Ser Leu Ser Tyr Met 20 25 30 His Trp Tyr Gln Gln Lys
Pro Gly Lys Ser Pro Lys Arg Trp Ile Tyr 35 40 45 Asp Thr Ser Lys
Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 50 55 60 Gly Ser
Gly Thr Glu Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu 65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Trp Thr 85
90 95 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210>
SEQ ID NO 162 <211> LENGTH: 107 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 162 Asp Ile Gln Met Thr
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val
Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Val Thr Ala 20 25 30 Val
Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile 35 40
45 Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Tyr Ser
Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile
Lys 100 105 <210> SEQ ID NO 163 <211> LENGTH: 112
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
163 Asp Ala Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly
1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu
Asn Thr 20 25 30 Asn Gly Asn Thr Phe Leu Asn Trp Phe Leu Gln Lys
Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn
Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu
Asp Val Gly Val Tyr Phe Cys Leu Gln Val 85 90 95 Thr His Val Pro
Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110
<210> SEQ ID NO 164 <211> LENGTH: 112 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 164 Asp Ala Val Met Thr
Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 1 5 10 15 Gln Pro Ala
Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn
Gly Asn Thr Phe Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40
45 Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
Cys Leu Gln Val 85 90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly
Thr Lys Leu Glu Ile Lys 100 105 110 <210> SEQ ID NO 165
<211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 165 Asp Ala Val Met Thr Gln Thr
Pro Leu Ser Leu Ser Val Thr Glu Gly 1 5 10 15 Gln Pro Ala Ser Ile
Ser Cys Arg Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn Gly Asn
Thr Phe Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro
Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro 50 55
60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu
Gln Val 85 90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly Thr Lys
Leu Glu Ile Lys 100 105 110 <210> SEQ ID NO 166 <211>
LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 166 Asp Ala Val Met Thr Gln Thr Pro Leu Ser
Leu Ala Val Leu Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg
Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn Gly Asn Thr Phe Leu
Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu
Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Val 85
90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
Lys 100 105 110 <210> SEQ ID NO 167 <211> LENGTH: 112
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
167 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser Leu Glu
Asn Thr 20 25 30 Asn Gly Asn Thr Phe Leu Asn Trp Tyr Gln Gln Lys
Pro Gly Lys Ala 35 40 45 Pro Lys Leu Leu Ile Tyr Arg Val Ser Asn
Arg Phe Ser Gly Val Pro 50 55 60 Ser Arg Phe Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr Leu Thr Ile 65 70 75 80 Ser Ser Leu Gln Pro Glu
Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Val 85 90 95 Thr His Val Pro
Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110
<210> SEQ ID NO 168 <211> LENGTH: 112 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 168 Asp Ala Val Met Thr
Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Glu Pro Ala
Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn
Gly Asn Thr Phe Leu Asn Trp Phe Gln Gln Lys Pro Gly Gln Ser 35 40
45 Pro Arg Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
Cys Leu Gln Val 85 90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly
Thr Lys Leu Glu Ile Lys 100 105 110 <210> SEQ ID NO 169
<211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 169 Asp Ala Gln Met Thr Gln Ser
Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile
Thr Cys Arg Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn Gly Asn
Thr Phe Leu Asn Trp Phe Gln Gln Lys Pro Gly Lys Ala 35 40 45 Pro
Lys Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro 50 55
60 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
65 70 75 80 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu
Gln Val 85 90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly Thr Lys
Leu Glu Ile Lys 100 105 110 <210> SEQ ID NO 170 <211>
LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 170 Asp Ile Val Met Thr Gln Thr Pro Leu Ser
Leu Ser Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg
Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn Gly Asn Thr Phe Leu
Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu
Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Val 85
90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
Lys 100 105 110 <210> SEQ ID NO 171 <211> LENGTH: 112
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
171 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly
1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu
Asn Thr 20 25 30 Asn Gly Asn Thr Phe Leu Asn Trp Tyr Leu Gln Lys
Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn
Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu
Asp Val Gly Val Tyr Tyr Cys Leu Gln Val 85 90 95 Thr His Val Pro
Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110
<210> SEQ ID NO 172 <400> SEQUENCE: 172 000 <210>
SEQ ID NO 173 <400> SEQUENCE: 173 000 <210> SEQ ID NO
174 <400> SEQUENCE: 174 000 <210> SEQ ID NO 175
<400> SEQUENCE: 175 000 <210> SEQ ID NO 176 <400>
SEQUENCE: 176 000 <210> SEQ ID NO 177 <400> SEQUENCE:
177 000 <210> SEQ ID NO 178 <400> SEQUENCE: 178 000
<210> SEQ ID NO 179 <400> SEQUENCE: 179 000 <210>
SEQ ID NO 180 <400> SEQUENCE: 180 000 <210> SEQ ID NO
181 <211> LENGTH: 452 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 181 Gln Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Met His
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly
Trp Ile Asn Pro Asp Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 50 55
60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65 70 75 80 Met Glu Leu Asn Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asp Gln Pro Leu Gly Tyr Cys Thr Asn Gly
Val Cys Ser Tyr 100 105 110 Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Ala Ser 115 120 125 Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Cys Ser Arg Ser Thr 130 135 140 Ser Glu Ser Thr Ala Ala
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro 145 150 155 160 Glu Pro Val
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val 165 170 175 His
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser 180 185
190 Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr
195 200 205 Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
Thr Val 210 215 220 Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro
Ala Pro Pro Val 225 230 235 240 Ala Gly Pro Ser Val Phe Leu Phe Pro
Pro Lys Pro Lys Asp Thr Leu 245 250 255 Met Ile Ser Arg Thr Pro Glu
Val Thr Cys Val Val Val Asp Val Ser 260 265 270 His Glu Asp Pro Glu
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285 Val His Asn
Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr 290 295 300 Phe
Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn 305 310
315 320 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala
Pro 325 330 335 Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg
Glu Pro Gln 340 345 350 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
Thr Lys Asn Gln Val 355 360 365 Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile Ala Val 370 375 380 Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400 Pro Met Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415 Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 420 425 430
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 435
440 445 Ser Pro Gly Lys 450 <210> SEQ ID NO 182 <211>
LENGTH: 214 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 182 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Gly Ile Tyr Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln
Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile 35 40 45 Tyr Thr Ala Ser
Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ile Phe Pro Leu 85
90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala
Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu
Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala
Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln
Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr
Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys
Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205
Phe Asn Arg Gly Glu Cys 210 <210> SEQ ID NO 183 <400>
SEQUENCE: 183 000 <210> SEQ ID NO 184 <400> SEQUENCE:
184 000 <210> SEQ ID NO 185 <400> SEQUENCE: 185 000
<210> SEQ ID NO 186 <400> SEQUENCE: 186 000 <210>
SEQ ID NO 187 <400> SEQUENCE: 187 000 <210> SEQ ID NO
188 <400> SEQUENCE: 188 000 <210> SEQ ID NO 189
<400> SEQUENCE: 189 000 <210> SEQ ID NO 190 <400>
SEQUENCE: 190 000 <210> SEQ ID NO 191 <400> SEQUENCE:
191 000 <210> SEQ ID NO 192 <400> SEQUENCE: 192 000
<210> SEQ ID NO 193 <400> SEQUENCE: 193 000 <210>
SEQ ID NO 194 <400> SEQUENCE: 194 000 <210> SEQ ID NO
195 <400> SEQUENCE: 195 000 <210> SEQ ID NO 196
<400> SEQUENCE: 196 000 <210> SEQ ID NO 197 <400>
SEQUENCE: 197 000 <210> SEQ ID NO 198 <400> SEQUENCE:
198 000 <210> SEQ ID NO 199 <400> SEQUENCE: 199 000
<210> SEQ ID NO 200 <211> LENGTH: 15 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 200 Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10 15
1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 200
<210> SEQ ID NO 1 <211> LENGTH: 10 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 1 Gly Tyr Thr Phe Thr Ser
Tyr Trp Ile Thr 1 5 10 <210> SEQ ID NO 2 <211> LENGTH:
10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 2 Gly
Tyr Thr Phe Thr Gly Tyr Trp Ile Gln 1 5 10 <210> SEQ ID NO 3
<211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 3 Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asn 1 5
10 <210> SEQ ID NO 4 <211> LENGTH: 10 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 4 Gly Phe Thr Phe Ser Asp
Tyr Tyr Met Ser 1 5 10 <210> SEQ ID NO 5 <211> LENGTH:
11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 5 Gly
Tyr Ser Ile Thr Thr Asn Tyr Asn Trp Asn 1 5 10 <210> SEQ ID
NO 6 <211> LENGTH: 10 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide <400> SEQUENCE: 6 Gly Tyr Thr Phe Thr Ser Tyr Trp Met
His 1 5 10 <210> SEQ ID NO 7 <211> LENGTH: 10
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 7 Gly
Tyr Thr Phe Thr Asp Tyr Tyr Ile Asn 1 5 10 <210> SEQ ID NO 8
<211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 8 Gly Tyr Ser Ile Thr Ser Asn Tyr Tyr Trp Asn
1 5 10 <210> SEQ ID NO 9 <211> LENGTH: 11 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic peptide <400> SEQUENCE: 9 Gly Tyr Ser Ile
Ser Ser Asn Tyr Tyr Trp Asn 1 5 10 <210> SEQ ID NO 10
<211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 10 Gly Tyr Asp Ile Thr Ser Asn Tyr Tyr Trp
Asn 1 5 10 <210> SEQ ID NO 11 <211> LENGTH: 17
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 11 Glu
Ile Asn Pro Gly Ser Gly Ser Thr Asn Tyr Asn Glu Lys Phe Lys 1 5 10
15 Ser <210> SEQ ID NO 12 <211> LENGTH: 17 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic peptide <400> SEQUENCE: 12 Glu Ile Leu
Pro Gly Gly Asp His Thr Lys Tyr Asn Glu Lys Phe Arg 1 5 10 15 Gly
<210> SEQ ID NO 13 <211> LENGTH: 17 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 13 Asp Ile Asn Pro Asn Asn
Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210>
SEQ ID NO 14 <211> LENGTH: 19 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 14 Phe Ile Arg Asn Lys Ala
Asn Gly Tyr Thr Thr Glu Phe Ser Ala Ser 1 5 10 15 Val Lys Gly
<210> SEQ ID NO 15 <211> LENGTH: 16 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 15 Tyr Ile Arg His Asp Gly
Thr Asn Asn Tyr Asn Pro Ser Leu Lys Asn 1 5 10 15 <210> SEQ
ID NO 16 <211> LENGTH: 17 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide <400> SEQUENCE: 16
Asn Ile Asp Pro Ser Asn Gly Glu Thr His Tyr Asn Gln Lys Phe Lys 1 5
10 15 Asp <210> SEQ ID NO 17 <211> LENGTH: 17
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 17 Trp
Ile Phe Pro Gly Ser Gly Ser Val Tyr Cys Asn Glu Gln Phe Lys 1 5 10
15 Gly <210> SEQ ID NO 18 <211> LENGTH: 16 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic peptide <400> SEQUENCE: 18 Tyr Ile Arg
Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu Lys Asn 1 5 10 15
<210> SEQ ID NO 19 <211> LENGTH: 17 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 19 Asn Ile Asp Pro Ser Asn
Gly Glu Thr His Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210>
SEQ ID NO 20 <211> LENGTH: 17 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 20 Trp Ile Phe Pro Gly Ser
Gly Ser Val Tyr Ser Asn Glu Gln Phe Lys 1 5 10 15 Gly <210>
SEQ ID NO 21 <211> LENGTH: 16 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 21 Tyr Ile Arg Tyr Asp Gly
Ser Asn Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> SEQ
ID NO 22 <211> LENGTH: 16 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide <400> SEQUENCE: 22 Tyr Ile Arg Tyr Asp Gly Ser Asn
Asn Tyr Asn Pro Ser Leu Lys Gly 1 5 10 15 <210> SEQ ID NO 23
<400> SEQUENCE: 23 000 <210> SEQ ID NO 24 <400>
SEQUENCE: 24 000 <210> SEQ ID NO 25 <400> SEQUENCE: 25
000 <210> SEQ ID NO 26 <400> SEQUENCE: 26 000
<210> SEQ ID NO 27 <400> SEQUENCE: 27 000 <210>
SEQ ID NO 28 <400> SEQUENCE: 28 000 <210> SEQ ID NO 29
<400> SEQUENCE: 29 000 <210> SEQ ID NO 30 <400>
SEQUENCE: 30 000 <210> SEQ ID NO 31 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 31 Asn
Arg Gly Thr Gly Asp Tyr 1 5 <210> SEQ ID NO 32 <211>
LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 32 Val Gly Gly Asp Tyr 1 5 <210> SEQ ID NO 33
<211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 33 Arg Gly Gly Leu Gly Arg Gly Thr Tyr Ala
Leu Asp Tyr 1 5 10 <210> SEQ ID NO 34 <211> LENGTH: 12
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 34 Tyr
Gly Gly Leu Arg Gln Gly Trp Tyr Phe Asp Val 1 5 10 <210> SEQ
ID NO 35 <211> LENGTH: 3 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide <400> SEQUENCE: 35 Leu Asp Tyr 1 <210> SEQ ID
NO 36 <211> LENGTH: 16 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide <400> SEQUENCE: 36 Glu Arg Ile Tyr Tyr Ser Gly Ser
Thr Tyr Asp Gly Tyr Phe Asp Val 1 5 10 15 <210> SEQ ID NO 37
<211> LENGTH: 7 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 37 Ser Leu Gly Lys Phe Ala
Tyr 1 5 <210> SEQ ID NO 38 <400> SEQUENCE: 38 000
<210> SEQ ID NO 39 <400> SEQUENCE: 39 000 <210>
SEQ ID NO 40 <211> LENGTH: 277 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 40 Met Val
Arg Leu Pro Leu Gln Cys Val Leu Trp Gly Cys Leu Leu Thr 1 5 10 15
Ala Val His Pro Glu Pro Pro Thr Ala Cys Arg Glu Lys Gln Tyr Leu 20
25 30 Ile Asn Ser Gln Cys Cys Ser Leu Cys Gln Pro Gly Gln Lys Leu
Val 35 40 45 Ser Asp Cys Thr Glu Phe Thr Glu Thr Glu Cys Leu Pro
Cys Gly Glu 50 55 60 Ser Glu Phe Leu Asp Thr Trp Asn Arg Glu Thr
His Cys His Gln His 65 70 75 80 Lys Tyr Cys Asp Pro Asn Leu Gly Leu
Arg Val Gln Gln Lys Gly Thr 85 90 95 Ser Glu Thr Asp Thr Ile Cys
Thr Cys Glu Glu Gly Trp His Cys Thr 100 105 110 Ser Glu Ala Cys Glu
Ser Cys Val Leu His Arg Ser Cys Ser Pro Gly 115 120 125 Phe Gly Val
Lys Gln Ile Ala Thr Gly Val Ser Asp Thr Ile Cys Glu 130 135 140 Pro
Cys Pro Val Gly Phe Phe Ser Asn Val Ser Ser Ala Phe Glu Lys 145 150
155 160 Cys His Pro Trp Thr Ser Cys Glu Thr Lys Asp Leu Val Val Gln
Gln 165 170 175 Ala Gly Thr Asn Lys Thr Asp Val Val Cys Gly Pro Gln
Asp Arg Leu 180 185 190 Arg Ala Leu Val Val Ile Pro Ile Ile Phe Gly
Ile Leu Phe Ala Ile 195 200 205 Leu Leu Val Leu Val Phe Ile Lys Lys
Val Ala Lys Lys Pro Thr Asn 210 215 220 Lys Ala Pro His Pro Lys Gln
Glu Pro Gln Glu Ile Asn Phe Pro Asp 225 230 235 240 Asp Leu Pro Gly
Ser Asn Thr Ala Ala Pro Val Gln Glu Thr Leu His 245 250 255 Gly Cys
Gln Pro Val Thr Gln Glu Asp Gly Lys Glu Ser Arg Ile Ser 260 265 270
Val Gln Glu Arg Gln 275 <210> SEQ ID NO 41 <211>
LENGTH: 261 <212> TYPE: PRT <213> ORGANISM: Homo
sapiens <400> SEQUENCE: 41 Met Ile Glu Thr Tyr Asn Gln Thr
Ser Pro Arg Ser Ala Ala Thr Gly 1 5 10 15 Leu Pro Ile Ser Met Lys
Ile Phe Met Tyr Leu Leu Thr Val Phe Leu 20 25 30 Ile Thr Gln Met
Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg 35 40 45 Arg Leu
Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val 50 55 60
Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser 65
70 75 80 Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe
Val Lys 85 90 95 Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu
Asn Ser Phe Glu 100 105 110 Met Gln Lys Gly Asp Gln Asn Pro Gln Ile
Ala Ala His Val Ile Ser 115 120 125 Glu Ala Ser Ser Lys Thr Thr Ser
Val Leu Gln Trp Ala Glu Lys Gly 130 135 140 Tyr Tyr Thr Met Ser Asn
Asn Leu Val Thr Leu Glu Asn Gly Lys Gln 145 150 155 160 Leu Thr Val
Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr 165 170 175 Phe
Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser 180 185
190 Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala
195 200 205 Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser
Ile His 210 215 220 Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser
Val Phe Val Asn 225 230 235 240 Val Thr Asp Pro Ser Gln Val Ser His
Gly Thr Gly Phe Thr Ser Phe 245 250 255 Gly Leu Leu Lys Leu 260
<210> SEQ ID NO 42 <400> SEQUENCE: 42 000 <210>
SEQ ID NO 43 <400> SEQUENCE: 43 000 <210> SEQ ID NO 44
<400> SEQUENCE: 44 000 <210> SEQ ID NO 45 <400>
SEQUENCE: 45 000 <210> SEQ ID NO 46 <400> SEQUENCE: 46
000 <210> SEQ ID NO 47 <400> SEQUENCE: 47 000
<210> SEQ ID NO 48 <400> SEQUENCE: 48 000 <210>
SEQ ID NO 49 <400> SEQUENCE: 49 000 <210> SEQ ID NO 50
<400> SEQUENCE: 50 000 <210> SEQ ID NO 51 <211>
LENGTH: 16 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 51 Arg Ser Ser Gln Ser Leu Val His Ser Tyr Gly Asn Thr
Tyr Leu His 1 5 10 15 <210> SEQ ID NO 52 <211> LENGTH:
16 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 52 Arg
Ser Ser Gln Ser Leu Val Asn Ser Asn Glu Asn Thr Tyr Leu His 1 5 10
15 <210> SEQ ID NO 53 <211> LENGTH: 11 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic peptide <400> SEQUENCE: 53
Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> SEQ
ID NO 54 <211> LENGTH: 11 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide <400> SEQUENCE: 54 Arg Ala Ser Gln Asp Ile Arg Asn
Tyr Leu Asn 1 5 10 <210> SEQ ID NO 55 <211> LENGTH: 16
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 55 Arg
Ser Ser Gln Ser Leu Glu Asn Ser Tyr Gly Asn Thr Phe Leu Asn 1 5 10
15 <210> SEQ ID NO 56 <211> LENGTH: 10 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic peptide <400> SEQUENCE: 56 Ser Ala Ser
Ser Ser Leu Ser Tyr Met His 1 5 10 <210> SEQ ID NO 57
<211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 57 Lys Ala Ser Gln Ser Val Val Thr Ala Val
Ala 1 5 10 <210> SEQ ID NO 58 <211> LENGTH: 16
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 58 Arg
Ser Ser Gln Ser Leu Glu Asn Thr Asn Gly Asn Thr Phe Leu Asn 1 5 10
15 <210> SEQ ID NO 59 <211> LENGTH: 16 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic peptide <400> SEQUENCE: 59 Arg Ser Ser
Gln Ser Leu Glu Asn Ser Asn Gly Asn Thr Phe Leu Asn 1 5 10 15
<210> SEQ ID NO 60 <400> SEQUENCE: 60 000 <210>
SEQ ID NO 61 <211> LENGTH: 7 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 61 Lys Val Ser Asn Arg Ile
Ser 1 5 <210> SEQ ID NO 62 <211> LENGTH: 7 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic peptide <400> SEQUENCE: 62 Lys Val Phe
Asn Arg Tyr Ser 1 5 <210> SEQ ID NO 63 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 63 Tyr
Thr Ser Arg Leu His Leu 1 5 <210> SEQ ID NO 64 <211>
LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 64 Tyr Thr Ser Arg Leu His Ser 1 5 <210> SEQ ID NO
65 <211> LENGTH: 7 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
peptide <400> SEQUENCE: 65 Arg Val Ser Asn Arg Phe Cys 1 5
<210> SEQ ID NO 66 <211> LENGTH: 7 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 66 Asp Thr Ser Lys Leu Ala
Ser 1 5 <210> SEQ ID NO 67 <211> LENGTH: 7 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic peptide <400> SEQUENCE: 67 Ser Ala Ser
Asn Arg Tyr Thr 1 5 <210> SEQ ID NO 68 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 68 Arg
Val Ser Asn Arg Phe Ser 1 5 <210> SEQ ID NO 69 <211>
LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 69 Arg Ile Ser Asn Arg Phe Ser 1 5 <210> SEQ ID NO
70 <400> SEQUENCE: 70 000 <210> SEQ ID NO 71
<400> SEQUENCE: 71 000 <210> SEQ ID NO 72
<400> SEQUENCE: 72 000 <210> SEQ ID NO 73 <400>
SEQUENCE: 73 000 <210> SEQ ID NO 74 <400> SEQUENCE: 74
000 <210> SEQ ID NO 75 <400> SEQUENCE: 75 000
<210> SEQ ID NO 76 <400> SEQUENCE: 76 000 <210>
SEQ ID NO 77 <400> SEQUENCE: 77 000 <210> SEQ ID NO 78
<400> SEQUENCE: 78 000 <210> SEQ ID NO 79 <400>
SEQUENCE: 79 000 <210> SEQ ID NO 80 <400> SEQUENCE: 80
000 <210> SEQ ID NO 81 <211> LENGTH: 9 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic peptide <400> SEQUENCE: 81 Ser Gln Ser
Thr His Val Pro Tyr Thr 1 5 <210> SEQ ID NO 82 <211>
LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic peptide <400>
SEQUENCE: 82 Phe Gln Ser Thr His Val Pro Trp Thr 1 5 <210>
SEQ ID NO 83 <211> LENGTH: 9 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 83 Gln Gln Gly Asn Thr Leu
Pro Leu Thr 1 5 <210> SEQ ID NO 84 <211> LENGTH: 9
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 84 Gln
Gln Gly Lys Thr Leu Pro Trp Thr 1 5 <210> SEQ ID NO 85
<211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 85 Leu Gln Val Thr His Val Pro Tyr Thr 1 5
<210> SEQ ID NO 86 <211> LENGTH: 9 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic peptide <400> SEQUENCE: 86 Gln Gln Trp Ser Ser Asn
Pro Trp Thr 1 5 <210> SEQ ID NO 87 <211> LENGTH: 9
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 87 Gln
Gln Tyr Ser Ser Tyr Pro Tyr Thr 1 5 <210> SEQ ID NO 88
<211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic peptide
<400> SEQUENCE: 88 Leu Gln Val Thr His Val Pro Phe Thr 1 5
<210> SEQ ID NO 89 <400> SEQUENCE: 89 000 <210>
SEQ ID NO 90 <400> SEQUENCE: 90 000 <210> SEQ ID NO 91
<400> SEQUENCE: 91 000 <210> SEQ ID NO 92 <400>
SEQUENCE: 92 000 <210> SEQ ID NO 93 <400> SEQUENCE: 93
000 <210> SEQ ID NO 94 <400> SEQUENCE: 94 000
<210> SEQ ID NO 95 <400> SEQUENCE: 95 000 <210>
SEQ ID NO 96 <400> SEQUENCE: 96 000 <210> SEQ ID NO 97
<400> SEQUENCE: 97 000 <210> SEQ ID NO 98 <400>
SEQUENCE: 98 000
<210> SEQ ID NO 99 <400> SEQUENCE: 99 000 <210>
SEQ ID NO 100 <400> SEQUENCE: 100 000 <210> SEQ ID NO
101 <211> LENGTH: 116 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 101 Gln Val Gln Leu Gln Gln Pro
Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Ile Thr
Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly
Glu Ile Asn Pro Gly Ser Gly Ser Thr Asn Tyr Asn Glu Lys Phe 50 55
60 Lys Ser Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr
65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Thr Gly Asp Tyr Trp Gly Gln
Gly Thr Thr Leu 100 105 110 Thr Val Ser Ser 115 <210> SEQ ID
NO 102 <211> LENGTH: 114 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 102 Gln Val Gln Leu Gln Gln Ser
Gly Ala Glu Leu Met Lys Pro Gly Ala 1 5 10 15 Ser Ala Lys Leu Ser
Cys Lys Ala Thr Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Trp Ile Gln
Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 35 40 45 Gly
Glu Ile Leu Pro Gly Gly Asp His Thr Lys Tyr Asn Glu Lys Phe 50 55
60 Arg Gly Lys Ala Thr Phe Thr Ser Asp Thr Ser Ser Asn Thr Val Tyr
65 70 75 80 Met Gln Leu Ser Ser Leu Thr Thr Glu Asp Ser Ala Ile Tyr
Tyr Cys 85 90 95 Ala Arg Val Gly Gly Asp Tyr Trp Gly Gln Gly Thr
Thr Leu Thr Val 100 105 110 Ser Ser <210> SEQ ID NO 103
<211> LENGTH: 122 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 103 Glu Val Gln Leu Gln Gln Ser
Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Asn
Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly
Asp Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe 50 55
60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Arg Gly Gly Leu Gly Arg Gly Thr Tyr Ala
Leu Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Ser Val Thr Val Ser Ser
115 120 <210> SEQ ID NO 104 <211> LENGTH: 113
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
104 Leu Val Gln Pro Gly Gly Ser Leu Ser Leu Ser Cys Ala Ala Ser Gly
1 5 10 15 Phe Thr Phe Ser Asp Tyr Tyr Met Ser Trp Val Arg Gln Pro
Pro Gly 20 25 30 Lys Ala Leu Glu Trp Leu Gly Phe Ile Arg Asn Lys
Ala Asn Gly Tyr 35 40 45 Thr Thr Glu Phe Ser Ala Ser Val Lys Gly
Arg Phe Thr Ile Ser Arg 50 55 60 Asp Asn Ser Gln Ser Ile Leu Tyr
Leu Gln Met Asn Ala Leu Arg Ala 65 70 75 80 Glu Asp Ser Ala Thr Tyr
Tyr Cys Ala Arg Tyr Gly Gly Leu Arg Gln 85 90 95 Gly Trp Tyr Phe
Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser 100 105 110 Ser
<210> SEQ ID NO 105 <211> LENGTH: 112 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 105 Asp Val Gln Leu Gln
Glu Ser Gly Pro Gly Leu Val Glu Pro Ser Gln 1 5 10 15 Ser Leu Phe
Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Thr Asn 20 25 30 Tyr
Asn Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 35 40
45 Met Gly Tyr Ile Arg His Asp Gly Thr Asn Asn Tyr Asn Pro Ser Leu
50 55 60 Lys Asn Arg Ile Ser Ile Ile Arg Asp Thr Pro Lys Asn Gln
Phe Phe 65 70 75 80 Leu Lys Leu Asn Ser Val Thr Thr Glu Asp Thr Ala
Ile Tyr Phe Cys 85 90 95 Thr Arg Leu Asp Tyr Trp Gly Gln Gly Thr
Ser Val Thr Val Ser Ser 100 105 110 <210> SEQ ID NO 106
<211> LENGTH: 125 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 106 Gln Val Gln Leu Gln Gln Pro
Gly Ala Glu Leu Val Arg Pro Gly Ser 1 5 10 15 Ser Val Lys Leu Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His
Trp Val Lys Gln Arg Pro Ile Gln Gly Leu Glu Trp Ile 35 40 45 Gly
Asn Ile Asp Pro Ser Asn Gly Glu Thr His Tyr Asn Gln Lys Phe 50 55
60 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Glu Arg Ile Tyr Tyr Ser Gly Ser Thr Tyr
Asp Gly Tyr Phe 100 105 110 Asp Val Trp Gly Thr Gly Thr Thr Val Thr
Val Ser Ser 115 120 125 <210> SEQ ID NO 107 <211>
LENGTH: 116 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 107 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu
Leu Val Lys Ser Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Ile Asn Trp Val Lys
Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Phe
Pro Gly Ser Gly Ser Val Tyr Cys Asn Glu Gln Phe 50 55 60 Lys Gly
Gln Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr 65 70 75
80
Met Leu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85
90 95 Ala Ser Ser Leu Gly Lys Phe Ala Tyr Trp Gly Gln Gly Thr Leu
Val 100 105 110 Thr Val Ser Ala 115 <210> SEQ ID NO 108
<211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 108 Asp Val Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Ser Leu Ser Leu Thr
Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp
Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 35 40 45 Met
Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55
60 Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
65 70 75 80 Leu Lys Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr
Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu
Thr Val Ser Ser 100 105 110 <210> SEQ ID NO 109 <211>
LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 109 Asp Val Gln Leu Gln Glu Ser Gly Pro Gly
Leu Val Lys Pro Ser Gln 1 5 10 15 Ser Leu Ser Leu Thr Cys Ser Val
Thr Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp Asn Trp Ile
Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 35 40 45 Met Gly Tyr Ile
Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55 60 Lys Asn
Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 65 70 75 80
Leu Arg Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85
90 95 Thr Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser
Ser 100 105 110 <210> SEQ ID NO 110 <211> LENGTH: 125
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
110 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly
Leu Glu Trp Ile 35 40 45 Gly Asn Ile Asp Pro Ser Asn Gly Glu Thr
His Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Arg Ala Thr Leu Thr Val
Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu
Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Arg
Ile Tyr Tyr Ser Gly Ser Thr Tyr Asp Gly Tyr Phe 100 105 110 Asp Val
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210>
SEQ ID NO 111 <211> LENGTH: 125 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 111 Glu Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp
Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40
45 Gly Asn Ile Asp Pro Ser Asn Gly Glu Thr His Tyr Asn Gln Lys Phe
50 55 60 Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr
Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Arg Ile Tyr Tyr Ser Gly Ser
Thr Tyr Asp Gly Tyr Phe 100 105 110 Asp Val Trp Gly Gln Gly Thr Thr
Val Thr Val Ser Ser 115 120 125 <210> SEQ ID NO 112
<211> LENGTH: 125 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 112 Glu Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly
Asn Ile Asp Pro Ser Asn Gly Glu Thr His Tyr Ala Gln Lys Phe 50 55
60 Gln Gly Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Glu Arg Ile Tyr Tyr Ser Gly Ser Thr Tyr
Asp Gly Tyr Phe 100 105 110 Asp Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 125 <210> SEQ ID NO 113 <211>
LENGTH: 116 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 113 Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Ile Asn Trp Val Arg
Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Phe
Pro Gly Ser Gly Ser Val Tyr Cys Asn Glu Gln Phe 50 55 60 Lys Gly
Arg Ala Thr Leu Thr Val Asp Arg Ser Thr Ser Thr Ala Tyr 65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85
90 95 Ala Ser Ser Leu Gly Lys Phe Ala Tyr Trp Gly Gln Gly Thr Leu
Val 100 105 110 Thr Val Ser Ser 115 <210> SEQ ID NO 114
<211> LENGTH: 116 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 114 Glu Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Ile Asn
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly
Trp Ile Phe Pro Gly Ser Gly Ser Val Tyr Ser Asn Glu Gln Phe 50 55
60 Lys Gly Arg Ala Thr Leu Thr Val Asp Arg Ser Thr Ser Thr Ala Tyr
65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr
Phe Cys 85 90 95 Ala Ser Ser Leu Gly Lys Phe Ala Tyr Trp Gly Gln
Gly Thr Leu Val
100 105 110 Thr Val Ser Ser 115 <210> SEQ ID NO 115
<211> LENGTH: 116 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 115 Glu Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Ile Asn
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly
Trp Ile Phe Pro Gly Ser Gly Ser Val Tyr Cys Asn Glu Gln Phe 50 55
60 Lys Gly Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Ser Ser Leu Gly Lys Phe Ala Tyr Trp Gly Gln
Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> SEQ ID
NO 116 <211> LENGTH: 112 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 116 Glu Val Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr
Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp
Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met
Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55
60 Lys Asn Arg Ile Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser
65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Val
Thr Val Ser Ser 100 105 110 <210> SEQ ID NO 117 <211>
LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 117 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly
Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val
Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp Asn Trp Ile
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met Gly Tyr Ile
Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55 60 Lys Asn
Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser 65 70 75 80
Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser
Ser 100 105 110 <210> SEQ ID NO 118 <211> LENGTH: 112
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
118 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Ser
Ser Asn 20 25 30 Tyr Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys
Gly Leu Glu Trp 35 40 45 Met Gly Tyr Ile Arg Tyr Asp Gly Ser Asn
Asn Tyr Asn Pro Ser Leu 50 55 60 Lys Ser Arg Val Thr Ile Ser Arg
Asp Thr Ser Lys Asn Gln Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val
Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Asp
Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110
<210> SEQ ID NO 119 <211> LENGTH: 112 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 119 Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Glu 1 5 10 15 Thr Leu Ser
Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40
45 Met Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu
50 55 60 Lys Gly Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln
Phe Tyr 65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr
Thr Val Thr Val Ser Ser 100 105 110 <210> SEQ ID NO 120
<211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 120 Glu Val Gln Leu Val Glu Ser
Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp
Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met
Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55
60 Lys Gly Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Leu Tyr
65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser 100 105 110 <210> SEQ ID NO 121 <211>
LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 121 Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Lys Pro Gly Glu 1 5 10 15 Thr Leu Ile Leu Thr Cys Thr Val
Ser Gly Tyr Asp Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp Asn Trp Ile
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met Gly Tyr Ile
Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55 60 Lys Gly
Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Tyr 65 70 75 80
Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser
Ser 100 105 110 <210> SEQ ID NO 122 <211> LENGTH: 112
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
122
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5
10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser
Asn 20 25 30 Tyr Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly
Leu Glu Trp 35 40 45 Met Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn
Tyr Asn Pro Ser Leu 50 55 60 Lys Asn Arg Ile Thr Ile Ser Arg Asp
Thr Ser Lys Asn Gln Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val Thr
Ala Ala Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 100 105 110 <210>
SEQ ID NO 123 <211> LENGTH: 112 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 123 Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr
Tyr Trp Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 35 40
45 Met Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu
50 55 60 Lys Asn Arg Ile Thr Ile Ser Arg Asp Thr Ser Lys Asn Thr
Phe Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr
Leu Val Thr Val Ser Ser 100 105 110 <210> SEQ ID NO 124
<400> SEQUENCE: 124 000 <210> SEQ ID NO 125 <400>
SEQUENCE: 125 000 <210> SEQ ID NO 126 <400> SEQUENCE:
126 000 <210> SEQ ID NO 127 <400> SEQUENCE: 127 000
<210> SEQ ID NO 128 <400> SEQUENCE: 128 000 <210>
SEQ ID NO 129 <400> SEQUENCE: 129 000 <210> SEQ ID NO
130 <211> LENGTH: 442 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 130 Glu Val Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr
Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp
Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met
Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55
60 Lys Asn Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser
65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Val
Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala
Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185
190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val Ser His
Glu Asp Pro Glu Val Lys Phe Asn Trp 260 265 270 Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu Gln Tyr
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300 His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310
315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu Trp Glu
Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr Ser Lys
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415 Val Phe
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420 425 430
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 <210> SEQ ID
NO 131 <211> LENGTH: 441 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 131 Glu Val Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr
Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp
Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met
Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 50 55
60 Lys Asn Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser
65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr Thr Val
Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr Ala Ala
Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly Val His
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170 175 Leu
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 180 185
190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys 245 250 255
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 260
265 270 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu 275 280 285 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
Thr Val Leu 290 295 300 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn 305 310 315 320 Lys Ala Leu Pro Ala Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly 325 330 335 Gln Pro Arg Glu Pro Gln
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 340 345 350 Met Thr Lys Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 355 360 365 Pro Ser
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385
390 395 400 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn 405 410 415 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr 420 425 430 Gln Lys Ser Leu Ser Leu Ser Pro Gly 435
440 <210> SEQ ID NO 132 <211> LENGTH: 442 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic polypeptide <400> SEQUENCE: 132 Glu Val
Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20
25 30 Tyr Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
Trp 35 40 45 Met Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn
Pro Ser Leu 50 55 60 Lys Asn Arg Val Thr Ile Ser Arg Asp Thr Ser
Lys Asn Gln Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly
Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe
Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150
155 160 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
Ser 165 170 175 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly
Thr Gln Thr 180 185 190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
Thr Lys Val Asp Lys 195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys
Thr His Thr Cys Pro Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly
Gly Pro Ser Val Phe Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val
Val Asp Val Ser His Glu Asp Pro Glu Glu Lys Phe Asn Trp 260 265 270
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275
280 285 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
Leu 290 295 300 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
Val Ser Asn 305 310 315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
Ile Ser Lys Ala Lys Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr
Thr Leu Pro Pro Ser Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395
400 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
405 410 415 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
Tyr Thr 420 425 430 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440
<210> SEQ ID NO 133 <211> LENGTH: 441 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 133 Glu Val Gln Leu Gln
Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser
Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40
45 Met Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu
50 55 60 Lys Asn Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln
Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr
Thr Val Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val
Phe Pro Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly
Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170
175 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
180 185 190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
Asp Lys 195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
Cys Pro Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met
Ile Ser Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val
Ser His Glu Asp Pro Glu Glu Lys Phe Asn Trp 260 265 270 Tyr Val Asp
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295
300 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
305 310 315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
Ala Lys Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
Pro Ser Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr
Cys Leu Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu
Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420
425 430 Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 <210> SEQ
ID NO 134 <211> LENGTH: 442 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 134 Glu Val Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr
Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr Tyr Trp
Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40 45 Met
Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu
50 55 60 Lys Asn Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln
Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr
Thr Val Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val
Phe Pro Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly
Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170
175 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
180 185 190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
Asp Lys 195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
Cys Pro Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met
Ile Ser Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val
Ser His Glu Asp Pro Glu Tyr Lys Phe Asn Trp 260 265 270 Tyr Val Asp
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295
300 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
305 310 315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
Ala Lys Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
Pro Ser Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr
Cys Leu Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu
Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420
425 430 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 <210>
SEQ ID NO 135 <211> LENGTH: 441 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 135 Glu Val Gln Leu Gln
Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser
Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asn 20 25 30 Tyr
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 35 40
45 Met Gly Tyr Ile Arg Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu
50 55 60 Lys Asn Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln
Phe Ser 65 70 75 80 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Asp Tyr Trp Gly Gln Gly Thr
Thr Val Thr Val Ser Ser 100 105 110 Ala Ser Thr Lys Gly Pro Ser Val
Phe Pro Leu Ala Pro Ser Ser Lys 115 120 125 Ser Thr Ser Gly Gly Thr
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 130 135 140 Phe Pro Glu Pro
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 145 150 155 160 Gly
Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 165 170
175 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
180 185 190 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
Asp Lys 195 200 205 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
Cys Pro Pro Cys 210 215 220 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro 225 230 235 240 Lys Pro Lys Asp Thr Leu Met
Ile Ser Arg Thr Pro Glu Val Thr Cys 245 250 255 Val Val Val Asp Val
Ser His Glu Asp Pro Glu Tyr Lys Phe Asn Trp 260 265 270 Tyr Val Asp
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285 Glu
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295
300 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
305 310 315 320 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
Ala Lys Gly 325 330 335 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
Pro Ser Arg Glu Glu 340 345 350 Met Thr Lys Asn Gln Val Ser Leu Thr
Cys Leu Val Lys Gly Phe Tyr 355 360 365 Pro Ser Asp Ile Ala Val Glu
Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380 Asn Tyr Lys Thr Thr
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400 Leu Tyr
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 405 410 415
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420
425 430 Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 <210> SEQ
ID NO 136 <400> SEQUENCE: 136 000 <210> SEQ ID NO 137
<400> SEQUENCE: 137 000 <210> SEQ ID NO 138 <400>
SEQUENCE: 138 000 <210> SEQ ID NO 139 <400> SEQUENCE:
139 000 <210> SEQ ID NO 140 <211> LENGTH: 219
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
140 Asp Ala Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly
1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu
Asn Thr 20 25 30 Asn Gly Asn Thr Phe Leu Asn Trp Tyr Leu Gln Lys
Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn
Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu
Asp Val Gly Val Tyr Tyr Cys Leu Gln Val 85 90 95 Thr His Val Pro
Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg Thr
Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130
135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp
Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu
Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu
Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe
Asn Arg Gly Glu Cys 210 215
<210> SEQ ID NO 141 <211> LENGTH: 219 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 141 Asp Ile Val Met Thr
Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 1 5 10 15 Gln Pro Ala
Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn
Gly Asn Thr Phe Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40
45 Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
Cys Leu Gln Val 85 90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly
Thr Lys Leu Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val
Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr
Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu
Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170
175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu
Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210
215 <210> SEQ ID NO 142 <211> LENGTH: 219 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Description of Artificial
Sequence: Synthetic polypeptide <400> SEQUENCE: 142 Asp Val
Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu Asn Thr 20
25 30 Asn Gly Asn Thr Phe Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln
Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser
Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly
Val Tyr Tyr Cys Leu Gln Val 85 90 95 Thr His Val Pro Phe Thr Phe
Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150
155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp
Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His
Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly
Glu Cys 210 215 <210> SEQ ID NO 143 <400> SEQUENCE: 143
000 <210> SEQ ID NO 144 <400> SEQUENCE: 144 000
<210> SEQ ID NO 145 <400> SEQUENCE: 145 000 <210>
SEQ ID NO 146 <400> SEQUENCE: 146 000 <210> SEQ ID NO
147 <400> SEQUENCE: 147 000 <210> SEQ ID NO 148
<400> SEQUENCE: 148 000 <210> SEQ ID NO 149 <400>
SEQUENCE: 149 000 <210> SEQ ID NO 150 <400> SEQUENCE:
150 000 <210> SEQ ID NO 151 <211> LENGTH: 112
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
151 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val
His Ser 20 25 30 Tyr Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys
Pro Gly Gln Ser 35 40 45 Pro Lys Phe Leu Ile Tyr Lys Val Ser Asn
Arg Ile Ser Gly Val Pro 50 55 60 Asp Arg Leu Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Pro Glu
Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 85 90 95 Thr His Val Pro
Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110
<210> SEQ ID NO 152 <211> LENGTH: 112 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 152 Asp Val Val Met Thr
Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala
Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Asn Ser 20 25 30 Asn
Glu Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40
45 Pro Lys Leu Leu Ile Tyr Lys Val Phe Asn Arg Tyr Ser Gly Val Pro
50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe
Cys Phe Gln Ser 85 90 95 Thr His Val Pro Trp Thr Phe Gly Gly Gly
Thr Lys Leu Glu Ile Lys 100 105 110 <210> SEQ ID NO 153
<211> LENGTH: 107 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 153 Asp Ile Gln Met Thr Gln Thr
Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile
Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp
Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Pro Leu Ile 35 40 45
Tyr Tyr Thr Ser Arg Leu His Leu Gly Val Pro Ser Arg Phe Ser Gly 50
55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu
Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr
Leu Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 <210> SEQ ID NO 154 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
154 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly
1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Arg
Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val
Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val
Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser
Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr
Phe Cys Gln Gln Gly Lys Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly
Gly Ser Lys Leu Glu Met Lys 100 105 <210> SEQ ID NO 155
<211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 155 Asp Ala Val Met Thr Gln Thr
Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile
Ser Cys Arg Ser Ser Gln Ser Leu Glu Asn Ser 20 25 30 Tyr Gly Asn
Thr Phe Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser 35 40 45 Pro
Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Cys Gly Val Pro 50 55
60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Phe Cys Leu
Gln Val 85 90 95 Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys
Leu Glu Ile Lys 100 105 110 <210> SEQ ID NO 156 <211>
LENGTH: 106 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 156 Gln Ile Val Leu Thr Gln Ser Pro Ala Ile
Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Met Thr Cys Ser
Ala Ser Ser Ser Leu Ser Tyr Met 20 25 30 His Trp Tyr Gln Gln Lys
Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr 35 40 45 Asp Thr Ser Lys
Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser
Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 65 70 75 80
Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Trp Thr 85
90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210>
SEQ ID NO 157 <211> LENGTH: 106 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 157 Gln Ile Val Leu Thr
Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val
Thr Met Thr Cys Ser Ala Ser Ser Ser Leu Ser Tyr Met 20 25 30 His
Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr 35 40
45 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser
50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
Gly Glu 65 70 75 80 Asp Gly Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser
Asn Pro Trp Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 <210> SEQ ID NO 158 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
158 Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Thr Val Gly
1 5 10 15 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Ser Val Val
Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro
Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val
Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Ala
Leu Thr Ile Arg Thr Met Gln Ser 65 70 75 80 Glu Asp Leu Ala Asp Tyr
Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gly
Gly Thr Lys Leu Glu Ile Lys 100 105 <210> SEQ ID NO 159
<211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 159 Asp Ala Val Met Thr Gln Thr
Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile
Ser Cys Arg Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn Gly Asn
Thr Phe Leu Asn Trp Phe Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro
Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro 50 55
60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Leu
Gln Val 85 90 95 Thr His Val Pro Phe Thr Phe Gly Ser Gly Thr Lys
Leu Glu Ile Lys 100 105 110 <210> SEQ ID NO 160 <211>
LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 160 Asp Ala Val Met Thr Gln Thr Pro Leu Ser
Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg
Ser Ser Gln Ser Leu Glu Asn Ser 20 25 30 Asn Gly Asn Thr Phe Leu
Asn Trp Phe Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu
Ile Tyr Arg Ile Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Leu Gln Val 85
90 95 Thr His Val Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile
Lys 100 105 110 <210> SEQ ID NO 161 <211> LENGTH: 106
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 161 Asp Ile Gln Leu Thr
Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val
Thr Ile Thr Cys Ser Ala Ser Ser Ser Leu Ser Tyr Met 20 25 30 His
Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Arg Trp Ile Tyr 35 40
45 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60 Gly Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Ser Leu Gln
Pro Glu 65 70 75 80 Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser
Asn Pro Trp Thr 85 90 95 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 <210> SEQ ID NO 162 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
162 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Val
Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro
Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val
Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr
Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr
Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gly
Gly Thr Lys Val Glu Ile Lys 100 105 <210> SEQ ID NO 163
<211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 163 Asp Ala Val Met Thr Gln Thr
Pro Leu Ser Leu Ser Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile
Ser Cys Arg Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn Gly Asn
Thr Phe Leu Asn Trp Phe Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro
Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro 50 55
60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Phe Cys Leu
Gln Val 85 90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly Thr Lys
Leu Glu Ile Lys 100 105 110 <210> SEQ ID NO 164 <211>
LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 164 Asp Ala Val Met Thr Gln Thr Pro Leu Ser
Leu Ser Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg
Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn Gly Asn Thr Phe Leu
Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu
Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Val 85
90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
Lys 100 105 110 <210> SEQ ID NO 165 <211> LENGTH: 112
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
165 Asp Ala Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Glu Gly
1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu
Asn Thr 20 25 30 Asn Gly Asn Thr Phe Leu Asn Trp Tyr Leu Gln Lys
Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn
Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu
Asp Val Gly Val Tyr Tyr Cys Leu Gln Val 85 90 95 Thr His Val Pro
Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110
<210> SEQ ID NO 166 <211> LENGTH: 112 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 166 Asp Ala Val Met Thr
Gln Thr Pro Leu Ser Leu Ala Val Leu Pro Gly 1 5 10 15 Gln Pro Ala
Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn
Gly Asn Thr Phe Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40
45 Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
Cys Leu Gln Val 85 90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly
Thr Lys Leu Glu Ile Lys 100 105 110 <210> SEQ ID NO 167
<211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 167 Asp Ile Gln Met Thr Gln Ser
Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile
Thr Cys Arg Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn Gly Asn
Thr Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala 35 40 45 Pro
Lys Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro 50 55
60 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
65 70 75 80 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu
Gln Val 85 90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly Thr Lys
Val Glu Ile Lys 100 105 110 <210> SEQ ID NO 168 <211>
LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Description of Artificial Sequence: Synthetic polypeptide
<400> SEQUENCE: 168 Asp Ala Val Met Thr Gln Ser Pro Leu Ser
Leu Pro Val Thr Leu Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg
Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn Gly Asn Thr Phe Leu
Asn Trp Phe Gln Gln Lys Pro Gly Gln Ser 35 40 45 Pro Arg Leu Leu
Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75
80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Val 85
90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
Lys 100 105 110 <210> SEQ ID NO 169 <211> LENGTH: 112
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
169 Asp Ala Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser Leu Glu
Asn Thr 20 25 30 Asn Gly Asn Thr Phe Leu Asn Trp Phe Gln Gln Lys
Pro Gly Lys Ala 35 40 45 Pro Lys Leu Leu Ile Tyr Arg Val Ser Asn
Arg Phe Ser Gly Val Pro 50 55 60 Ser Arg Phe Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr Leu Thr Ile 65 70 75 80 Ser Ser Leu Gln Pro Glu
Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Val 85 90 95 Thr His Val Pro
Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110
<210> SEQ ID NO 170 <211> LENGTH: 112 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 170 Asp Ile Val Met Thr
Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 1 5 10 15 Gln Pro Ala
Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn
Gly Asn Thr Phe Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40
45 Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
Cys Leu Gln Val 85 90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly
Thr Lys Leu Glu Ile Lys 100 105 110 <210> SEQ ID NO 171
<211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Description of Artificial Sequence: Synthetic
polypeptide <400> SEQUENCE: 171 Asp Val Val Met Thr Gln Thr
Pro Leu Ser Leu Ser Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile
Ser Cys Arg Ser Ser Gln Ser Leu Glu Asn Thr 20 25 30 Asn Gly Asn
Thr Phe Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro
Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro 50 55
60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu
Gln Val 85 90 95 Thr His Val Pro Phe Thr Phe Gly Gln Gly Thr Lys
Leu Glu Ile Lys 100 105 110 <210> SEQ ID NO 172 <400>
SEQUENCE: 172 000 <210> SEQ ID NO 173 <400> SEQUENCE:
173 000 <210> SEQ ID NO 174 <400> SEQUENCE: 174 000
<210> SEQ ID NO 175 <400> SEQUENCE: 175 000 <210>
SEQ ID NO 176 <400> SEQUENCE: 176 000 <210> SEQ ID NO
177 <400> SEQUENCE: 177 000 <210> SEQ ID NO 178
<400> SEQUENCE: 178 000 <210> SEQ ID NO 179 <400>
SEQUENCE: 179 000 <210> SEQ ID NO 180 <400> SEQUENCE:
180 000 <210> SEQ ID NO 181 <211> LENGTH: 452
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic polypeptide <400> SEQUENCE:
181 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
Gly Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly
Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asp Ser Gly Gly Thr
Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg
Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Asn Arg Leu
Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gln
Pro Leu Gly Tyr Cys Thr Asn Gly Val Cys Ser Tyr 100 105 110 Phe Asp
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser 115 120 125
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr 130
135 140 Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
Pro 145 150 155 160 Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
Thr Ser Gly Val 165 170 175 His Thr Phe Pro Ala Val Leu Gln Ser Ser
Gly Leu Tyr Ser Leu Ser 180 185 190 Ser Val Val Thr Val Pro Ser Ser
Asn Phe Gly Thr Gln Thr Tyr Thr 195 200 205 Cys Asn Val Asp His Lys
Pro Ser Asn Thr Lys Val Asp Lys Thr Val 210 215 220 Glu Arg Lys Cys
Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val 225 230 235 240 Ala
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250
255 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
260 265 270 His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
Val Glu 275 280 285 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
Phe Asn Ser Thr 290 295 300 Phe Arg Val Val Ser Val Leu Thr Val Val
His Gln Asp Trp Leu Asn 305 310 315 320 Gly Lys Glu Tyr Lys Cys Lys
Val Ser Asn Lys Gly Leu Pro Ala Pro 325 330 335 Ile Glu Lys Thr Ile
Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350 Val Tyr Thr
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 355 360 365 Ser
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375
380
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385
390 395 400 Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
Leu Thr 405 410 415 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
Ser Cys Ser Val 420 425 430 Met His Glu Ala Leu His Asn His Tyr Thr
Gln Lys Ser Leu Ser Leu 435 440 445 Ser Pro Gly Lys 450 <210>
SEQ ID NO 182 <211> LENGTH: 214 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
Synthetic polypeptide <400> SEQUENCE: 182 Asp Ile Gln Met Thr
Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val
Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Tyr Ser Trp 20 25 30 Leu
Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile 35 40
45 Tyr Thr Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn
Ile Phe Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile
Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro
Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys
Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp
Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu
Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170
175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> SEQ ID
NO 183 <400> SEQUENCE: 183 000 <210> SEQ ID NO 184
<400> SEQUENCE: 184 000 <210> SEQ ID NO 185 <400>
SEQUENCE: 185 000 <210> SEQ ID NO 186 <400> SEQUENCE:
186 000 <210> SEQ ID NO 187 <400> SEQUENCE: 187 000
<210> SEQ ID NO 188 <400> SEQUENCE: 188 000 <210>
SEQ ID NO 189 <400> SEQUENCE: 189 000 <210> SEQ ID NO
190 <400> SEQUENCE: 190 000 <210> SEQ ID NO 191
<400> SEQUENCE: 191 000 <210> SEQ ID NO 192 <400>
SEQUENCE: 192 000 <210> SEQ ID NO 193 <400> SEQUENCE:
193 000 <210> SEQ ID NO 194 <400> SEQUENCE: 194 000
<210> SEQ ID NO 195 <400> SEQUENCE: 195 000 <210>
SEQ ID NO 196 <400> SEQUENCE: 196 000 <210> SEQ ID NO
197 <400> SEQUENCE: 197 000 <210> SEQ ID NO 198
<400> SEQUENCE: 198 000 <210> SEQ ID NO 199 <400>
SEQUENCE: 199 000 <210> SEQ ID NO 200 <211> LENGTH: 15
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Description of
Artificial Sequence: Synthetic peptide <400> SEQUENCE: 200
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10
15
* * * * *